Treatment of cancer with conditionally active anti-ROR2 antibody-drug conjugates
By developing polypeptide antibodies or antibody fragments that specifically bind ROR2 protein and forming conditionally active biological agents, the insufficient efficacy and side effects of existing antibodies in cancer treatment are solved, and efficient and safe cancer treatment is achieved.
Patent Information
- Application Number
- CN202380036629.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-25
- Filing Date
- 2023-02-24
- Publication Date
- 2024-12-06
AI Technical Summary
The existing monoclonal antibodies against ROR2 have not been used for cancer treatment and have side effects, making it difficult to effectively play a therapeutic role in cancer.
Develop polypeptide antibodies or antibody fragments that specifically bind ROR2 protein, improve binding affinity in the tumor microenvironment by mutation of specific amino acid sequences in the heavy and light chain variable regions, and through conditional active biological agents and drug affixation To form antibody drug conjugates (ADCs) to improve therapeutic efficacy.
It achieves efficient binding of ROR2 in the tumor microenvironment, extends the half-life of the antibody, reduces side effects, provides a higher dose of treatment choice, and significantly improves the therapeutic effect on cancer.
Smart Images

Figure CN119095877A_ABST
Abstract
Description
[0001] Reference to a sequence listing
[0002] This application includes an accompanying sequence listing, which was created on February 10, 2023, as an XML file named "BIAT-1035WO Sequence Listing" and contains 174,000 bytes. The information contained in this file is incorporated herein by reference.
[0003] CROSS-REFERENCE TO RELATED APPLICATIONS
[0004] This application claims priority to U.S. Provisional Application No. 63 / 313,943, filed on February 25, 2022, the entire disclosure of which is incorporated herein by reference as if fully set forth herein. Technical Field
[0005] The present invention relates to anti-ROR2 antibodies, antibody fragments and immunoconjugates of such antibodies and antibody fragments, as well as uses of the antibodies, antibody fragments and immunoconjugates in diagnostic and therapeutic methods. Background Art
[0006] Receptor tyrosine kinases (RTKs) are a family of cell surface receptors that regulate a range of normal cellular processes through ligand-controlled tyrosine kinase activity. Over the past 20 years, RTK dysregulation has been shown to play a key role in the development and progression of cancer. RTKs are now recognized as prognostic molecular biomarkers and targets for cancer therapy.
[0007] ROR2, also known as receptor tyrosine kinase-like orphan receptor 2, is a membrane-bound RTK that is activated by non-canonical Wnt signaling during normal bone and cartilage development through association with the Wnt5A glycoprotein. ROR2 has only one transmembrane domain that separates its extracellular and intracellular domains. Figure 1). ROR2 is known to play a vital role in the normal development of various organs and tissues. In mammals, ROR2-deficient mice and Wnt5A-deficient mice show similar abnormalities during developmental morphogenesis, reflecting their defects in convergent extension movement and planar cell polarity. In addition, mutations in the human ROR2 gene are the culprits for the genetic skeletal disorders dominant brachydactyly type B and recessive Robinow syndrome. ROR2 has been found to mediate polarized cell migration, and dysfunction of ROR2 leads to heritable skeletal diseases and tumor invasion (Minami et al., "Ror-family receptor tyrosine kinases in noncanonical Wnt signaling: their implications in developmental morphogenesis and human diseases," Dev Dyn., vol. 239, pp. 1-15, 2010).
[0008] It has also been reported that ROR2 has a tumor-promoting effect. US2014 / 0322234 discloses that the expression and activity of ROR2 in various cancers are different from those in normal tissues. Therefore, this suggests that the disorder of ROR2 plays a role in the pathogenesis of various human cancers. US2014 / 0322234 also contemplates that antibodies against ROR2 can be used to diagnose cancer and inhibit the growth of cancer cells. For example, such antibodies can be conjugated with cytotoxic agents that are highly cytotoxic to cancer cells expressing ROR2, so that the cytotoxic agent can effectively kill cancer cells. Based on the ROR2 expression pattern in cancer, the ROR2 gene can also be used to classify cancer.
[0009] Ford et al. (“The dual role of the novel Wnt receptor tyrosine kinase, ROR2, in human carcinogenesis,” International Journal of Cancer, vol. 133, pp. 779–787, 2013) further explored the mechanism of action of ROR2 in carcinogenesis. This reference discloses that ROR2 is involved in the occurrence and progression of cancer. Specifically, ROR2 has been found to play a key role in the carcinogenesis of various cancers, including colon cancer, hepatocellular carcinoma, metastatic melanoma, and renal cell carcinoma. For example, ROR2 is overexpressed in osteosarcoma, melanoma, renal cell carcinoma, prostate cancer, head and neck squamous cell carcinoma, and mesenchymal tumors. Therefore, ROR2 has the potential to become a drug target for cancer treatment by inhibiting the Wnt signaling pathway.
[0010] In addition, Debebe et al. (“ROR2 as a therapeutic target in cancer,” Pharmacol. Ther., vol. 50, pp. 143-148, 2015) disclosed that ROR2 mediates canonical and non-canonical signaling pathways. ROR2 is highly expressed in osteosarcoma and renal cell carcinoma, as well as melanoma, colon cancer, head and neck squamous cell carcinoma, and breast cancer. In most of these cancer types, ROR2 expression is associated with a more aggressive cancer state. Therefore, this reference also suggests that ROR2 is a potential target for cancer treatment.
[0011] WO2013 / 103637 discloses the use of ROR2 as a therapeutic target and prognostic marker for cancer, and a conjugate comprising an antibody that recognizes and binds to ROR2 and a cytotoxic agent (see abstract).
[0012] WO2017 / 197234 discloses polypeptides having heavy chain variable regions and / or light chain variable regions that specifically bind to the ROR2 protein, as well as antibodies and antibody fragments containing the heavy chain variable regions and / or light chain variable regions that bind to the ROR2 protein. Pharmaceutical compositions and kits containing the polypeptides or antibodies and antibody fragments containing the polypeptides are also provided.
[0013] In “Novel conditionally active biologic anti-Axl antibody-drug conjugate demonstrates anti-tumor efficacy and improved safety profile,” presented at the AACR Annual Meeting in April 2016, Chang C. et al. described conjugating a conditionally active biologic (CAB)-Axl antibody to a model toxin payload to generate a CAB-Axl-ADC (antibody drug conjugate) (abstract).
[0014] WO2016 / 138071 describes methods for producing conditionally active biological proteins that are more active under abnormal conditions than under normal physiological conditions (see abstract).
[0015] Although monoclonal antibodies against ROR2 are commercially available, no anti-ROR2 antibodies suitable for cancer treatment have been reported. The present invention provides anti-ROR2 antibodies or antibody fragments suitable for therapeutic and diagnostic purposes, in particular for the diagnosis and treatment of cancer. Compared to ROR2 present in normal tissues, some anti-ROR2 antibodies or antibody fragments have a higher binding affinity for ROR2 in tumors. Compared to monoclonal anti-ROR2 antibodies known in the art, these anti-ROR2 antibodies or antibody fragments of the present invention have at least comparable efficacy and a longer half-life, but with reduced side effects. This can allow the use of higher doses of these anti-ROR2 antibodies or antibody fragments, thereby providing a more effective treatment option without a corresponding significant increase in side effects. Summary of the Invention
[0016] In one aspect, the present invention provides isolated polypeptides that specifically bind to a ROR2 protein, and uses of the polypeptides in methods of treating tumors expressing ROR2, the methods involving administering the polypeptides to a human in need of such treatment.
[0017] The polypeptide comprises a heavy chain variable region having three complementarity determining regions (CDRs): an H1 sequence, an H2 sequence, and an H3 sequence, wherein:
[0018] The H1 sequence is GYTX1TEX2X3X4H (SEQ ID NO: 1) or GYSITTGX 29 YWN (SEQ ID NO: 4);
[0019] H2 sequence is X5X6X7X8NNGGTGYNQKFKG (SEQ ID NO: 2) or YITYDGSX 30NYNPSLKN (SEQ ID NO: 5); and
[0020] H3 sequence is X9X 10 X 11 SX 12 YX 13 YX 14 X 15 SYFX 16 X 17 X 18 (SEQ ID NO: 3) or CSX 31 X 32 X 33 X 34 VX 35 X 36 X 37 LDX 38 (SEQ ID NO: 6);
[0021] in
[0022] X1 is F or E,
[0023] X2 is Y or D,
[0024] X3 is T or C,
[0025] X4 is M or D or E or Y,
[0026] X5 is G or S,
[0027] X6 is I or E,
[0028] X7 is N or C or L or V,
[0029] X8 is T or D or E,
[0030] X9 is A or M or T,
[0031] X 10 is R or H,
[0032] X 11 It's G or E,
[0033] X 12 It is L or F,
[0034] X 13 It is S or G,
[0035] X 14 It's G or D,
[0036] X 15 is N or E,
[0037] X 16 It is D or L,
[0038] X 17 It's Y or C or T,
[0039] X 18 It is W or L,
[0040] X 29 It is Y or E or R or T,
[0041] X 30 is K or N,
[0042] X 31 It is R or G or H or W or Y,
[0043] X 32 It's F or C or N or Q,
[0044] X 33 It is E or S,
[0045] X 34 It's G or E or F or H or M or Q or S,
[0046] X 35 It is W or A or I or P or Q or T or V,
[0047] X 36 It's Y or G or N or Q,
[0048] X 37 is G or S or T, and
[0049] X 38 is Y or I; and
[0050] A light chain variable region having three complementarity determining regions (CDRs): L1 sequence, L2 sequence, and L3 sequence, wherein:
[0051] L1 sequence is SATSSX 19 X 20 X 21 MX 22 (SEQ ID NO: 7) or RASESVDRYGNSX 39 IH (SEQ ID NO: 10);
[0052] The L2 sequence is X 23 TSNLAS (SEQ ID NO: 8) or X 40 TYX 41 LES (SEQ ID NO: 11); and
[0053] L3 sequence is QX 24 X 25 SX 26 YPFX 27 X28 (SEQ ID NO: 9) or QQX 42 NX 43 DPX 44 TX 45 (SEQ ID NO: 12);
[0054] in
[0055] X 19 is V or E,
[0056] X 20 is S or D,
[0057] X 21 It's Y or C or D,
[0058] X 22 It's H or G or L,
[0059] X 23 It's G or C or H or P,
[0060] X 24 It's Q or E,
[0061] X 25 is R or H,
[0062] X 26 It's S or D or G or I or Q or V,
[0063] X 27 is T or D,
[0064] X 28 It's F or D or E,
[0065] X 39 It's F or S or T,
[0066] X 40 It is R or C or D or E or W,
[0067] X 41 is N or D,
[0068] X 42 It is T or I or P,
[0069] X 43 is E or V,
[0070] X 44 is W or T, and
[0071] X 45 It is F or T.
[0072] In one embodiment of this aspect, the heavy chain variable region polypeptide comprises three complementarity determining regions H1, H2 and H3 having an amino acid sequence selected from the group consisting of SEQ ID NOs: 18-26.
[0073] In one embodiment of this aspect, the light chain variable region polypeptide comprises three complementarity determining regions L1, L2 and L3 having an amino acid sequence selected from SEQ ID NOs: 13-17 and 27.
[0074] In another embodiment of this aspect, any of the heavy chain variable region polypeptides described in the above embodiments can be combined with any of the light chain variable region polypeptides described in the above embodiments.
[0075] In another aspect, the invention provides an isolated polypeptide as described above having at most one substitution in CDR H1, H2 and H3 relative to a parent polypeptide and / or having at most one substitution in CDR L1, L2 and L3 relative to a parent polypeptide. This includes (1) an isolated polypeptide having one substitution in CDR H1, H2 and H3 relative to a parent polypeptide, (2) an isolated polypeptide having one substitution in CDR L1, L2 and L3 relative to a parent polypeptide, and (3) an isolated polypeptide having one substitution in CDR H1, H2 and H3 and one substitution in CDR L1, L2 and L3 relative to a parent polypeptide.
[0076] In one embodiment of this aspect, possible single point mutations in CDRs H1, H2 and H3 are as follows Figure 2A-1 and Figure 2A-2 As shown, possible single point mutations in CDR L1, L2 and L3 are as follows Figure 3A-1 and Figure 3A-2 shown.
[0077] In another embodiment of this aspect, possible single point mutations of CDRs H1, H2 and H3 are as follows Figure 2B-1 and Figure 2B-2 As shown, possible single point mutations of CDR L1, L2 and L3 are as follows Figure 3B-1 and Figure 3B-2 shown.
[0078] In another aspect, each heavy chain variable region polypeptide and each light chain variable region polypeptide can each have 1, 2, 3, 4 or 5 independently selected substitutions in a CDR selected from Figure 2B-1 to Figure 2B-2 and Figure 2A-1 to Figure 2A-2 The point mutations shown in .
[0079] In yet another aspect, the present invention provides an anti-ROR2 antibody or antibody fragment comprising any of the polypeptides of the present invention as described above.
[0080] In one embodiment of this aspect, the present invention provides an anti-ROR2 antibody or antibody fragment comprising any of the heavy chain variable region polypeptides described above in combination with any of the light chain variable region polypeptides described above.
[0081] In one embodiment of this aspect, the present invention provides an anti-ROR2 antibody or antibody fragment comprising a heavy chain variable region having an amino acid sequence selected from SEQ ID NOs: 18-26 in combination with a light chain variable region having an amino acid sequence selected from SEQ ID NOs: 13-17 and 27.
[0082] In another embodiment of this aspect, the present invention provides an anti-ROR2 antibody or antibody fragment comprising a heavy chain variable region having an amino acid sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 21 and SEQ ID NO: 22 in combination with a light chain variable region having an amino acid sequence selected from the group consisting of SEQ ID NO: 13-16.
[0083] In another embodiment of this aspect, the present invention provides anti-ROR2 antibodies or antibody fragments that specifically bind to ROR2 protein at a certain value of a certain condition in a tumor microenvironment with a higher binding affinity than their binding affinity for ROR2 protein at a different value of the same condition present in a non-tumor microenvironment.
[0084] In yet another embodiment of this aspect, the condition in the tumor microenvironment and the condition in the non-tumor microenvironment is pH.
[0085] In yet another embodiment of this aspect, the pH in the tumor microenvironment is in the range of 5.8 to 6.8 and the pH in the non-tumor microenvironment is in the range of 7.0 to 7.6.
[0086] In another embodiment of this aspect, the ratio of the binding affinity of the antibody or antibody fragment for ROR2 protein at a certain value of a certain condition in a tumor microenvironment to the binding affinity for ROR2 protein at a different value of the same condition in a non-tumor microenvironment is at least about 1.5:1, at least about 2:1, at least about 3:1, at least about 4:1, at least about 5:1, at least about 6:1, at least about 7:1, at least about 8:1, at least about 9:1, at least about 10:1, at least about 20:1, at least about 30:1, at least about 50:1, at least about 70:1, or at least about 100:1.
[0087] In yet another embodiment of this aspect, the antibody or antibody fragment of any of the above embodiments is a chimeric antibody, a multispecific antibody, or a humanized antibody.
[0088] In yet another aspect, the present invention provides an immunoconjugate comprising an antibody or antibody fragment of the present invention as described above, conjugated to at least one agent selected from a chemotherapeutic agent, a radioactive atom, a cytostatic agent, and a cytotoxic agent.
[0089] In one embodiment of this aspect, the immunoconjugate is an antibody-drug conjugate (ADC) in which a conditionally active biologic (CAB) anti-ROR2 antibody or antibody fragment is conjugated to one or more heterologous molecules via a cleavable linker (CAB-ROR2-ADC). The CAB anti-ROR2 antibody or antibody fragment can be BA3021, wherein BA3021 is an antibody or antibody fragment having a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO: 16 and the light chain variable region has the amino acid sequence of SEQ ID NO: 21. The CAB-ROR2-ADC can be BA3021-cleavable linker-MMAE (n) , wherein the heterologous molecule is monomethyl auristatin E (MMAE), and (n) is an integer from 1 to 4 (inclusive).
[0090] In yet another aspect, the present invention provides a pharmaceutical composition comprising the polypeptide, antibody or antibody fragment or immunoconjugate of the present invention as described above and a pharmaceutically acceptable carrier.
[0091] In yet another aspect, the present invention provides a kit for diagnosis or treatment, comprising the polypeptide, antibody or antibody fragment or immunoconjugate of the present invention as described above.
[0092] In yet another aspect, the present invention provides a method for treating a tumor expressing ROR2 using the polypeptide, antibody or antibody fragment or immunoconjugate of the present invention as described above.
[0093] In one embodiment of this aspect, the method of the invention for treating a tumor expressing ROR2 comprises administering to a human subject in need of such treatment a conditionally active ROR2 polypeptide, antibody or antibody fragment or immunoconjugate as described above.
[0094] In another embodiment of this aspect, a method of treating a ROR2-expressing tumor comprises administering a CAB-ROR2-ADC as described above to a human individual in need of such treatment.
[0095] In another embodiment of this aspect, the human subject in need of such treatment is a human subject suffering from cancer or a human subject suffering from a tumor expressing ROR2.
[0096] In a specific embodiment of this aspect, the cancer may be selected from sarcoma, ovarian cancer, melanoma, non-small cell lung cancer (NSCLC), breast cancer, and head and neck cancer.
[0097] In another embodiment of this aspect, a method of treating a tumor expressing ROR2 comprises administering to a human subject in need of such treatment as described in any of the above embodiments a pharmaceutical composition comprising a CAB-ROR2-ADC, wherein the CAB-ROR2-ADC is BA3021-cleavable linker-MMAE as described above. (n) .
[0098] In yet another embodiment of this aspect, the pharmaceutical composition as described in any of the above embodiments is administered at a dose of up to 3.3 mg / kg body weight of the human subject every 21 days or 3 weeks.
[0099] In yet another embodiment of this aspect, the pharmaceutical composition as described in any of the above embodiments is administered at a dose of 1.8 mg / kg body weight of the human subject every 14 days or 2 weeks. BRIEF DESCRIPTION OF THE DRAWINGS
[0100] Figure 1 This is a schematic diagram of the structure of the human ROR2 protein. The protein contains an Ig-like domain (Ig), a frizzled or cysteine-rich domain (CRD), and a kringle (Kr) domain in the extracellular domain. The extracellular and intracellular domains are separated by a transmembrane (TM) domain. The intracellular domain contains a tyrosine kinase (TK) domain and a proline-rich (PR) domain flanked by serine / threonine-rich (ST) domains.
[0101] Figure 2A Show Figure 2A-1 and Figure 2A-2 The index of . Figure 2B Show Figure 2B-1 and Figure 2B-2 The index of . Figure 2A-1 、 Figure 2A-2 、 Figure 2B-1 and Figure 2B-2 Shown is a sequence alignment of exemplary heavy chain variable regions of the anti-ROR2 antibodies of the present invention.
[0102] Figure 3A Show Figure 3A-1 and Figure 3A-2 The index of . Figure 3B Show Figure 3B-1 and Figure 3B-2 The index of . Figure 3A-1 、 Figure 3A-2 、 Figure 3B-1 and Figure 3B-2 Shown is a sequence alignment of exemplary light chain variable regions of the anti-ROR2 antibodies of the present invention.
[0103] Figure 4 A size exclusion chromatograph as described in Example 1 is shown, which demonstrates that the anti-ROR2 antibodies of the present invention do not aggregate.
[0104] Figure 5 The pH-dependent binding profile of the anti-ROR2 antibodies of the present invention as described in Example 1 to ROR2 is shown.
[0105] Figures 6A to 6B Shown are the on and off rates of the conditionally active antibodies of the invention measured by surface plasmon resonance (SPR) assay as described in Example 1.
[0106] 7A to 7C The effect of treating xenografted mice with paclitaxel-conjugated anti-ROR2 antibodies of the invention as described in Example 2 on tumor volume is shown.
[0107] Figure 8 Shown is the pH-dependent binding affinity of exemplary conditionally active antibody BAP048 measured by pH titration.
[0108] Figure 9 The binding affinities of the conditionally active antibody BAP048 to human ROR2 protein (hROR2), cynomolgus monkey ROR2 protein (CynoROR2), and mouse ROR2 protein (mROR2) are shown.
[0109] Figure 10 Shown are cell killing of HEK293 cells expressing human ROR2 by the conditionally active antibody BAP048 conjugated to monomethyl auristatin E (MMAE).
[0110] Figures 11A to 11C Shown is cell killing of LCLC103H cells by conditionally active antibody BAP048 conjugated to MMAE.
[0111] 12A to 12C Shown is cell killing of HT1080 cells by the conditionally active antibody BAP048 conjugated to MMAE.
[0112] Figure 13Shown is the treatment of LCLC103H-induced mouse tumors using the conditionally active antibody BAP048 conjugated to MMAE.
[0113] Figure 14 Shown is the treatment of LCLC103H-induced mouse tumors using the conditionally active antibody BAP048 conjugated to MMAE via different linkers.
[0114] FIG. 15A to FIG. 15B Shown are the treatments of mouse tumors induced by HT1080 or MDA-MB-436, respectively, using the conditionally active antibody BAP048 conjugated to MMAE.
[0115] Figure 16 Figure 3: Variable dosing response of NSCLC patients enrolled in the BA3021 Phase 1 trial as measured by ROR tumor membrane percent score (TmPS). In two of five NSCLC patients with evaluable ROR2 TmPS, tumor membrane ROR2 expression correlated with antitumor response.
[0116] Figure 17 Shown is the dose response for two evaluable metastatic melanoma patients enrolled in the BA3021 Phase 1 trial.
[0117] Figure 18 A to Figure 18 B shows a pre-treatment CT scan of one of two lung lesions cleared in a metastatic melanoma patient who achieved a complete response to BA3021 (ozuriftamab vedotin). Figure 18 A) and post-treatment CT scan ( Figure 18 B).
[0118] Figure 19 A to Figure 19 D shows ROR2 staining in sarcoma at 40x magnification. Figure 19 A (Q9403, % score ≥1+: 100, slide #88), Figure 19 B (QMTB313-08, % score ≥1+: 70, slide #75) and Figure 19 C (Q9453, % score ≥1+: 50, slide #93) shows ROR2 H-1 in sarcoma, Figure 19 D shows mouse IgG1 in sarcoma (negative control, slide #88).
[0119] Figure 20 A to Figure 20 D shows ROR2 staining in ovarian cancer at 40x magnification. Figure 20 A (Q5488, % score ≥1+: 70, slide #120), Figure 20 B (Q7499-02, % score ≥1+: 50, slide #124) and Figure 20 C (Q6946-01, % score ≥1+: 20, slide #122) shows ROR2 H-1 in ovarian cancer, Figure 20 D shows mouse IgG1 in ovarian cancer (negative control, slide #175).
[0120] Figure 21 A to Figure 21 D shows ROR2 staining in NSCLC at 40x magnification. Figure 21 A (QMTB397-09, % score ≥1+: 100, slide #239), Figure 21 B (Q4044-049, % score ≥1+: 10, slide #253) and Figure 21 C (QMTB249-02, % score ≥1+:0, slide #238) shows ROR2 H-1 in NSCLC, Figure 21 D shows mouse IgG1 in NSCLC (QMTB397-09, negative control, slide #294).
[0121] Figure 22 A to Figure 22 D shows ROR2 staining in triple-negative breast cancer (TNBC) at 40× magnification. Figure 22 A (Q933, % score ≥1+: 90, slide #369), Figure 22 B (Q9286, % score ≥1+: 60, slide #290) and Figure 22 C (Q9335, % score ≥1+: 15, slide #371) shows ROR2 H-1 in TNBC, Figure 22 D shows mouse IgG1 in TNBC (negative control, slide #384).
[0122] Figure 23 Shown are the proportions of ROR2-positive and ROR2-negative cases in various cancer indications based on the ROR2 Cut-Off: intensity ≥1+ in ≥10% of tumor cells, indicating a positive case.
[0123] Figure 24 Shown are the mean ROR2 plasma membrane H-scores by cancer indication.
[0124] Figure 25 A to Figure 25 F shows ROR2 in normal human TMA tissue at 20x magnification. Figure 25 A shows ROR2 in normal kidney, % score ≥1+:0 (slide #375), Figure 25 B shows ROR2 in normal liver, % score ≥1+:0 (slide #375), Figure 25 C shows ROR2 in normal intestine, % score ≥1+:0 (slide #375), Figure 25 D shows ROR2 in normal brain, % score ≥1+:0 (slide #375), Figure 25 E shows ROR2 in normal thyroid, % score ≥1+:10 (slide #375), and Figure 25 F shows ROR2 in normal tonsil, % score ≥1+:10 (slide #375).
[0125] Figure 26 Showing accuracy and reproducibility of ROR2 in sarcoma Q9403.
[0126] Figure 27 Shown is the accuracy and reproducibility of ROR2 in sarcoma QMTB313-07.
[0127] Figure 28 Shown is the accuracy and reproducibility of ROR2 in ovarian cancer Q7499-02.
[0128] Figure 29 Shown is the accuracy and reproducibility of ROR2 in ovarian cancer QMTB400-05.
[0129] Figure 30 Shown are the accuracy and reproducibility of ROR2 in NSCLC Q6949-01.
[0130] Figure 31 The accuracy and reproducibility of ROR2 in NSCLC Q4044 are shown.
[0131] Figure 32 Showing the accuracy and reproducibility of ROR2 in TNBC Q9333.
[0132] Figure 33 Showing the accuracy and reproducibility of ROR2 in TNBC Q9250.
[0133] Figure 34 An embodiment of a dosing schedule for treating non-small cell lung cancer using the polypeptide of the present invention is shown. DETAILED DESCRIPTION
[0134] To facilitate understanding of the embodiments provided herein, certain frequently occurring terms are defined herein.
[0135] As used herein, the term "about" in relation to a measured amount refers to the normal variation in the measured amount that would be expected by a skilled artisan making the measurements and exercising a degree of care commensurate with the purpose of the measurements and the precision of the measuring equipment used. Unless otherwise indicated, "about" refers to a variation of + / - 10% of the value provided.
[0136] The term "affinity" as used herein refers to the strength of the sum of the non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (binding partner) (e.g., an antigen). Unless otherwise indicated, "binding affinity" as used herein refers to intrinsic binding affinity, which reflects a 1:1 interaction between binding pair members (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y can generally be represented by a dissociation constant (Kd). Affinity can be measured by conventional methods known in the art, including those described herein. Specific illustrative and exemplary embodiments for measuring binding affinity are described below.
[0137] The term "affinity matured" antibody as used herein refers to an antibody having one or more alterations in one or more hypervariable regions (HVRs) compared to a parent antibody that does not have such alterations, such alterations resulting in an improvement in the affinity of the antibody for the antigen. The term "amino acid" as used herein refers to any organic compound containing an amino (-NH2) and a carboxyl (-COOH) group; preferably as free groups or optionally as part of a peptide bond after condensation. The "twenty naturally encoded polypeptide-forming alpha amino acids" are understood in the art and refer to: alanine (ala or A), arginine (arg or R), asparagine (asn or N), aspartic acid (asp or D), cysteine (cys or C), glutamic acid (glu or E), glutamine (gin or Q), glycine (gly or G), histidine (his or H), isoleucine (ile or I), leucine (leu or L), lysine (lys or K), methionine (met or M), phenylalanine (phe or F), proline (pro or P), serine (ser or S), threonine (thr or T), tryptophan (tip or W), tyrosine (tyr or Y), and valine (val or V).
[0138] The term "antibody" as used herein refers to intact immunoglobulin molecules and immunoglobulin molecule fragments that are capable of binding to an epitope of an antigen, such as Fab, Fab', (Fab')2, Fv and SCA fragments. These antibody fragments can be prepared using methods well known in the art (see, for example, Harlow and Lane, supra), which retain some ability to selectively bind to the antigen (e.g., polypeptide antigen) from which the antibody is derived, as further described below. Antibodies can be used to separate prepared amounts of antigen by immunoaffinity chromatography. Various other uses of such antibodies are for diagnosing disease and / or staging disease (e.g., neoplasia) and for therapeutic applications for treating disease, such as neoplasia, autoimmune disease, AIDS, cardiovascular disease, infection, and the like. Chimeric antibodies, humanoid antibodies, humanized antibodies or fully human antibodies are particularly suitable for administration to human patients.
[0139] Fab fragments consist of a monovalent antigen-binding fragment of an antibody molecule and can be produced by digesting the whole antibody molecule with the enzyme papain to produce a fragment consisting of an intact light chain and a portion of the heavy chain.
[0140] Fab' fragments of an antibody molecule can be obtained by treating the whole antibody molecule with pepsin, followed by reduction, to produce a molecule consisting of an intact light chain and a partial heavy chain. Two Fab' fragments are obtained per antibody molecule treated in this manner.
[0141] The (Fab')2 fragment of an antibody can be obtained by treating the whole antibody molecule with the enzyme pepsin without subsequent reduction. The (Fab')2 fragment is a dimer of two Fab' fragments held together by two disulfide bonds.
[0142] An Fv fragment is defined as a genetically engineered fragment containing the light chain variable region and the heavy chain variable region expressed as two chains.
[0143] As used herein, the term "antibody fragment" refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments.
[0144] As used herein, the terms "anti-ROR2 antibody," "ROR2 antibody," and "antibody that binds to ROR2" refer to an antibody that binds to ROR2 with sufficient affinity so that the antibody can be used as a diagnostic and / or therapeutic agent targeting ROR2. In one embodiment, the extent of binding of an anti-ROR2 antibody to an unrelated, non-ROR2 protein is less than about 10% of the extent of binding of the antibody to ROR2 as measured, for example, by radioimmunoassay (RIA). In certain embodiments, the dissociation constant (Kd) of the antibody that binds to ROR2 is ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g., 10 -8 M or less, for example 10 -8 M to 10 -13 M, for example 10 -9 M to 10 -13 M). In certain embodiments, an anti-ROR2 antibody binds to a ROR2 epitope that is conserved among ROR2 of different species.
[0145] As used herein, the term "binding" refers to the interaction of the variable region or Fv of an antibody with an antigen, which depends on the presence of a specific structure (e.g., antigenic determinant or epitope) on the antigen. For example, an antibody variable region or Fv typically recognizes and binds to a specific protein structure rather than to an protein. As used herein, the term "specific binding" or "specifically binding" refers to the binding or association of an antibody variable region or Fv with a specific antigen more frequently, more rapidly, for a longer duration, and / or with greater affinity than with other proteins. For example, an antibody variable region or Fv specifically binds to its antigen with greater affinity, greater avidity, more readily, and / or for a longer duration than with other antigens. For another example, the binding affinity of an antibody variable region or Fv to a cell surface protein (antigen) is materially greater than the binding affinity of the antigen to which it is bound to a related protein or other cell surface protein or to an antigen commonly recognized by a polyreactive natural antibody (i.e., a naturally occurring antibody known to bind to a variety of antigens naturally occurring in the human body). However, "specific binding" does not necessarily require exclusive binding or undetectable binding to another antigen, which is the meaning of the term "selective binding." In one example, "specific binding" of an antibody variable region or Fv (or other binding region) to an antigen means that the equilibrium constant (KD) for binding of the antibody variable region or Fv to the antigen is 100 nM or less, such as 50 nM or less, for example 20 nM or less, such as 15 nM or less, or 10 nM or less, or 5 nM or less, 2 nM or less, or 1 nM or less.
[0146] As used herein, the terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth / proliferation. Examples of cancer include, but are not limited to, melanoma, carcinoma, lymphoma (e.g., Hodgkin's and non-Hodgkin's lymphoma), blastoma, sarcoma, and leukemia. More specific examples of such cancers include squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer (NSCLC), lung adenocarcinoma, squamous carcinoma of the lung, peritoneal cancer, hepatocellular cancer, gastrointestinal cancer, pancreatic cancer, glioma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine cancer, salivary gland cancer, kidney cancer, liver cancer, prostate cancer, vulvar cancer, thyroid cancer, hepatic carcinoma, leukemias and other lymphoproliferative diseases, fibrosarcoma, osteosarcoma, and various types of head and neck cancer.
[0147] As used herein, the terms "cell proliferative disorder" and "proliferative disorder" refer to a disease that is associated with some degree of abnormal cell proliferation. In one embodiment, the cell proliferative disorder is cancer.
[0148] As used herein, the term "chemotherapeutic agent" refers to a compound that can be used to treat cancer. Examples of chemotherapeutic agents include thiotepa and cyclosphosphamide. ) alkylating agent agents); alkyl sulfonates such as busulfan, improsulfan, and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines, including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimethylomelamine; acetogenins (especially bullatacin and bullatacinone); delta-9-tetrahydrocannabinol (dronabinol, ); beta-lapachone; lapachol; colchicines; betulinic acid; camptothecin (including the synthetic analogue topotecan, ), CPT-11 (irinotecan, ), acetylcamptothecin, scopolectin, and 9-aminocamptothecin); bryostatin; callystatin; CC-1065 (including its synthetic analogs adozelesin, carzelesin, and bizelesin); podophyllotoxin; podophyllinic acid; teniposide; cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin (d olastatin; duocarmycin (including synthetic analogs KW-2189 and CB1-TM1); eleutherobin; pancratistatin; sarcodictyin; spongistatin; such as chlorambucil, chlornaphazine, chlorophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine hydrochloride, Nitrogen mustards such as phenesterine, prednimustine, trofosfamide, and uracil mustard; nitrosoureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; and enediyne antibiotics (e.g., calicheamicin, in particular calicheamicin gamma 1I and calicheamicin omega 1I) (see, for example, Nicolaou et al., Angew. Chem. Intl. Ed. Engl., 33:183-186 (1994)); CDP323, an oral α-4 integrin inhibitor; dynemicins, including dynemicin A ( A; esperamicin; and neocarzinostatin chromophores and related chromoprotein enediyne antibiotic chromophores), aclacinomycins, actinomycin, authramycin, azaserine, bleomycin, cactinomycin, carabicin, caminomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including Morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, doxorubicin HCl liposome injection Liposomal doxorubicin TLCD-99 PEGylated liposomal doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; such as methotrexate and gemcitabine Tegafur Capecitabine Anti-metabolites of epothilone and 5-fluorouracil (5-FU); folic acid analogs such as denopterin, methotrexate, pteropterin, and trimetrexate; purines such as fludarabine, 6-mercaptopurine, thiamiprine, and thioguanine Analogs; such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, pyrimidine analogs of floxuridine; such as calusterone, dromostanolone propionate, androgens such as propionate, epitiostanol, mepitiostane, and testolactone; anti-adrenals such as aminoglutethimide, mitotane, and trilostane; folic acid supplements such as folinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; and acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformithine; elliptinium acetate; epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine;maytansinoids such as maytansine and ansamitocin; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; 2-ethylhydrazide; and procarbazine. Polysaccharide complex (JHS Natural Products, Eugene, Oregon); razoxane; rhizoxin; sizofuran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2'-trichlorotriethylamine; trichothecenes (particularly T-2 toxin, verracurin A, roridin A, and anguidine); urethan; vindesine Dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); thiotepa; taxane compounds such as paclitaxel Albumin-engineered paclitaxel nanoparticle formulation (ABRAXANE TM ) and docetaxel taxoid; chloranbucil; 6-thioguanine; mercaptopurine; methotrexate; cisplatin, oxaliplatin (e.g. Platinum agents such as vinblastine and carboplatin; vincas, which prevent tubulin from polymerizing to form microtubules; vincristine Vindesine and vinorelbine Etoposide (VP-16); ifosfamide; mitoxantrone; leucovorin; novantrone; edatrexate; daunomycin; aminopterin; ibandronate; the topoisomerase inhibitor RFS2000; difluoromethylornithine Retinoids such as retinoic acid, including bexarotene Such as clodronate (e.g. or ), etidronate NE-58095, zoledronic acid / zoledronate alendronate Pamidronate tiludronate or risedronate Bisphosphonates of troxacitabine (a 1,3-dioxolane nucleoside cytosine analog); antisense oligonucleotides, particularly those that inhibit the expression of genes in signaling pathways involved in abnormal cell proliferation, such as, for example, PKC-α, Raf, H-Ras, and epidermal growth factor receptor (EGF-R); vaccines, and vaccine, Vaccines and Gene therapy vaccines; topoisomerase 1 inhibitors (e.g. );rmRH (e.g. ); BAY439006 (sorafenib; Bayer); SU-11248 (sunitinib, Pfizer); perifosine, COX-2 inhibitors (such as celecoxib or etoricoxib), proteosome inhibitors (such as PS341); bortezomib CCI-779; tipifarnib (R11577); sorafenib, ABT510; such as oblimersen sodium Bcl-2 inhibitors; pixantrone; EGFR inhibitors (see below for definition); tyrosine kinase inhibitors (see below for definition); such as rapamycin (sirolimus, ) serine-threonine kinase inhibitors; such as lonafarnib (SCH 6636, SARASAR TM ) farnesyltransferase inhibitors; and pharmaceutically acceptable salts, acids or derivatives of any of the above drugs; and combinations of two or more of the above drugs, such as CHOP, which is an abbreviation for combination therapy of cyclophosphamide, doxorubicin, vincristine and prednisolone; and FOLFOX, which is an abbreviation for oxaliplatin (ELOXATIN TM ) with 5-FU and leucovorin.
[0149] Chemotherapeutic agents as defined herein include "antihormonal agents" or "endocrine therapeutic agents" which are used to modulate, reduce, block or inhibit the effects of hormones that promote cancer growth. They can themselves be hormones and include, but are not limited to, antiestrogens with mixed agonist / antagonist profiles, including tamoxifen. 4-hydroxytamoxifen, toremifene Idoxifene, droloxifene, raloxifene Trioxifene, keoxifene, and selective estrogen receptor modulators (SERMs) such as SERM3; pure antiestrogens without agonist properties, such as fulvestrant and EM800 (agents that block estrogen receptor (ER) dimerization, inhibit DNA binding, increase ER turnover, and / or suppress ER levels); aromatase inhibitors, including formestane and exemestane Steroidal aromatase inhibitors such as anastrozole Letrozole Nonsteroidal aromatase inhibitors such as glutathione and aminoglutethimide, as well as other aromatase inhibitors including vorozole megestrolacetate fadrozole and 4(5)-imidazoles; lutenizing hormone-releasing hormone agonists, including leuprolide ( and ), goserelin, buserelin, and tripterelin; sex steroids, including progestines such as megestrol acetate and medroxyprogesterone acetate, estrogens such as diethylstilbestrol and premarin, and estrogens such as fluoxymesterone, all-trans retinoic acid, and acetaminophen. androgens / retinoids such as fenretinide and fenretinide; onapristone; anti-progesterones; estrogen receptor downregulators (ERDs); anti-androgens such as flutamide, nilutamide, and bicalutamide; and pharmaceutically acceptable salts, acids, or derivatives of any of the foregoing drugs; and combinations of two or more of the foregoing drugs.
[0150] As used herein, the term "chimeric" antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.
[0151] As used herein, the term "class" of an antibody refers to the type of constant domain or region possessed by its heavy chain. There are five main classes of antibodies: IgA, IgD, IgE, IgG, and IgM, several of which are further divided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains corresponding to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.
[0152] The term "conditionally active antibody" as used herein refers to an antibody that is more active under conditions in a tumor microenvironment than under conditions in a non-tumor microenvironment. Conditions in the tumor microenvironment include a lower pH, higher concentrations of lactate and pyruvate, hypoxia, lower concentrations of glucose, and slightly higher temperatures than those in the non-tumor microenvironment. For example, a conditionally active antibody is actually inactive at normal body temperature, but is active at higher temperatures in the tumor microenvironment. In another aspect, the conditionally active antibody has lower activity in normal oxygenated blood, but is more active in the hypoxic environment present in the tumor. In another aspect, the conditionally active antibody has lower activity at normal physiological pH 7.2 to 7.8, but is more active at the acidic pH 5.8 to 7.0 or 6.0 to 6.8 present in the tumor microenvironment. Other conditions known to those skilled in the art that exist in the tumor microenvironment can also be used as conditions in the present invention, under which the anti-ROR2 antibody has different binding affinities for ROR2.
[0153] The term "constitutive" as used herein, for example when applied to ROR2 activity, refers to the continuous signaling activity of the receptor kinase, which is independent of the presence of a ligand or other activating molecules. Depending on the properties of the receptor kinase, all activities may be constitutive, or the activity of the receptor may be further activated by binding to other molecules (e.g., ligands). Cellular events that lead to activation of receptor kinases are well known to those of ordinary skill in the art. For example, activation may include oligomerization, such as dimerization, trimerization, etc., to form a higher order receptor complex. The complex may comprise a single species of protein, i.e., a homologous complex. Alternatively, the complex may comprise at least two different species of proteins, i.e., a heterologous complex. The formation of the complex may be caused, for example, by overexpression of normal or mutant forms of the receptor on the cell surface. The formation of the complex may also be caused by one or more specific mutations in the receptor.
[0154] As used herein, the term "cytostatic agent" refers to a compound or composition that inhibits cell growth in vitro or in vivo. Thus, a cytostatic agent may be an agent that significantly reduces the percentage of cells in the S phase. Further examples of cytostatic agents include agents that block cell cycle progression by inducing G0 / G1 arrest or M phase arrest. Humanized anti-Her2 antibody trastuzumab is an example of a cytostatic that induces G0 / G1 arrest. Classic M-phase arresters include the vinca class (vincristine and vinblastine), taxanes, and topoisomerase II inhibitors such as doxorubicin, epirubicin, daunomycin, etoposide, and bleomycin. Some agents that arrest G1 can also spill over to cause S-phase arrest, such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and DNA alkylating agents such as ara-C. For more information, see Mendelsohn and Israel, eds., The Molecular Basis of Cancer, Chapter 1, entitled “Cell cycle regulation, oncogenes, and antineoplastic drugs” by Murakami et al. (WB Saunders, Philadelphia, 1995), e.g., page 13. Taxanes (paclitaxel and docetaxel) are anticancer drugs derived from the yew tree. Docetaxel ( Rhone-Poulenc Rorer) is derived from the European yew tree and is a A semisynthetic analog of paclitaxel (Bristol-Myers Squibb). Paclitaxel and docetaxel promote microtubule assembly of tubulin dimers and stabilize microtubules by preventing depolymerization, which leads to the inhibition of mitosis in cells.
[0155] As used herein, the term "cytotoxic agent" refers to a substance that inhibits or prevents cell function and / or causes cell death or destruction. Cytotoxic agents include, but are not limited to, radioactive isotopes (e.g., At 211 , I 131 , I 125 、Y 90 、Re 186 、Re 188 、Sm 153 、Bi 212 、P 32 , Pb 212and radioisotopes of Lu); chemotherapeutic agents or drugs (e.g., methotrexate, adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunomycin or other intercalating agents); growth inhibitors; enzymes such as nucleolytic enzymes and fragments thereof; antibiotics; toxins, such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and / or variants thereof; and various anti-tumor or anti-cancer agents disclosed below.
[0156] As used herein, the term "diabodies" refers to small antibody fragments with two antigen-binding sites, which are bound to the same polypeptide chain (V H -V L ) in the light chain variable domain (V L ) linked to the heavy chain variable domain (V H By using a linker that is too short to allow pairing between the two domains on the same chain, the two domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites.
[0157] As used herein, the term "detectably label" refers to any substance that can indicate the presence of CTCs in a sample by direct or indirect detection or measurement by physical or chemical methods. Representative examples of useful detectable labels include, but are not limited to, the following: molecules or ions that are directly or indirectly detectable based on absorbance, fluorescence, reflectance, light scattering, phosphorescence, or luminescence; molecules or ions that are detectable by their radioactive properties; molecules or ions that are detectable by their nuclear magnetic resonance or paramagnetic properties. The group of molecules that are indirectly detectable based on absorbance or fluorescence includes, for example, various enzymes that can cause the conversion of an appropriate substrate, such as from a non-light-absorbing molecule to a light-absorbing molecule or from a non-fluorescent molecule to a fluorescent molecule.
[0158] As used herein, the term "diagnostics" refers to determining an individual's susceptibility to a disease or condition, determining whether an individual is currently affected by a disease or condition, prognosis of an individual affected by a disease or condition (e.g., identifying a pre-metastatic or metastatic cancerous state, a cancer stage, or a cancer's responsiveness to treatment), and therapeutic evaluation (therametrics) (e.g., monitoring an individual's condition to provide information about the effectiveness or efficacy of a treatment). In some embodiments, the diagnostic methods of the present invention are particularly suitable for detecting early-stage cancer.
[0159] As used herein, the term "diagnostic agent" refers to a molecule that can be detected directly or indirectly and used for diagnostic purposes. The diagnostic agent can be administered to an individual or sample. The diagnostic agent can be provided alone or can be conjugated to a carrier such as a conditionally active antibody.
[0160] As used herein, the term "effector function" refers to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement-dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; downregulation of cell surface receptors (e.g., B cell receptors); and B cell activation.
[0161] As used herein, the term "effective amount" of a pharmaceutical agent, such as a pharmaceutical formulation, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.
[0162] As used herein, the term "Fc region" is used to define the C-terminal region of an immunoglobulin heavy chain, which comprises at least a portion of a constant region. The term includes native sequence Fc regions and variant Fc regions. In one embodiment, the human IgG heavy chain Fc region extends from Cys226 or from Pro230 to the carboxyl terminus of the heavy chain. However, the C-terminal lysine (Lys447) in the Fc region may be present or absent. Unless otherwise indicated herein, the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also referred to as the EU index (EU index), as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991.
[0163] As used herein, the term "framework" or "FR" refers to the variable domain residues excluding the hypervariable region (HVR or H1 to H3 in the heavy chain and L1 to L3 in the light chain) residues. The FR of the variable domain is generally composed of four FR domains: FR1, FR2, FR3 and FR4. Thus, HVR and FR sequences are generally arranged in V H (or V L ) appear in the following order: FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.
[0164] The term "full length antibody", "intact antibody" or "whole antibody" refers to an antibody comprising an antigen-binding variable region (V H or V L ) and light chain constant domains (CL) and heavy chain constant domains CH1, CH2 and CH3. The constant domains can be native sequence constant domains (e.g., human native sequence constant domains) or amino acid sequence variants thereof. Full-length antibodies can be classified into different "classes" based on the amino acid sequence of their heavy chain constant domains. There are five main classes of full-length antibodies: IgA, IgD, IgE, IgG and IgM, several of which can be further divided into "subclasses" (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA and IgA2. The heavy chain constant domains corresponding to different classes of antibodies are called α, δ, ε, γ and μ, respectively. The subunit structure and three-dimensional configuration (configuration) of different classes of immunoglobulins are well known.
[0165] As used herein, the terms "host cell," "host cell line," and "host cell culture" are used interchangeably to refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," which include the primary transformed cell and progeny derived therefrom, regardless of the number of passages. The nucleic acid content of progeny cells may not be identical to that of the parent cell, but may contain mutations. Mutant progeny having the same function or biological activity as that screened or selected for in the primary transformed cell are included herein.
[0166] As used herein, the term "human antibody" refers to an antibody having an amino acid sequence corresponding to an antibody produced by a human or human cell, or an antibody derived from a non-human source utilizing a human antibody library or other human antibody coding sequences. This definition of a human antibody specifically excludes humanized antibodies comprising non-human antigen-binding residues.
[0167] The term "human consensus framework" as used herein refers to human immunoglobulin V L or V H The framework sequence is selected from the most frequently occurring amino acid residues. L or V HThe selection of sequences is derived from a subset of variable domain sequences. Typically, the subset of sequences is a subset as described in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda Md. (1991), vols. 1-3. In one embodiment, for V L , subgroup is subgroup κI as described by Kabat et al. (supra). In one embodiment, for V H , subgroup is subgroup III as described by Kabat et al. (supra).
[0168] The term "humanized" antibody as used herein refers to a chimeric antibody comprising amino acid residues derived from non-human HVRs and amino acid residues derived from human FRs. In certain embodiments, a humanized antibody will substantially comprise all of at least one domain (typically two variable domains), wherein all or substantially all of the HVRs (e.g., CDRs) correspond to the HVRs of non-human antibodies, and all or substantially all of the FRs correspond to the FRs of human antibodies. A humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody, such as a non-human antibody, refers to an antibody that has undergone humanization.
[0169] As used herein, the term "hypervariable region" or "HVR" refers to each region of an antibody variable domain that is hypervariable in sequence and / or forms structurally defined loops ("hypervariable loops"). Typically, a natural four-chain antibody comprises six HVRs: V H Three (H1, H2, H3) and V LThe HVRs are comprised of three (L1, L2, and L3). HVRs typically comprise amino acid residues derived from hypervariable loops and / or "complementarity determining regions" (CDRs), the latter of which have the highest sequence variability and / or are involved in antigen recognition. Exemplary hypervariable loops occur at amino acid residues 26 to 32 (L1), 50 to 52 (L2), 91 to 96 (L3), 26 to 32 (H1), 53 to 55 (H2), and 96 to 101 (H3) (Chothia and Lesk, J. Mol. Biol., vol. 196, pp. 901-917 1987). Exemplary CDRs (CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3) occur at amino acid residues 24 to 34 of L1, 50 to 56 of L2, 89 to 97 of L3, 31 to 35B of H1, 50 to 65 of H2, and 95 to 102 of H3 (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. 1991). H In addition to the CDR1 in the CDR, the CDR generally includes amino acid residues that form hypervariable loops. CDRs also include "specificity determining residues" or "SDRs," which are residues that contact the antigen. SDRs are contained within CDR regions known as abbreviated-CDRs or a-CDRs. Exemplary a-CDRs (a-CDR-L1, a-CDR-L2, a-CDR-L3, a-CDR-H1, a-CDR-H2, and a-CDR-H3) occur at amino acid residues 31 to 34 of L1, 50 to 55 of L2, 89 to 96 of L3, 31 to 35B of H1, 50 to 58 of H2, and 95 to 102 of H3 (see Almagro and Fransson, Front. Biosci., vol. 13, pp. 1619-1633, 2008). Unless otherwise indicated, HVR residues and other residues in the variable domain (eg, FR residues) are numbered herein according to Kabat et al., supra.
[0170] As used herein, the term "immunoconjugate" is an antibody conjugated to one or more heterologous molecules, including but not limited to a cytotoxic agent.
[0171] As used herein, the term "individual" or "subject" refers to a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is a human.
[0172] As used herein, the term "inhibit cell growth or proliferation" refers to a decrease in cell growth or proliferation by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 100%, including induction of cell death.
[0173] As used herein, the term "isolated" antibody refers to an antibody that has been separated from the components of its natural environment. In some embodiments, the antibody is purified to a purity greater than 95% or 99%, as determined by, for example, electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reversed-phase high performance liquid chromatography (HPLC)). For a review of methods for evaluating antibody purity, see, for example, Flatman et al., J. Chromatogr. B, vol. 848, pp. 79-87, 2007.
[0174] As used herein, the term "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that normally contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.
[0175] As used herein, the term "isolated nucleic acid encoding an anti-ROR2 antibody" refers to more than one nucleic acid molecule encoding the antibody heavy and light chains (or fragments thereof), including such nucleic acid molecules in a single vector or separate vectors, and such nucleic acid molecules present in more than one location in a host cell.
[0176] As used herein, the term "ligand-independent," for example, when applied to receptor signaling activity, refers to signaling activity that is independent of the presence of a ligand. A receptor with ligand-independent kinase activity does not necessarily prevent ligand binding to the receptor to further activate kinase activity.
[0177] The term "metastasis" as used herein refers to all processes involving ROR2 that support the spread of cancer cells from primary tumors, infiltration into lymphatic vessels and / or blood vessels, circulation through the bloodstream, and growth (metastasis) in distant lesions of normal tissues elsewhere in the body. Specifically, it refers to cellular events (e.g., proliferation, migration, anchorage independence, escape of apoptosis, or secretion of angiogenic factors) of tumor cells that constitute the basis of metastasis and are stimulated or mediated by the non-catalytic or catalytic activity of ROR2, preferably including ROR2 phosphorylation and / or ROR2-mediated signal transduction.
[0178] The term "microenvironment" as used herein refers to any part or region of a tissue or body that has constant or temporary physical or chemical differences compared to other tissue regions or body regions. For tumors, the term "tumor microenvironment" as used herein refers to the environment in which the tumor exists, which is the non-cellular area within the tumor and the intracellular compartment (intracellular compartment) directly outside the tumor tissue but not belonging to the cancer cells themselves. Tumors are closely associated with and constantly interact with the tumor microenvironment. Tumors can change their microenvironment, which can affect the growth and spread of tumors. Typically, the pH of the tumor microenvironment is low, ranging from 5.8 to 7.0, more commonly ranging from 6.0 to 6.8, and in the range of 6.2 to 6.8. On the other hand, normal physiological pH is in the range of 7.2 to 7.8. It is also known that the tumor microenvironment has lower concentrations of glucose and other nutrients than plasma, but higher concentrations of lactate. In addition, the temperature of the tumor microenvironment can be 0.3°C to 1°C higher than the normal physiological temperature. The tumor microenvironment is discussed in Gillies et al., “MRI of the Tumor Microenvironment,” Journal of Magnetic Resonance Imaging, vol. 16, pp. 430-450, 2002, which is incorporated herein by reference in its entirety. The term “non-tumor microenvironment” refers to the microenvironment of sites other than the tumor.
[0179] The term "monoclonal antibody" as used herein refers to an antibody obtained from a group of substantially homologous antibodies, i.e., except for example, possible variant antibodies (such variants are generally present in small amounts) containing naturally occurring mutations or produced during the production of monoclonal antibody preparations, the single antibodies constituting the group are identical and / or in conjunction with the same epi-position. Unlike the polyclonal antibody preparations that generally comprise different antibodies for different determinants (epi-topes), each monoclonal antibody in a monoclonal antibody preparation is directed to a single determinant on the antigen. Therefore, the modifier "monoclonal" represents that the characteristic of an antibody is obtained from a group of substantially homologous antibodies, and should not be construed as requiring antibody production by any ad hoc method. For example, the monoclonal antibody used according to the present invention can be prepared by various techniques, including but not limited to hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of human immunoglobulin loci, and such methods and other exemplary methods for preparing monoclonal antibodies are described herein.
[0180] As used herein, the term "naked antibody" refers to an antibody that is not conjugated to a heterologous moiety (eg, a cytotoxic moiety) or a radiolabel. Naked antibodies can be present in pharmaceutical formulations.
[0181] As used herein, the term "natural antibody" refers to naturally occurring immunoglobulin molecules of varying structures. For example, natural IgG antibodies are heterotetrameric glycoproteins of approximately 150,000 daltons, consisting of two identical light chains and two identical heavy chains linked by disulfide bonds. From N-terminus to C-terminus, each heavy chain has a variable region (V H ), also called the variable heavy chain domain or heavy chain variable domain, followed by three constant domains (CH1, CH2 and CH3). Similarly, from N-terminus to C-terminus, each light chain has a variable region (V L ), also called the variable light domain or light chain variable domain, followed by the constant light (CL) domain. The light chains of antibodies can be classified into one of two types, called kappa and lambda, based on the amino acid sequence of their constant domains.
[0182] As used herein, the term "package insert" refers to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and / or warnings concerning the use of such therapeutic products.
[0183] As used herein, the term "percent (%) amino acid sequence identity" relative to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in a reference polypeptide sequence, after aligning the sequences and, if necessary, introducing gaps to achieve maximum sequence identity and not considering any conservative substitutions as part of the sequence identity. Alignment for determining percentage amino acid sequence identity can be accomplished in various ways within the skill of the art, such as using publicly available computer software such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. One skilled in the art can determine appropriate parameters for aligning sequences, including any algorithm required to achieve maximum alignment over the full length of the compared sequences. However, for the purposes of this article, the sequence comparison computer program ALIGN-2 is used to generate % amino acid sequence identity values. The ALIGN-2 sequence comparison computer program was written by Genentech, Inc., and its source code has been submitted to the U.S. Copyright Office at Washington, D.C., 20559, along with user documentation, under the U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc. in South San Francisco, California, or can be compiled from source code. The ALIGN-2 program should be compiled for UNIX operating systems including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
[0184] When ALIGN-2 is used for amino acid sequence comparison, the % amino acid sequence identity of a given amino acid sequence A to, with, or relative to a given amino acid sequence B (which can also be alternatively expressed as a given amino acid sequence A having or comprising a specific % amino acid sequence identity to, with, or relative to a given amino acid sequence B) is calculated as follows:
[0185] 100×(X / Y)
[0186] where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be understood that when the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless expressly stated otherwise, all % amino acid sequence identity values used herein are obtained using the ALIGN-2 computer program as described in the preceding paragraph.
[0187] As used herein, the term "pharmaceutical formulation" refers to a preparation in such form as to permit the biological activity of the active ingredient contained therein to be effective, without containing additional ingredients that are unacceptably toxic to a subject to which the formulation would be administered.
[0188] The term "pharmaceutically acceptable carrier" as used herein refers to a component of a pharmaceutical preparation other than the active ingredient that is non-toxic to an individual. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.
[0189] As used herein, the terms "purified" and "isolated" refer to antibodies or nucleotide sequences according to the present invention, wherein the indicated molecule is present in the substantial absence of other biomacromolecules of the same type. As used herein, the term "purified" preferably refers to the presence of at least 75% by weight, more preferably at least 85% by weight, still more preferably at least 95% by weight, and most preferably at least 98% by weight of biomacromolecules of the same type. An "isolated" nucleic acid molecule encoding a particular polypeptide refers to a nucleic acid molecule that is substantially free of other nucleic acid molecules that do not encode the polypeptide; however, the molecule may include some additional bases or moieties that do not adversely affect the essential characteristics of the composition.
[0190] As used herein, the term "recombinant antibody" refers to an antibody (eg, a chimeric, humanized, or human antibody or antigen-binding fragment thereof) expressed by a recombinant host cell comprising nucleic acid encoding the antibody. Examples of "host cells" for producing recombinant antibodies include: (1) mammalian cells, such as Chinese hamster ovary cells (CHO), COS, myeloma cells (including Y0 and NS0 cells), baby hamster kidney cells (BHK), Hela cells and Vero cells; (2) insect cells, such as sf9, sf21 and Tn5; (3) plant cells, such as plants belonging to the genus Nicotiana (e.g., Nicotiana tabacum); (4) yeast cells, such as those belonging to the genus Saccharomyces (e.g., Saccharomyces cerevisiae) or Aspergillus (e.g., Aspergillus niger); (5) bacterial cells, such as Escherichia coli cells or Bacillus subtilis cells, etc.
[0191] As used herein, the term "ROR2" refers to receptor tyrosine kinase-like orphan receptor 2, a 943 amino acid protein predicted to have in vitro protein kinase activity, with Genbank accession number AAI30523. Many lineage-restricted receptor tyrosine kinases were initially identified as "orphans" homologous to known receptors and subsequently used only to identify their unknown growth factors. DeChiara et al. (2000) identified a receptor tyrosine kinase that is expressed by, for example, Figure 1 ROR2 is shown to encode such an orphan protein.
[0192] The term "therapeutically effective amount" of an antibody of the present invention refers to a sufficient amount of the antibody to treat the cancer at a reasonable benefit / risk ratio applicable to any medical treatment. However, it should be understood that the total daily dosage of the antibodies and compositions of the present invention will be determined by the attending physician within the scope of reasonable medical judgment. For any particular patient, the specific therapeutically effective dosage level will depend on a variety of factors, including the disease being treated and the severity of the disease; the activity of the specific antibody used; the specific composition used, the patient's age, weight, general health, sex and diet; the administration time, route of administration and excretion rate of the specific antibody used; the duration of treatment; drugs used in combination with or concurrently with the specific antibody used; and similar factors well known in the medical field. For example, it is well known to those skilled in the art that the initial dosage level of the compound should be lower than the dosage level required to achieve the desired therapeutic effect, and the dosage should be gradually increased until the desired effect is achieved.
[0193] As used herein, the term "single-chain Fv" ("scFv") is a covalently linked V H ::V L Heterodimers, which are typically composed of V and V connected by a linker encoding a peptide H and V L "dsFv" is a V stabilized by disulfide bonds. H ::V L Heterodimers. Divalent and multivalent antibody fragments can be formed spontaneously by the association of monovalent scFvs or can be produced by coupling monovalent scFvs by a peptide linker, e.g., a bivalent sc(Fv)2.
[0194] As used herein, the terms "treatment," "treat," or "treating" refer to clinical interventions that attempt to alter the natural course of a disease in a treated individual and can be performed prophylactically or during clinical pathology. Desirable effects of treatment include, but are not limited to, preventing the onset or recurrence of the disease, alleviation of symptoms, reduction in any direct or indirect pathological consequences of the disease, prevention of metastasis, reduction in the rate of disease progression, amelioration or alleviation of the disease state, and remission or improved prognosis. In some embodiments, the antibodies of the invention are used to delay the development of the disease or slow the progression of the disease.
[0195] As used herein, the term "tumor" refers to the growth and proliferation of all neoplastic cells, whether malignant or benign, and all precancerous and cancerous cells and tissues. The terms "cancer," "cancerous," "cell proliferative disease," "proliferative disease," and "tumor" as used herein are not mutually exclusive.
[0196] The term "variable region" or "variable domain" as used herein refers to the domain of an antibody heavy chain or light chain that is involved in binding the antibody to the antigen. H and V L ) generally have a similar structure, each domain comprising four conserved framework regions (FR) and three hypervariable regions (HVR) (see, for example, Kindt et al. Kuby Immunology, 6th ed., WH Freeman and Co., page 91 (2007). A single V H or V L The V domain may be sufficient to confer antigen binding specificity. In addition, V domains from antibodies that bind to a specific antigen may be used. H or V L domains to screen for complementary V L or V H A library of protein domains is prepared and antibodies that bind to the antigen are isolated (see, for example, Portolano et al., J. Immunol., vol. 150, pp. 880-887, 1993; Clarkson et al., Nature, vol. 352, pp. 624-628, 1991).
[0197] As used herein, the term "vector" refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes vectors that are self-replicating nucleic acid structures as well as vectors that are incorporated into the genome of a host cell into which they are introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operably linked. Such vectors are referred to herein as "expression vectors." DETAILED DESCRIPTION
[0199] For the purpose of illustration, the principles of the present invention are described with reference to various exemplary embodiments. Although certain embodiments of the present invention are described in detail herein, it should be readily apparent to those skilled in the art that the same principles apply equally to and can be used in other systems and methods. Before the embodiments disclosed herein are explained in detail, it should be understood that the present invention is not limited to the details of any particular embodiment shown. In addition, the terms used herein are for descriptive purposes only and not for limiting purposes. In addition, although certain methods are described with reference to the steps presented herein in a particular order, in many cases, these steps can be performed in any order that can be understood by those skilled in the art; therefore, the new methods are not limited to the specific arrangement of the steps disclosed herein.
[0200] It must be noted that, as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Furthermore, the terms "a" (or "an"), "more than one," and "at least one" are used interchangeably herein. The terms "comprising," "including," "having," and "consisting of" are also used interchangeably.
[0201] Unless otherwise indicated, all numerals representing the amount of a component, the characteristics such as molecular weight, percentage, ratio, reaction conditions, etc. used in the specification and claims should be understood to be modified by the term "about" in all cases, whether or not the term "about" exists. Thus, unless otherwise indicated, the numerical parameters listed in the specification and claims are approximate values, which can vary according to the desired characteristics sought to be obtained by the present invention. At least, it is not intended to limit the application of the doctrine of equivalents to the scope of the claims, and each numerical parameter should at least be interpreted according to the number of reported significant figures and by applying common rounding techniques. Although the numerical ranges and parameters setting forth the wide range of the present invention are approximate values, the numerical values listed are reported as accurately as possible in the specific examples. However, any numerical value inherently contains the inevitable errors caused by the standard deviations present in the respective test measurements.
[0202] It should be understood that each component, compound, substituent or parameter disclosed herein should be interpreted as disclosed for use alone or in combination with one or more of each other component, compound, substituent or parameter disclosed herein.
[0203] It should also be understood that the various amounts / values or amount / value ranges of each component, compound, substituent or parameter disclosed herein should be interpreted as also being disclosed in combination with the various amounts / values or amount / value ranges of any other component, compound, substituent or parameter disclosed herein, and thus, any combination of amounts / values or amount / value ranges of two or more components, compounds, substituents or parameters disclosed herein is also disclosed in combination with each other for purposes of this specification.
[0204] It should also be understood that each lower limit of each range disclosed herein should be interpreted as disclosed in combination with each upper limit of each range of the same component, compound, substituent or parameter disclosed herein. Therefore, the disclosure of two ranges should be interpreted as the disclosure of four ranges obtained by combining each lower limit of each range with each upper limit of each range. The disclosure of three ranges should be interpreted as the disclosure of nine ranges obtained by combining each lower limit of each range with each upper limit of each range, and so on. In addition, the specific amount / value of the component, compound, substituent or parameter disclosed in the specification or examples should be interpreted as the disclosure of the lower limit or upper limit of the range, and therefore can be combined with any other lower limit or upper limit of the range or specific amount / value of the same component, compound, substituent or parameter disclosed elsewhere in the application to form the scope of the component, compound, substituent or parameter.
[0205] A. Anti-ROR2 Antibody
[0206] In one aspect, the present invention provides an isolated polypeptide that specifically binds to human ROR2 protein, and the use of the polypeptide in a method of treating a tumor expressing ROR2, the method involving administering the polypeptide to a human in need of such treatment.
[0207] The polypeptide comprises a heavy chain variable region having three complementarity determining regions: an H1 sequence, an H2 sequence, and an H3 sequence, wherein:
[0208] The H1 sequence is GYTX1TEX2X3X4H (SEQ ID NO: 1) or GYSITTGX 29 YWN (SEQ ID NO: 4);
[0209] H2 sequence is X5X6X7X8NNGGTGYNQKFKG (SEQ ID NO: 2) or YITYDGSX 30 NYNPSLKN (SEQ ID NO: 5); and
[0210] H3 sequence is X9X 10 X 11 SX 12 YX 13 YX 14 X 15 SYFX 16 X 17 X 18 (SEQ ID NO: 3) or CSX 31 X 32 X 33 X 34 VX 35 X 36 X 37 LDX 38 (SEQ ID NO: 6);
[0211] in
[0212] X1 is F or E,
[0213] X2 is Y or D,
[0214] X3 is T or C,
[0215] X4 is M or D or E or Y,
[0216] X5 is G or S,
[0217] X6 is I or E,
[0218] X7 is N or C or L or V,
[0219] X8 is T or D or E,
[0220] X9 is A or M or T,
[0221] X 10 is R or H,
[0222] X 11 It's G or E,
[0223] X 12 It is L or F,
[0224] X 13 It is S or G,
[0225] X 14 It's G or D,
[0226] X 15 is N or E,
[0227] X 16 It is D or L,
[0228] X 17 It's Y or C or T,
[0229] X 18 It is W or L,
[0230] X 29 It is Y or E or R or T,
[0231] X 30 is K or N,
[0232] X 31 It is R or G or H or W or Y,
[0233] X 32 It's F or C or N or Q,
[0234] X 33 It is E or S,
[0235] X 34 It's G or E or F or H or M or Q or S,
[0236] X 35 It is W or A or I or P or Q or T or V,
[0237] X 36 It's Y or G or N or Q,
[0238] X 37 is G or S or T, and
[0239] X 38 is Y or I; and
[0240] A light chain variable region having three complementarity determining regions: L1, L2, and L3, wherein:
[0241] L1 sequence is SATSSX 19 X 20 X 21 MX 22 (SEQ ID NO: 7) or RASESVDRYGNSX 39 IH (SEQ ID NO: 10);
[0242] The L2 sequence is X 23 TSNLAS (SEQ ID NO: 8) or X 40 TYX 41 LES (SEQ ID NO: 11); and
[0243] L3 sequence is QX 24 X 25 SX 26 YPFX 27 X 28 (SEQ ID NO: 9) or QQX 42 NX 43DPX 44 TX 45 (SEQ ID NO: 12);
[0244] in
[0245] X 19 is V or E,
[0246] X20 is S or D,
[0247] X 21 It's Y or C or D,
[0248] X 22 It's H or G or L,
[0249] X 23 It's G or C or H or P,
[0250] X 24 It's Q or E,
[0251] X 25 is R or H,
[0252] X 26 It's S or D or G or I or Q or V,
[0253] X 27 is T or D,
[0254] X 28 It's F or D or E,
[0255] X 39 It's F or S or T,
[0256] X 40 It is R or C or D or E or W,
[0257] X 41 is N or D,
[0258] X 42 It is T or I or P,
[0259] X 43 is E or V,
[0260] X 44 is W or T, and
[0261] X 45 It is F or T,
[0262] The condition is X1 to X 28 It cannot be F, Y, T, M, G, I, N, T, A, R, G, L, S, G, N, D, Y, W, V, S, Y, H, G, Q, R, S, T and F at the same time to exclude parent antibodies with unconditional activity.
[0263] Figure 2A-1 、 Figure 2A-2 、 Figure 2B-1 and Figure 2B-2 Alignment of the heavy chain variable regions is shown.
[0264] Figure 3A-1 、 Figure 3A-2 、 Figure 3B-1 and Figure 3B-2 An alignment of the light chain variable regions is shown.
[0265] In another aspect, the invention provides an isolated polypeptide as described above, which has at most one substitution in CDR H1, H2 and H3 relative to a parent polypeptide, and at most one substitution in CDR L1, L2 and L3 relative to a parent polypeptide. This includes (1) an isolated polypeptide having one substitution in CDR H1, H2 and H3 relative to a parent polypeptide, (2) an isolated polypeptide having one substitution in CDR L1, L2 and L3 relative to a parent polypeptide, and (3) an isolated polypeptide having one substitution in CDR H1, H2 and H3 and one substitution in CDR L1, L2 and L3 relative to a parent polypeptide.
[0266] Possible single point mutations in CDRs H1, H2, and H3 are Figure 2A-1 and Figure 2A-2 As shown, possible single point mutations in CDR L1, L2 and L3 are as follows Figure 3A-1 and Figure 3A-2 Other possible single point mutations in CDR H1, H2 and H3 are as follows. Figure 2B-1 and Figure 2B-2 As shown, other possible single point mutations in CDR L1, L2 and L3 are as follows Figure 3B-1 and Figure 3B-2 shown.
[0267] In another aspect, each heavy chain variable region polypeptide and each light chain variable region polypeptide can each have 0, 1, 2, 3, 4 or 5 independently selected substitutions in a CDR, each selected from Figure 2B-1 to Figure 2B-2 and Figure 2A-1 to Figure 2A-2 The point mutations shown in , as long as at least one of the heavy chain variable region polypeptide and the light chain variable region polypeptide has at least one point mutation relative to the parent polypeptide. For example, the heavy chain variable region polypeptide may have three point mutations relative to the parent polypeptide, and the light chain variable region polypeptide may have five point mutations relative to the parent polypeptide.
[0268] The present invention identifies these heavy chain variable regions and light chain variable regions from the heavy chain variable regions and light chain variable regions of parent antibodies, respectively, by the method disclosed in U.S. Patent No. 870975. This method for generating conditionally active antibodies is incorporated herein by reference.
[0269] Comprehensive Positional Evolution (CPE) was used to evolve the DNA encoding the heavy chain variable region and light chain variable region of the parent antibody to generate a mutant antibody library, wherein each position in the heavy chain variable region and light chain variable region of the parent antibody was randomized one by one. Each mutant heavy chain / light chain in the library has only one single point mutation compared to the heavy chain variable region or light chain variable region of the parent antibody ( Figure 2A-1 、 Figure 2A-2 、 Figure 2B-1 、 Figure 2B-2 、 Figure 3A-1 、 Figure 3A-2 、 Figure 3B-1 and Figure 3B-2 ). Mutants with higher selective binding affinity for human ROR2 at pH 6.0 relative to pH 7.4 were screened from the library by ELISA. Mutated heavy chain variable regions / light chain variable regions that were more active at pH 6.0 than at pH 7.4 were selected as the heavy chain variable regions / light chain variable regions of conditionally active antibodies, and single point mutations were shown in each heavy chain variable region and light chain variable region (Tables 1 and 2, Figure 2A-1 、 Figure 2A-2 、 Figure 2B-1 、 Figure 2B-2 、 Figure 3A-1 、 Figure 3A-2 、 Figure 3B-1 and Figure 3B-2 ).
[0270] Table 1 Light chain variable regions of conditionally active anti-ROR2 antibodies
[0271]
[0272] Table 2 Heavy chain variable regions of conditionally active anti-ROR2 antibodies
[0273]
[0274] In another aspect, the present invention comprises Figure 2A-1 、 Figure 2A-2 、 Figure 2B-1 and Figure 2B-2 The heavy chain variable region shown and Figure 3A-1 、 Figure 3A-2 、 Figure 3B-1 and Figure 3B-2The amino acid sequences of the heavy chain variable regions are SEQ ID NOs: 18-26. The amino acid sequences of the light chain variable regions are SEQ ID NOs: 13-17 and 27. These heavy chain variable regions and light chain variable regions can specifically bind to human ROR2. It has been found that antibodies or antibody fragments comprising one of these heavy chain variable regions and light chain variable regions have a higher binding affinity for ROR2 at the pH in the tumor microenvironment than at the pH in the non-tumor microenvironment. For example, the binding affinity of the antibodies and antibody fragments for ROR2 at pH 6.0 is higher than the binding affinity for ROR2 at pH 7.4.
[0275] Anti-ROR2 antibodies or antibody fragments have a higher binding affinity for ROR2 in tumors than for ROR2 in normal tissues. Compared to monoclonal anti-ROR2 antibodies known in the art, these anti-ROR2 antibodies or antibody fragments have a longer half-life and reduced side effects, as well as comparable efficacy. These characteristics allow the use of higher doses of these anti-ROR2 antibodies or antibody fragments for delivery to patients, making them a more effective treatment option.
[0276] Although the present invention includes Figure 2A-1 、 Figure 2A-2 、 Figure 2B-1 、 Figure 2B-2 、 Figure 3A-1 、 Figure 3A-2 、 Figure 3B-1 and Figure 3B-2 The present invention also provides variants thereof that can specifically bind to human ROR2. In order to derive these variants, the complementarity determining regions (CDRs) (H1 to H3) of the heavy chain variable region and the complementarity determining regions (L1 to L3) of the light chain variable region should remain intact. However, the amino acid sequences outside the complementarity determining regions in the heavy chain variable region and the light chain variable region can be mutated according to the principles of substitution, insertion and deletion discussed in this application.
[0277] When deriving these variants, the methods described herein can be followed. Variants of the heavy chain variable region and the light chain variable region can be prepared by introducing appropriate modifications into the nucleotide sequences encoding the heavy chain variable region and the light chain variable region, or by peptide synthesis. Such modifications include, for example, deletions and / or insertions and / or substitutions of residues within the amino acid sequences of the heavy chain variable region and the light chain variable region. Any combination of deletions, insertions, and substitutions can be performed to arrive at the antibodies or antibody fragments of the present invention, as long as they have the desired characteristics, such as binding to the human ROR2 antigen and / or conditional activity.
[0278] Substitution, insertion, and deletion variants
[0279] In certain embodiments, there is provided an antibody or antibody fragment variant with more than one amino acid replacement. The site of interest for substitution mutagenesis (substitutional mutagenesis) includes CDR and framework region (FR). Conservative replacement is shown under the title of " conservative replacement (conservative substitutions) " in Table 3. More substantial (substantial) changes are provided under the title of " exemplary replacement (exemplary substitutions) " in Table 3, and are further described hereinafter with reference to amino acid side chain categories. Amino acid replacement can be introduced into interested antibody or antibody fragment, and screen out the immunogenic product with desired activity such as the antigen binding of retention / improvement or reduction.
[0280] Table 3 Amino acid substitutions
[0281]
[0282]
[0283] Amino acids can be grouped according to common side chain properties:
[0284] (1) Hydrophobicity: norleucine, Met, Ala, Val, Leu, Ile;
[0285] (2) Neutral hydrophilicity: Cys, Ser, Thr, Asn, Gln;
[0286] (3) Acidic: Asp, Glu;
[0287] (4) Basic: His, Lys, Arg;
[0288] (5) Residues that affect chain orientation: Gly, Pro;
[0289] (6) Aromatic: trp, tyr, phe.
[0290] Non-conservative substitutions will entail exchanging a member of one of these classes for another class.
[0291] A type of substitution variant involves replacing one or more hypervariable region residues of a parent antibody (e.g., humanized or human antibody). Typically, the resulting variant selected for further study will have modifications (e.g., improvements) and / or will substantially retain some biological properties of the parent antibody in terms of certain biological properties (e.g., increased affinity, reduced immunogenicity) relative to the parent antibody. Exemplary substitution variants are affinity-matured antibodies, which can be readily produced, for example, using affinity maturation techniques based on phage display as described herein. In short, one or more CDR residues are mutated, and the variant antibody is displayed on phage and screened for antibodies with specific biological activity (e.g., binding affinity).
[0292] Changes (e.g., substitutions) can be made in the CDRs, for example, to improve antibody affinity. Such changes can occur in CDR "hotspots," i.e., residues encoded by codons that mutate at high frequencies during somatic maturation (see, e.g., Chowdhury, Methods Mol. Biol., vol. 207, pp. 179-196, 2008) and / or SDRs (a-CDRs), and the binding affinity of the resulting variant VH or VL is tested. Affinity maturation by constructing a secondary library and reselecting from the secondary library has been described in, e.g., Hoogenboom et al. in Methods in Molecular Biology, vol. 178, pp. 1-37, 2001). In some embodiments of affinity maturation, diversity is introduced into the selected variable genes for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then created. The library is then screened to identify any antibody variants with the desired affinity. Another method for introducing diversity involves CDR-directed approaches, in which several CDR residues (e.g., 4 to 6 residues at a time) are randomized. CDR residues involved in antigen binding can be specifically identified, for example, using alanine scanning mutagenesis or modeling. In particular, CDR-H3 and CDR-L3 are often targeted.
[0293] In certain embodiments, substitutions, insertions, or deletions may occur within one or more HVRs, provided that such changes do not substantially reduce the ability of the antibody or antibody fragment to bind to the antigen. For example, conservative changes that do not substantially reduce binding affinity (e.g., conservative substitutions as provided herein) may be made in the CDRs. Such changes may be outside of CDR "hot spots" or SDRs. In the variant V provided above, H and V LIn certain embodiments of the sequences, each CDR is unchanged or contains no more than one, two, or three amino acid substitutions.
[0294] As described in Cunningham and Wells, Science, vol. 244, pp. 1081-1085, 1989, a useful method for identifying antibody residues or regions that can be targets for mutagenesis is called "alanine scanning mutagenesis". In this method, a residue or a group of target residues (e.g., charged residues such as arg, asp, his, lys, and glu) are identified and replaced with neutral or negatively charged amino acids (e.g., alanine or polyalanine) to determine whether the interaction of the antibody or antibody fragment with the antigen is affected. Further substitutions can be introduced at amino acid positions that exhibit functional sensitivity to the initial substitutions. Alternatively or additionally, the crystal structure of the antigen-antibody complex is used to identify contact points between the antibody or antibody fragment and the antigen. Such contact residues or adjacent residues can be targeted or eliminated as candidates for substitution. Variants can be screened to determine whether they contain the desired properties.
[0295] Amino acid sequence insertions include amino- and / or carboxyl-terminal fusions of polypeptides ranging in length from one residue to more than one hundred residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include antibodies with an N-terminal methionyl residue. Other insertional variants of antibodies include fusing the N- or C-terminus of the antibody to an enzyme (e.g., for ADEPT) or a polypeptide that increases the serum half-life of the antibody.
[0296] Amino acid sequence modifications of the antibodies described herein are contemplated. For example, it may be desirable to improve the binding affinity and / or other biological properties of the antibodies. H and V L The CDRs in the human antibody are simply transplanted into the V H and V L When humanized antibodies are produced by using FRs derived from non-human animals, their antigen binding activity is reduced compared to the original antibody derived from non-human animals. H and V L Several amino acid residues in V are directly or indirectly related to antigen binding activity. H and V L Replacing these amino acid residues with different amino acid residues of the FR of the human antibody will reduce the binding activity. In order to solve this problem, it is necessary to try to replace the V H and V LThe amino acid residues directly involved in antibody binding, amino acid residues that interact with CDR amino acid residues, or amino acid residues that maintain the three-dimensional structure of the antibody and are directly involved in antigen binding are identified in the amino acid sequence of the FR. The decreased antigen binding activity can be increased by replacing the identified amino acids with amino acid residues from the original antibody derived from a non-human animal.
[0297] The structure of the antibodies of the present invention, as well as the DNA sequences encoding them, can be modified and altered and still obtain functional molecules encoding antibodies with the desired properties.
[0298] When making changes to the amino acid sequence, the hydropathic index of the amino acids can be considered. The importance of the hydropathic amino acid index in conferring interactive biological function on proteins is generally understood in the art. It is generally believed that the relative hydrophilicity characteristics of amino acids contribute to the secondary structure of the resulting protein, which in turn determines the interaction of the protein with other molecules such as enzymes, substrates, receptors, DNA, antibodies, antigens, etc. Each amino acid is assigned a hydropathic index based on its hydrophobicity and charge characteristics, which are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine / cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamic acid (-3.5); glutamine (-3.5); aspartic acid (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).
[0299] A further object of the present invention also encompasses function-conservative variants of the antibodies of the present invention.
[0300] "Function-conservative variants" refers to variants in which a given amino acid residue in a protein or enzyme is changed without changing the overall conformation and function of the polypeptide, including but not limited to replacing an amino acid with an amino acid having similar properties (e.g., polarity, hydrogen bonding potential, acidity, basicity, hydrophobicity, aromaticity, etc.). Amino acids other than those indicated as conserved in a protein may be different, such that the percentage of protein or amino acid sequence similarity between any two proteins having similar functions may vary or may be, for example, 70% to 99% as determined by an alignment scheme such as the Cluster Method, wherein the similarity is based on the MEGALIGN algorithm. "Function-conservative variants" also include polypeptides having at least 60% amino acid identity as determined by the BLAST or FASTA algorithms, preferably at least 75%, more preferably at least 85%, yet more preferably at least 90%, and even more preferably at least 95%, which have the same or substantially similar properties or functions as the native or parent protein to which they are compared.
[0301] Two amino acid sequences are "substantially homologous" or "substantially similar" when greater than 80%, preferably greater than 85%, and preferably greater than 90% of the amino acids are identical, or greater than about 90%, preferably greater than 95% similar (functionally identical) over the entire length of a shorter sequence. Preferably, similar or homologous sequences are identified by alignment using, for example, the GCG (Genetics Computer Group, Program Manual for the GCG Package, Version 7, Madison, Wis.) pileup program or any sequence comparison algorithm such as BLAST, FASTA, or the like.
[0302] For example, certain amino acids in a protein structure can be replaced by other amino acids without significantly losing activity. Since the interaction ability and properties of a protein determine the biological activity of the protein, certain amino acid substitutions can be made in the protein sequence, and of course, certain amino acid substitutions can also be made in its DNA coding sequence, while obtaining a protein with the same properties. Therefore, it is expected that various changes can be made to the sequence of the antibodies or antibody fragments of the present invention, or the corresponding DNA sequences encoding the antibodies or antibody fragments, without significantly losing their biological activity.
[0303] It is known in the art that certain amino acids can be substituted with other amino acids having a similar hydropathic index or score and still produce a protein with similar biological activity, ie, still obtain a biologically functionally equivalent protein.
[0304] As described above, amino acid substitutions are therefore generally based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, etc. Exemplary substitutions that take into account various of the foregoing characteristics are well known to those skilled in the art and include: arginine and lysine; glutamic acid and aspartic acid; serine and threonine; glutamine and asparagine; and valine, leucine, and isoleucine.
[0305] Glycosylation variants
[0306] In certain embodiments, the antibodies provided herein are altered to increase or decrease the extent of antibody glycosylation. Adding or deleting glycosylation sites to an antibody can be conveniently accomplished by altering the amino acid sequence such that more than one glycosylation site is generated or removed.
[0307] When the antibody comprises an Fc region, the carbohydrate attached thereto can be changed. Natural antibodies produced by mammalian cells typically comprise biantennary oligosaccharides of side chains, which are typically connected to the Asn297 of the CH2 domain of the Fc region via N-linkage. See, for example, Wright et al. TIBTECH, vol. 15, pp. 26-32, 1997. Oligosaccharides may include, for example, mannose, N-acetylglucosamine (GlcNAc), galactose, and sialic acid, as well as various carbohydrates of the fucose of the GlcNAc in the biantennary oligosaccharide structure "stem." In some embodiments, the oligosaccharides in the antibodies of the present invention may be modified to produce antibody variants with certain improved properties.
[0308] In one embodiment, antibody variants having a carbohydrate structure lacking fucose connected (directly or indirectly) to the Fc region are provided. For example, the amount of fucose in such antibodies can be 1% to 80%, 1% to 65%, 5% to 65% or 20% to 40%. The amount of fucose is determined by calculating the average amount of fucose within the sugar chain at Asn297 relative to the sum of all sugar structures (e.g., complexes, hybrids, and high mannose structures) connected to Asn297 by MALDI-TOF mass spectrometry, for example, as described in WO2008077546. Asn297 refers to an asparagine residue located at approximately position 297 (Eu numbering of Fc region residues) in the Fc region; however, due to minor sequence differences in antibodies, Asn297 can also be located approximately ±3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300. Such fucosylated variants can have improved ADCC function. See, for example, U.S. Patent Publication Nos. US2003 / 0157108 (Presta, L.); US2004 / 0093621 (Kyowa Hakko Kogyo Co., Ltd.). Examples of publications related to "defucosylated" or "fucose deficient" antibody variants include: US2003 / 0157108; WO2000 / 61739; WO2001 / 29246; US2003 / 0115614; US2002 / 0164328; US2004 / 0093621; US2004 / 0132140; US2004 / 0110704; US2004 / 0110282; US2004 / 0109865; WO2003 / 085119; W O2003 / 084570; WO2005 / 035586; WO2005 / 035778; WO2005 / 053742; WO2002 / 031140; Okazaki et al. J. Mol. Biol., vol. 336, pp. 1239-1249, 2004; Yamane-Ohnuki et al.Examples of cell lines capable of producing defucosylated antibodies include Lec13 CHO cells defective in protein fucosylation (Ripka et al. Arch. Biochem. Biophys., vol. 249, pp. 533-545, 1986; U.S. Patent Application No. US2003 / 0157108A; and WO2004 / 056312A1, particularly Example 11), and knockout cell lines, such as CHO cells in which the α-1,6-fucosyltransferase gene (FUT8) is knocked out (see, e.g., Yamane-Ohnuki et al. Biotech. Bioeng., vol. 87, pp. 614-622, 2004; Kanda, Y. et al., Biotechnol. Bioeng., vol. 94, pp. 680-688, 2006; and WO2003 / 085107).
[0309] Also provided are antibody variants with bisected oligosaccharides, for example, wherein the biantennary oligosaccharide attached to the Fc region of the antibody is divided into two by GlcNAc. Such antibody variants can have reduced fucosylation and / or improved ADCC function. Examples of such antibody variants are described in, for example, WO2003 / 011878, U.S. Patent No. 6,602,684; and US2005 / 0123546. Also provided are antibody variants having at least one galactose residue in the oligosaccharide attached to the Fc region. Such antibody variants can have improved CDC function. Such antibody variants are described in, for example, WO1997 / 30087, WO1998 / 58964, and WO1999 / 22764.
[0310] Fc region variants
[0311] In certain embodiments, one or more amino acid modifications can be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant. An Fc region variant can include a human Fc region sequence (e.g., human IgG1, IgG2, IgG3, or IgG4 Fc region) comprising an amino acid modification (e.g., substitution) at one or more amino acid positions.
[0312] In certain embodiments, the present invention contemplates antibody variants that have some, but not all, effector functions, making them ideal candidates for applications where the half-life of the antibody in vivo is important but certain effector functions (e.g., ADCC) are unnecessary or deleterious. In vitro and / or in vivo cytotoxicity assays can be performed to confirm reduction / depletion of CDC and / or ADCC activity. For example, an Fc receptor (FcR) binding assay can be performed to ensure that the antibody lacks FcγR binding (and therefore likely lacks ADCC activity) but retains FcRn binding ability. Primary cells used to mediate ADCC, NK cells, express only FcγRⅢ, while monocytes express FcγRI, FcγRII, and FcγRⅢ. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol., vol. 9, pp. 457-492, 1991. Non-limiting examples of in vitro assays for evaluating ADCC activity of a molecule of interest are described in U.S. Pat. No. 5,500,362 (see also, e.g., Hellstrom et al. Proc. Nat'l Acad. Sci. USA, vol. 83, pp. 7059-7063, 1986) and Hellstrom, I et al., Proc. Nat'l Acad. Sci. USA, vol. 82, pp. 1499-1502, 1985; U.S. Pat. No. 5,821,337 (see also, Bruggemann et al., J. Exp. Med., vol. 166, pp. 1351-1361, 1987). Alternatively, non-radioactive assays can be employed (see, e.g., ACTI for flow cytometry). TM Nonradioactive cytotoxicity assay (CellTechnology, Mountain View, CA; and CytoTox Non-radioactive cytotoxicity assays (Promega, Madison, Wisconsin). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells. Alternatively or additionally, ADCC activity of the molecule of interest can be assessed in vivo in an animal model such as that disclosed in Clynes et al. Proc. Nat'l Acad. Sci. USA, vol. 95, pp. 652-656, 1998. A C1q binding assay can also be performed to confirm that the antibody is unable to bind to C1q and therefore lacks CDC activity. See, e.g., C1q and C3c binding ELISAs in WO2006 / 029879 and WO2005 / 100402. To assess complement activation, a CDC assay can be performed (see, e.g., Gazzano-Santoro et al., J. Immunol. Methods, vol. 202, pp. 163-171, 1996; Cragg, M Set. al., Blood, vol. 101, pp. 1045-1052, 2003; and Cragg, MS, and MJ Glennie, Blood, vol. 103, pp. 2738-2743, 2004). FcRn binding and in vivo clearance / half-life determinations can also be performed using methods known in the art (see, for example, Petkova, SB et al., Int'l. Immunol., vol. 18, pp. 1759-1769, 2006).
[0313] Antibodies with reduced effector function include those in which one or more of the Fc region residues 238, 265, 269, 270, 297, 327, and 329 are substituted ( U.S. Pat. No. 6,737,056 ). Such Fc mutants include those with substitutions at two or more of amino acid positions 265, 269, 270, 297, and 327, including the so-called "DANA" Fc mutant in which residues 265 and 297 are substituted with alanine ( U.S. Pat. No. 7,332,581 ).
[0314] Certain antibody variants with improved or reduced FcR binding have been described (see, eg, US Pat. No. 6,737,056; WO 2004 / 056312 and Shields et al., J. Biol. Chem., vol. 9, pp. 6591-6604, 2001).
[0315] In certain embodiments, the antibody variant comprises an Fc region with one or more amino acid substitutions that improve ADCC, eg, substitutions at Fc region positions 298, 333, and / or 334 (Eu numbering of residues).
[0316] In some embodiments, changes in the Fc region result in altered (i.e., improved or reduced) C1q binding and / or complement dependent cytotoxicity (CDC), e.g., as described in U.S. Pat. No. 6,194,551, WO 99 / 51642, and Idusogie et al. J. Immunol., vol. 164, pp. 4178-4184, 2000.
[0317] Antibodies with increased half-life and improved binding to the neonatal Fc receptor (FcRn), which is responsible for the transfer of maternal IgG to the fetus (Guyer et al., J. Immunol., vol. 117, pp. 587-593, 1976 and Kim et al., J. Immunol., vol. 24, p. 249, 1994), are described in US 2005 / 0014934. These antibodies comprise an Fc region with one or more substitutions that improve binding of the Fc region to FcRn. Such Fc variants include those having substitutions at one or more of the following Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424, or 434, such as substitutions at Fc region residue 434 ( U.S. Pat. No. 7,371,826 ). For further examples of Fc region variants, see Duncan & Winter, Nature, vol. 322, pp. 738-740, 1988; U.S. Pat. No. 5,648,260; U.S. Pat. No. 5,624,821; and WO 94 / 29351.
[0318] Cysteine-engineered antibody variants
[0319] In certain embodiments, it may be desirable to create cysteine engineered antibodies, such as "thioMAbs," in which one or more residues of an antibody are replaced by cysteine residues. In a specific embodiment, the substituted residues occur at accessible sites of the antibody. By replacing those residues with cysteine, reactive thiol groups are thereby positioned at accessible sites of the antibody and can be used to conjugate the antibody to other moieties such as drug moieties or linker-drug moieties to produce immunoconjugates as further described herein. In certain embodiments, any one or more of the following residues can be replaced by cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and 5400 (EU numbering) of the heavy chain Fc region. Cysteine engineered antibodies can be produced as described, for example, in U.S. Patent No. 7,521,541.
[0320] Antibody derivatives
[0321] In certain embodiments, the antibodies or antibody fragments provided herein can be further modified to contain additional non-proteinaceous moieties known in the art and readily available. Suitable moieties for derivatization of antibodies or antibody fragments include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymer, polyamino acids (homopolymers or random copolymers), dextran or poly (n-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, polypropylene oxide / ethylene oxide copolymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde can have advantages in preparation due to its stability in water. The polymer can be of any molecular weight and can be branched or unbranched. The number of polymers attached to the antibody or antibody fragment can vary, and if more than one polymer is attached, they can be the same or different molecules. In general, the number and / or type of polymers used for derivatization can be determined based on factors considered, including but not limited to the specific properties or functions of the antibody or antibody fragment to be improved, whether the derivative will be used for treatment under defined conditions, etc.
[0322] In another embodiment, a conjugate of an antibody or antibody fragment with a non-protein moiety that can be selectively heated by exposure to radiation is provided. In one embodiment, the non-protein moiety is a carbon nanotube (Kam et al., Proc. Natl. Acad. Sci. USA, vol. 102, pp. 11600-11605, 2005). The radiation can be of any wavelength, including but not limited to, a wavelength that does not damage normal cells but heats the non-protein moiety to a temperature that kills cells in the vicinity of the antibody-non-protein moiety.
[0323] In another aspect, the present invention provides an anti-ROR2 antibody or antibody fragment comprising a heavy chain variable region polypeptide or a light chain variable region polypeptide. The heavy chain variable region polypeptide comprises an H1 region, an H2 region, and an H3 region having SEQ ID NOs: 1-6. The light chain variable region polypeptide comprises an L1 region, an L2 region, and an L3 region having SEQ ID NOs: 7-12.
[0324] The anti-ROR2 antibodies or antibody fragments of the present invention have a higher binding affinity for ROR2 under tumor microenvironment conditions than under non-tumor microenvironment conditions. In one embodiment, the conditions in the tumor microenvironment and the conditions in the non-tumor microenvironment are both pH. Therefore, the anti-ROR2 antibodies or antibody fragments of the present invention can selectively bind to ROR2 at a pH of about 5. to 6.8, but have a lower binding affinity for ROR2 at a pH of about 7.2 to 7.8 encountered in normal physiological environments. As shown in Example 1, the binding affinity of the anti-ROR2 antibody or antibody fragment for ROR2 at pH 6.0 is higher than the binding affinity for ROR2 at pH 7.4.
[0325] In certain embodiments, the dissociation constant (Kd) of the anti-ROR2 antibodies or antibody fragments of the present invention with ROR2 under tumor microenvironment conditions is about ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM or ≤0.001 nM (e.g., 10 -8 M or less, or 10 -8 M to 10 -13 M, or 10 -9 M to 10 -13 M). In one embodiment, the ratio of the Kd of the antibody or antibody fragment for ROR2 at a value under conditions in a tumor microenvironment to the Kd at a different value under the same conditions in a non-tumor microenvironment is at least about 1.5:1, at least about 2:1, at least about 3:1, at least about 4:1, at least about 5:1, at least about 6:1, at least about 7:1, at least about 8:1, at least about 9:1, at least about 10:1, at least about 20:1, at least about 30:1, at least about 50:1, at least about 70:1, or at least about 100:1.
[0326] In one embodiment, Kd is measured using the following assay by performing a radiolabeled antigen binding assay (RIA) with a Fab version of the antibody of interest and its antigen. 125 I) The labeled antigen and Fab are allowed to reach equilibrium, and then the bound antigen is captured using an anti-Fab antibody-coated plate to measure the solution binding affinity of Fab for the antigen (see, for example, Chen et al., J. Mol. Biol. 293: 865-881 (1999)). To establish the assay conditions, Multiwell plates (Thermo Scientific) were coated overnight with 5 μg / ml capture anti-Fab antibody (Cappel Labs) in 50 mM sodium carbonate (pH 9.6) and then blocked with 2% (w / v) bovine serum albumin in PBS at room temperature (approximately 23°C) for two to five hours. In non-adsorbent plates (Nunc #269620), 100 pM or 26 pM [ 125 The antigen is mixed with a serial dilution of the Fab of interest (e.g., consistent with the evaluation of the anti-VEGF antibody Fab-12 in Presta et al., Cancer Res. 57:4593-4599 (1997)). The Fab of interest is then incubated overnight; however, the incubation can be continued for a longer period (e.g., about 65 hours) to ensure that equilibrium is reached. Thereafter, the mixture is transferred to a capture plate for incubation at room temperature (e.g., one hour). The solution is then removed and washed with 0.1% polysorbate 20 in PBS. Wash the plate eight times. When the plate is dry, add 150 μl / well of scintillant (MICROSCINT-20 TM ; Packard Company), then TOPCOUNT TM The plates were counted for ten minutes in a gamma counter (Packard).Concentrations of each Fab less than or equal to 20% of maximal binding were selected for competitive binding assays.
[0327] According to another embodiment, at 25°C, surface plasmon resonance is used to determine the -2000 or Kd was measured using a BIACORE Biosensor CM5 chip (BIAcore, Piscavenger, NJ) with immobilized antigen at approximately 10 response units (RU). Briefly, carboxymethylated dextran biosensor chips (CM5, BIACORE) were activated with ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) according to the supplier's instructions. Antigen was diluted to 5 μg / ml (approximately 0.2 μM) in 10 mM sodium acetate (pH 4.8) and injected at a flow rate of 5 μl / min to obtain approximately 10 response units (RU) of coupled protein. Following antigen injection, 1 M ethanolamine was injected to block unreacted groups. For kinetic measurements, two-fold serial dilutions of Fab (0.78 nM to 500 nM) were injected into a 5% PBS containing 0.05% polysorbate 20 (TWEEN-20 TM ) surfactant (PBST) in PBS. Using a simple one-to-one Langmuir binding model (Langmuirbinding model) ( The association rate (kon) and dissociation rate (koff) were calculated by fitting the association and dissociation sensorgrams simultaneously. The equilibrium dissociation constant (Kd) was expressed as the ratio k off / k on Calculation. See, e.g., Chen et al., J. Mol. Biol. 293:865-881 (1999). If the on-rate measured by the surface plasmon resonance assay above exceeds 10 6 M -1 s -1 If the binding rate is greater than 0.05, the binding rate can be determined by using a fluorescence quenching technique, such as in a stop-flow equipped spectrophometer (Aviv Instruments) or a 8000 series SLM-AMINCO TM The increase or decrease in fluorescence emission intensity (excitation = 295 nm; emission = 340 nm, 16 nm bandpass) of 20 nM anti-antigen antibody (Fab form) in PBS (pH 7.2) at 25°C was measured in the spectrometer of a spectrophotometer (ThermoSpectronic) in the presence of increasing concentrations of antigen.
[0328] The anti-ROR2 antibodies of the present invention may be chimeric antibodies, humanized antibodies or human antibodies. In one embodiment, anti-ROR2 antibody fragments such as Fv, Fab, Fab', Fab'-SH, scFv, diabody, triabody, tetrabody or F(ab')2 fragments and multispecific antibodies formed by antibody fragments are used. In another embodiment, the antibody is a full-length antibody (full length antibody) of, for example, a complete IgG antibody or other antibody class or isotype as defined herein. For a review of specific antibody fragments, see Hudson et al. Nat. Med., vol. 9, pp. 129-134, 2003. For a review of scFv fragments, see, for example, Pluckthün, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., (Springer-Verlag, New York), pp. 269-315 (1994); see also WO 93 / 16185; and U.S. Pat. Nos. 5,571,894 and 5,587,458. For a discussion of Fab and F(ab')2 fragments comprising salvage receptor binding epitope residues and having increased in vivo half-life, see U.S. Pat. No. 5,869,046.
[0329] The diabodies of the present invention can be bivalent or bispecific. For examples of diabodies, see, for example, EP404097; WO1993 / 01161; Hudson et al., Nat. Med. 9:129-134 (2003); and Hollinger et al., Proc. Natl. Acad. Sci. USA, vol. 90, pp. 6444-6448, 1993. Examples of triabodies and tetrabodies are also described in Hudson et al., Nat. Med., vol. 9, pp. 129-134, 2003.
[0330] In some embodiments, the present invention includes single-domain antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, the single-domain antibody is a human single-domain antibody (Domantis, Waltham, MA; see, e.g., U.S. Patent No. 6,248,516 B1).
[0331] Antibody fragments can be made by a variety of techniques, including, but not limited to, proteolytic digestion of intact antibodies as described herein and production by recombinant host cells (eg, E. coli or phage).
[0332] In some embodiments, the anti-ROR2 antibodies of the present invention may be chimeric antibodies. Certain chimeric antibodies are described in, for example, U.S. Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, vol. 81, pp. 6851-6855, 1984. In one example, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate such as a monkey) and a human constant region. In a further example, a chimeric antibody is a "class switched" antibody in which the class or subclass of the antibody has been changed relative to the class or subclass of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.
[0333] In certain embodiments, the chimeric antibody of the present invention is a humanized antibody. Generally, such non-human antibodies are humanized to reduce immunogenicity to people while retaining the specificity and affinity of the parent non-human antibody. Generally, humanized antibodies comprise more than one variable domain, wherein CDR (or part thereof) is derived from non-human antibodies, and FR (or part thereof) is derived from human antibody sequences. Humanized antibodies can also optionally include at least a portion of human constant regions. In some embodiments, some FR residues in humanized antibodies are replaced by corresponding residues derived from non-human antibodies (e.g., antibodies derived from CDR residues), for example, to restore or improve antibody specificity or affinity.
[0334] Humanized antibodies and methods for their preparation are reviewed in, for example, Almagro and Fransson, Front.Biosci., vol. 13, pp. 1619-1633, 2008, and further described in, for example, Riechmann et al., Nature, vol. 332, pp. 323-329, 1988; Queen et al., Proc. Nat'l Acad. Sci. USA, vol. 86, pp. 10029-10033, 1989; U.S. Patents Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri ... et al., Methods, vol. 36, pp. 25-34, 2005 (describing SDR (a-CDR) grafting); Padlan, Mol. Immunol., vol. 28, pp. 489-498, 1991 (describing “surfacing”); Dall'Acqua et al., Methods, vol. 36, pp. 43-60, 2005 (describing “FR shuffling”); and Osbourn et al., Methods, vol. 36, pp. 61-68, 2005 and Klimka et al., Br. J. Cancer, vol. 83, pp. 252-260, 2000 (describing the “guided selection” method of FR shuffling).
[0335] Human framework regions that can be used for humanization include, but are not limited to, framework regions selected using the "best-fit" method (see, e.g., Sims et al. J. Immunol., vol. 151, p. 2296, 1993); framework regions derived from the consensus sequence of human antibodies of a particular subgroup of light or heavy chain variable regions (see, e.g., Carter et al. Proc. Natl. Acad. Sci. USA, vol. 89, p. 4285, 1992; and Presta et al. J. Immunol., vol. 151, p. 2623, 1993); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson, Front. Biosci., vol. 13, pp. 1619-1633, 2008); and framework regions derived from screening FR libraries (see, e.g., Baca et al. J. Immunol., vol. 151, p. 2623, 1993). al., J. Biol. Chem., vol. 272, pp. 10678-10684, 1997 and Rosok et al., J. Biol. Chem., vol. 271, pp. 22611-22618, 1996).
[0336] In some embodiments, the anti-ROR2 antibodies of the present invention are multispecific, such as bispecific antibodies. Multispecific antibodies are monoclonal antibodies that have binding specificity for at least two different sites. In certain embodiments, one binding specificity is for ROR2 and the other binding specificity is for another antigen. In certain embodiments, bispecific antibodies can bind to two different epitopes of ROR2. Bispecific antibodies can also be used to localize cytotoxic agents to cells expressing ROR2. Bispecific antibodies can be prepared as full-length antibodies or antibody fragments.
[0337] Techniques for making multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs with different specificities (see Milstein and Cuello, Nature, vol. 305, pp. 537-540, 1983), WO 93 / 08829 and Traunecker et al., EMBO J. vol. 10, pp. 3655-3659, 1991), and “knob-in-hole” engineering (see, e.g., U.S. Pat. No. 5,731,168). Multispecific antibodies can also be prepared by the following methods: engineering electrostatic steering effects for the preparation of antibody Fc-heterodimer molecules (WO2009 / 089004A1); cross-linking of two or more antibodies or fragments (see, for example, U.S. Patent No. 4,676,980 and Brennan et al., Science, vol. 229, pp. 81-83, 1985); using leucine zippers to produce bispecific antibodies (see, for example, Kostelny et al., J. Immunol., vol. 148, pp. 1547-1553, 1992); using "diabody" technology for the preparation of bispecific antibody fragments (see, for example, Hollinger et al., Proc. Natl. Acad. Sci. USA, vol. 90, pp. 6444-6448, 1993); and using single-chain Fv (scFv) dimers (see, for example, Gruber et al., J. Immunol., vol. 148, pp. 1547-1553, 1992). al., J. Immunol., vol. 152, pp. 5368-5374, 1994); and trispecific antibodies as described, for example, in Tuttet et al. J. Immunol., vol. 147, pp. 60-69, 1991.
[0338] Also included herein are engineered antibodies with more than three functional antigen binding sites, including "Octopus antibodies" (see, eg, US 2006 / 0025576 A1).
[0339] Antibodies or antibody fragments may also include "Dual Acting Fab" or "DAF" comprising antigen binding sites that bind to ROR2 as well as another, different antigen (eg, Ror1, see, eg, US 2008 / 0069820).
[0340] The anti-ROR2 antibodies or antibody fragments of the present invention can be produced using the recombinant methods and compositions described in detail in US2016 / 0017040.
[0341] The physical / chemical properties and / or biological activities of the anti-ROR2 antibodies or antibody fragments of the present invention can be tested and measured by various assays known in the art. Some of these assays are described in U.S. Pat. No. 8,853,369.
[0342] B. Immunoconjugates
[0343] In another aspect, the present invention also provides immunoconjugates comprising an anti-ROR2 antibody or antibody fragment conjugated to one or more cytotoxic agents, such as chemotherapeutic agents or drugs, growth inhibitory agents, toxins (e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant or animal origin, or fragments thereof), or radioactive isotopes.
[0344] In one embodiment, the immunoconjugate is an antibody-drug conjugate (ADC) in which an antibody or antibody fragment is conjugated to one or more drugs, including but not limited to maytansinoids (see U.S. Pat. Nos. 5,208,020, 5,416,064, and European Patent EP 0 425 235 B1); auristatins such as the monomethyl auristatin drug moieties DE and DF (MMAE and MMAF) (see U.S. Pat. Nos. 5,208,020, 5,416,064, and European Patent EP 0 425 235 B1); U.S. Patent Nos. 5,635,483, 5,780,588, and 7,498,298); dolastatin; calicheamicin or its derivatives (see U.S. Patent Nos. 5,712,374, 5,714,586, 5,739,116, 5,767,285, 5,770,701, 5,770,710, 5,773,001, and 5,877,296; Hinman et al., Cancer Res., vol. 53, pp. 3336-3342, 1993; and Lode et al., Cancer Res., vol. 58, pp. 2925-2928, 1998); anthracyclines such as daunorubicin or doxorubicin (see Kratz et al., Current Med. Chem., vol. 13, pp. 477-523, 2006; Jeffrey et al., Bioorganic & Med. Chem. Letters, vol. 16, pp. 358-362, 2006; Torgov et al., Bioconj. Chem., vol. 16, pp. 717-721, 2005; Nagy ... et al., Proc. Natl. Acad. Sci. USA, vol. 97, pp. 829-834, 2000; Dubowchik et al., Bioorg. & Med. Chem. Letters, vol. 12, vol. 1529-1532, 2002; King et al., J. Med. Chem., vol. 45, pp. 4336-4343, 2002; and U.S. Patent No. 6,630,579); methotrexate; vindesine; taxanes such as docetaxel, paclitaxel, larotaxel, tesetaxel, and ortataxel; trichothecenes; and CC1065.
[0345] In another embodiment, the immunoconjugate comprises an antibody or antibody fragment as described herein conjugated to an enzymatically active toxin or fragment thereof, including but not limited to diphtheria A chain, a non-binding active fragment of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor. inhibitor), gelonin, mitogellin, restrictocin, phenomycin, enomycin, and tricothecenes.
[0346] In another embodiment, the immunoconjugate comprises an antibody or antibody fragment as described herein conjugated to a radioactive atom to form a radioconjugate. A variety of radioisotopes can be used to produce radioconjugates. Examples include At 211 , I 131 , I 125 、Y 90 、Re 186 、Re 188 、Sm 153 、Bi 212 、P 32 , Pb 212 When the radioconjugate is used for detection, it may contain a radioactive atom such as Tc99m or I123 for scintigraphic studies, or a spin label such as iodine-123, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, MRI).
[0347] Conjugates of antibodies / antibody fragments with cytotoxic agents can be prepared using a variety of bifunctional protein coupling agents, such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate,
[0014] Examples of the present invention include sulfonated iodine (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (e.g., dimethyladipimide hydrochloride), active esters (e.g., disuccinimidyl suberate), aldehydes (e.g., glutaraldehyde), bisazido compounds (e.g., bis(p-azidobenzoyl)hexanediamine), bisdiazonium derivatives (e.g., bis(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (e.g., toluene 2,6-diisocyanate), and bisactive fluorine compounds (e.g., 1,5-difluoro-2,4-dinitrobenzene). For example, ricin immunotoxins can be prepared as described by Vitetta et al., Science, vol. 238, pp. 1098-, 1987. Carbon-14 labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugating radionucleotides to antibodies. See WO94 / 11026. The linker can be a "cleavable linker" that promotes the release of cytotoxic drugs in cells. For example, an acid-labile linker, a peptidase-sensitive linker, a photolabile linker, a dimethyl linker, or a disulfide-containing linker can be used (Chari et al., Cancer Res., vol. 52, pp. 127-131, 1992; U.S. Pat. No. 5,208,020).
[0348] The immunoconjugates herein specifically encompass, but are not limited to, conjugates prepared with cross-linking agents including, but not limited to, BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SLAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, and SVSB (succinimidyl-(4-vinylsulfone)benzoate), which are commercially available (e.g., from Pierce Biotechnology, Rockford, IL, USA).
[0349] Exemplary embodiments of ADCs include an antibody or antibody fragment (Ab) targeting tumor cells, a drug portion (D), and a linker portion (L) connecting Ab to D. In some embodiments, the antibody is linked to the linker portion (L) via one or more amino acid residues such as lysine and / or cysteine. In some embodiments, the drug portion is an anti-tumor agent. For example, CAB-ROR2-ADC can be BA3021-cleavable linker-MMAE (n) , wherein the heterologous molecule is monomethyl auristatin E (MMAE), and (n) is an integer between 1 and 4 (inclusive).
[0350] An exemplary ADC has as Ab-(LD) p Formula I, wherein p is 1 to about 20. In some embodiments, the number of drug moieties that can be conjugated to an antibody is limited by the number of free cysteine residues. In some embodiments, free cysteine residues are introduced into the antibody amino acid sequence by the methods described herein. Exemplary ADCs of Formula I include, but are not limited to, antibodies with 1, 2, 3 or 4 engineered cysteine amino acids (Lyon et al., Methods in Enzym., vol. 502, pp. 123-138, 2012). In some embodiments, more than one free cysteine residue is already present in the antibody without the need for engineering, in which case the existing free cysteine residues can be used to conjugate the antibody to the drug. In some embodiments, the antibody is exposed to reducing conditions to produce more than one free cysteine residue before antibody conjugation.
[0351] a) Exemplary linkers
[0352] "Linker" (L) is a bifunctional or multifunctional moiety that can be used to link one or more moieties (e.g., a drug moiety (D)) to an antibody or antibody fragment (Ab) to form an immunoconjugate such as an ADC of Formula I. In some embodiments, a linker having a reactive functional group can be used for covalent attachment to a drug and an antibody to prepare an ADC. For example, in some embodiments, a cysteine thiol group (thiol) of an antibody or antibody fragment (Ab) can form a bond with a reactive functional group of a linker or a drug-linker intermediate to prepare an ADC.
[0353] In one aspect, the linker has a functional group (functionality) that can react with the free cysteine present on the antibody to form a covalent bond. Non-limiting and exemplary such reactive functional groups include maleimide, haloacetamide, α-haloacetyl, active esters such as succinimide esters, 4-nitrophenyl esters, pentafluorophenyl esters, tetrafluorophenyl esters, anhydrides, acid chlorides (acid chlorides), sulfonyl chlorides, isocyanates and isothiocyanates. See, for example, the conjugation method of Klussman, et al, Bioconjugate Chemistry, vol. 15, pp. 765-773, 2004 page 766.
[0354] In some embodiments, the linker has a functional group that can react with the electrophilic group present on the antibody. Exemplary such electrophilic groups include but are not limited to aldehyde and ketone carbonyl (ketone carbonyl) group. In some embodiments, the heteroatom of the reactive functional group of the linker can react with the electrophilic group on the antibody and form a covalent bond with the antibody unit. Non-limiting and exemplary such reactive functional groups include but are not limited to hydrazides, oximes, amino, hydrazine, thiosemicarbazone (thiosemicarbazone), hydrazine carboxylate (hydrazine carboxylate) and arylhydrazide (arylhydrazide).
[0355] The linker may comprise one or more linker components. Exemplary linker components include 6-maleimidocaproyl ("MC"), maleimidopropanoyl ("MP"), valine-citrulline ("val-cit" or "vc"), alanine-phenylalanine ("ala-phe"), p-aminobenzyloxycarbonyl ("PAB"), N-succinimidyl 4-(2-pyridylthio)pentanoate ("SPP"), and 4-(N-maleimidomethyl)cyclohexane-1carboxylate ("MCC"). A variety of linker components are known in the art, some of which are described below.
[0356] The linker can be a "cleavable linker" that facilitates the release of the drug. Non-limiting and exemplary cleavable linkers include acid-labile linkers (e.g., containing hydrazone), protease-sensitive (e.g., peptidase-sensitive) linkers, photolabile linkers, or disulfide-containing linkers (Chari et al., Cancer Research, vol. 52, pp. 127-131, 1992; U.S. Pat. No. 5,208,020).
[0357] In certain embodiments, the linker has the following formula II: a —W w —Y y —, wherein A is a "stretcher unit", a is an integer from 0 to 1; W is an "amino acid unit", w is an integer from 0 to 12; Y is a "spacer unit", y is 0, 1 or 2. The ADC comprising the linker of formula II has the formula I(A): Ab-(A a —W w —Y y -D) p , wherein Ab, D, and p are as defined above for Formula I. Exemplary embodiments of such linkers are described in U.S. Patent No. 7,498,298.
[0358] In some embodiments, the linker component includes a "Stretcher unit" (A) that connects the antibody to another linker component or a drug moiety. Non-limiting exemplary Stretcher units are shown below (wherein the wavy line indicates the site of covalent attachment to the antibody, drug, or other linker component):
[0359]
[0360] In some embodiments, the linker component comprises an "amino acid unit" (W). In some such embodiments, the amino acid unit allows the linker to be cleaved by a protease, thereby promoting release of the drug from the immunoconjugate upon exposure to intracellular proteases such as lysosomal enzymes (Doronina et al., Nat. Biotechnol., vol. 21, pp. 778-784, 2003). Exemplary amino acid units include, but are not limited to, dipeptides, tripeptides, tetrapeptides, and pentapeptides. Exemplary dipeptides include, but are not limited to, valine-citrulline (vc or val-cit), alanine-phenylalanine (af or ala-phe); phenylalanine-lysine (fk or phe-lys); phenylalanine-homolysine (phenylalanine-homolysine, phe-homolys); and N-methyl-valine-citrulline (Me-val-cit). Exemplary tripeptides include, but are not limited to, glycine-valine-citrulline (gly-val-cit) and glycine-glycine-glycine (gly-gly-gly). The amino acid unit may comprise naturally occurring amino acid residues and / or minor amino acids and / or non-naturally occurring amino acid analogs, such as citrulline. The amino acid unit may be designed and optimized for enzymatic cleavage by specific enzymes, such as tumor-associated proteases, cathepsins B, C and D, or plasmin proteases.
[0361] Typically, peptide linkers can be prepared by forming a peptide bond between two or more amino acids and / or peptide fragments. Such peptide bonds can be prepared, for example, according to liquid phase synthesis methods (e.g., E. Schroder and K. Lübke (1965) "The Peptides", volume 1, pp 76-136, Academic Press).
[0362] In some embodiments, the linker component comprises a "Spacer unit" (Y) that connects the antibody to the drug moiety directly or through a Stretcher unit and / or an Amino Acid unit. The Spacer unit can be "self-immolative" or "non-self-immolative." A "non-self-immolative" Spacer unit refers to a Spacer unit in which part or all of the Spacer unit remains bonded to the Drug moiety after cleavage of the ADC. Examples of non-self-immolative Spacer units include, but are not limited to, glycine Spacer units and glycine-glycine Spacer units. In some embodiments, ADCs containing glycine-glycine Spacer units are enzymatically cleaved by tumor cell-associated proteases, thereby releasing the glycine-glycine-Drug moiety from the remainder of the ADC. In some such embodiments, the glycine-glycine-Drug moiety undergoes a hydrolysis step in tumor cells, thereby cleaving the glycine-glycine Spacer unit from the Drug moiety.
[0363] The "self-immolative" spacer unit allows for the release of the drug moiety. In certain embodiments, the spacer unit of the linker comprises a p-aminobenzyl unit. In some such embodiments, p-aminobenzyl alcohol is linked to the amino acid unit via an amide bond, forming a carbamate, methyl carbamate, or carbonate between the benzyl alcohol and the drug (Hamann et al. Expert Opin. Ther. Patents, vol. 15, pp. 1087-1103, 2005). In some embodiments, the spacer unit comprises p-aminobenzyloxycarbonyl (PAB). In some embodiments, an ADC comprising a self-immolative linker has the following structure:
[0364]
[0365] wherein Q is —C1-C8 alkyl, —O—(C1-C8 alkyl), -halogen, -nitro, or -cyano; m is an integer ranging from 0 to 4; X can be one or more additional spacer units or can be absent; and p ranges from 1 to about 20. In some embodiments, p ranges from 1 to 10, 1 to 7, 1 to 5, or 1 to 4. Non-limiting exemplary X spacer units include:
[0366]
[0367] wherein R1 and R2 are independently selected from H and C1-C6 alkyl. In some embodiments, R1 and R2 are each -CH3.
[0368] Other examples of self-immolative spacers include, but are not limited to, aromatic compounds that are electronically similar to the PAB group, such as 2-aminoimidazol-5-methanol derivatives (U.S. Pat. No. 7,375,078; Hay et al., Bioorg. Med. Chem. Lett., vol. 9, p. 2237-, 1999) and ortho- or para-aminobenzylacetals. In some embodiments, spacers that undergo cyclization after amide bond hydrolysis may be used, such as substituted and unsubstituted 4-aminobutyric acid amides (Rodrigues et al., Chemistry Biology, vol. 2, pp. 223-, 1995), appropriately substituted bicyclo [2.2.1] and bicyclo [2.2.2] ring systems (Storm et al., J. Amer. Chem. Soc., vol. 94, p. 5815-, 1972), and 2-aminophenylpropionic acid amides (Amsberry et al., J. Org. Chem., vol. 55, p. 5867, 1990). Attachment of the drug to the α-carbon of a glycine residue is another example of a self-immolative spacer that can be used in ADCs (Kingsbury et al., J. Med. Chem., vol. 27, p. 1447, 1984).
[0369] In some embodiments, the linker L can be a dendritic linker for covalently attaching more than one drug moiety to an antibody via a branched multifunctional linker portion (Sun et al. Bioorganic & Medicinal Chemistry Letters, vol. 12, pp. 2213-2215, 2002; Sun et al., Bioorganic & Medicinal Chemistry, vol. 11, pp. 1761-1768, 2003). Dendritic linkers can increase the molar ratio of drug to antibody, i.e., loading, which is related to the potency of the ADC. Therefore, when the antibody has only one reactive cysteine thiol group, multiple drug moieties can be attached via a dendritic linker.
[0370] In the context of the ADC of Formula I, non-limiting exemplary linkers are shown below:
[0371]
[0372] wherein R1 and R2 are independently selected from H and C1-C6 alkyl. In some embodiments, R1 and R2 are each -CH3.
[0373]
[0374] wherein n is 0 to 12. In some embodiments, n is 2 to 10. In some embodiments, n is 4 to 8.
[0375] Further non-limiting exemplary ADCs include the following structures:
[0376]
[0377] Where X is:
[0378]
[0379]
[0380] Y is:
[0381]
[0382] Each R is independently H or C1-C6 alkyl; n is 1 to 12.
[0383] In some embodiments, the linker is substituted with a group that modulates solubility and / or reactivity. As a non-limiting example, a sulfonate (—SO3 - ) or ammonium charged substituents can increase the water solubility of the linker reagent and promote the coupling reaction of the linker reagent with the antibody and / or drug portion, or promote the coupling reaction of Ab-L (antibody-linker intermediate) with D or DL (drug-linker intermediate) with Ab, depending on the synthetic route used to prepare the ADC. In some embodiments, a portion of the linker is coupled to the antibody, a portion of the linker is coupled to the drug, and then Ab-(linker portion) is coupled to the antibody. a and drug-(linker moiety) b Conjugation to form the ADC of Formula I.
[0384] The compounds of the present invention specifically encompass, but are not limited to, ADCs prepared with the following linker reagents: bis-maleimido-trioxyethylene glycol (BMPEO), N-(β-maleimidopropyloxy)-N-hydroxy succinimide ester (BMPS), N-(ε-maleimidocaproyloxy)succinimide ester (EMCS), N-[γ-maleimidobutyryloxy] ... ester, GMBS), 1,6-hexane-bis-vinylsulfone (HBVS), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxy-(6-amidocaproate, LC-SMCC), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), 4-(4-N-Maleimidophenyl)butyric acid hydrazide (MPBH), succinimidyl 3-(bromoacetamido)propionate (succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxy-(6-amidocaproate, LC-SMCC), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), 4-(4-N-Maleimidophenyl)butyric acid hydrazide (MPBH), succinimidyl 3-(bromoacetamido)propionate (succinimidyl 3-(bromoacetamido)propionate, SBAP), succinimidyl iodoacetate, SIA), succinimidyl(4-iodoacetyl)aminobenzoate, SIAB), N-succinimidyl-3-(2-pyridyldithio)propionate, SPDP), N-succinimidyl-4-(2-pyridylthio)pentanoate,SPP), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), succinimidyl 4-(p-maleimidophenyl)butyrate 4-(p-maleimidophenyl)butyrate, SMPB), succinimidyl 6-[(beta-maleimidopropionamido)hexanoate] (SMPH), iminothiolane (IT), sulfo-EMCS (sulfo-EMCS), sulfo-GMBS (sulfo-GMBS), sulfo-KMUS (sulfo-KMUS), sulfo-MBS (sulfo-MBS), sulfo-SIAB (sulfo-SIAB), sulfo-SMCC (sulfo-SMCC) and sulfo-SMPB (sulfo-SMPB), as well as Succinimidyl-(4-vinylsulfone)benzoate (SVSB), and including bis-maleimide reagents: dithiobismaleimidoethane (DTME), 1,4-bismaleimidobutane (1,4-Bismaleimidobutane, BMB), 1,4-bismaleimidyl-2,3-dihydroxybutane (1,4Bismaleimidyl-2,3-dihydroxybutane, BMDB), bismaleimidohexane (BMH), bismaleimidoethane (bis(p-azidobenzoyl)hexanediamine), bis(diazonium) derivatives (e.g., bis(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (e.g., toluene 2,6-diisocyanate), and bis(active fluorine) compounds (e.g., 1,5-difluoro-2,4-dinitrobenzene). In some embodiments, bismaleimide reagents allow the attachment of thiol groups of cysteine residues in antibodies to thiol-containing drug moieties, linkers, or linker-drug intermediates. Other functional groups that react with thiol groups include, but are not limited to, iodoacetamide, bromoacetamide, vinylpyridine, disulfide, pyridyl disulfide, isocyanate, and isothiocyanate.
[0385] Certain useful linker reagents can be obtained from various commercial sources, such as Pierce Biotechnology, Inc. (Rockford, IL), Molecular Biosciences, Inc. (Boulder, CO), or synthesized according to methods described in the art, for example, as follows; Toki et al., J. Org. Chem., vol. 67, pp. 1866-1872, 2002; Dubowchik, et al., Tetrahedron Letters, vol. 38, pp. 5257-60, 1997; Walker, J. Org. Chem., vol. 60, pp. 5352-5355, 1995; Frisch et al., Bioconjugate Chem., vol. 7, pp. 180-186, 1995; U.S. Patent No. 6,214,345; WO02 / 088172; US2003130189; US2003096743; WO03 / 026577; WO03 / 043583; and WO04 / 032828.
[0386] Carbon-14 labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugating radionucleotides to antibodies. See, for example, WO94 / 11026.
[0387] b) Exemplary Drug Moieties
[0388] 1) Maytansine and Maytansinoids
[0389] In some embodiments, immunoconjugates include antibodies conjugated to more than one maytansine molecule. Maytansine is a derivative of maytansine, a mitotic inhibitor by inhibiting tubulin polymerization. Maytansine was first isolated from the East African shrub Maytenus serrata (USP 3896111). Subsequently, it was found that some microorganisms also produced maytansine compounds such as maytansinol and C-3 maytansinol esters (USP 4151042). Synthetic maytansine compounds are disclosed in, for example, U.S. Patent Nos. 4,137,230; 4,248,870; 4,256,746; 4,260,608; 4,265,814; 4,294,757; 4,307,016; 4,308,268; 4,308,269; 4,309,428; 4,313,946; 4,315,929; 4,317,821; 4,322,348; 4,331,598; 4,361,650; 4,364,866; 4,424,219; 4,450,254; 4,362,663; and 4,371,533.
[0390] Maytansine drug moieties are worthy of consideration as drug moieties in antibody-drug conjugates because they: (i) are relatively easy to prepare by fermentation or chemical modification or derivatization of fermentation products, (ii) are easily derivatized with functional groups suitable for conjugation to antibodies via non-disulfide linkers, (iii) are stable in plasma, and (iv) are active against a variety of tumor cell lines.
[0391] Certain maytansine compounds suitable for use as drug moieties of maytansine compounds are known in the art and can be isolated from natural sources or produced using genetic engineering techniques according to known methods (see, for example, Yu et al., PNAS, vol. 99, pp. 7968-7973, 2002). Maytansine compounds can also be prepared synthetically according to known methods.
[0392] Exemplary maytansine drug moieties include, but are not limited to, those with modified aromatic rings, such as: C-19-dechloro (U.S. Pat. No. 4,256,746) (prepared, for example, by reduction of ansamytocin P2 with lithium aluminum hydride); C-20-hydroxy (or C-20-demethyl) + / - C-19-dechloro (U.S. Pat. Nos. 4,361,650 and 4,307,016); ) (prepared, for example, by demethylation using Streptomyces or Actinomyces or dechlorination using LAH); and C-20-demethoxy, C-20-acyloxy (-OCOR), + / -dechloro (U.S. Pat. No. 4,294,757) (prepared, for example, by acylation using acyl chlorides), and those modified at other positions on the aromatic ring.
[0393] Exemplary maytansine drug moieties also include those with the following modifications: C-9-SH (U.S. Pat. No. 4,424,219) (e.g., prepared by reacting maytansinol with H2S or P2S5); C-14-alkoxymethyl (demethoxy / CH2OR) (U.S. Pat. No. 4,331,598); C-14-hydroxymethyl or acyloxymethyl (CH2OH or CH2OAc) (U.S. Pat. No. 4,450,254) (e.g., prepared by Nocardia); C-15-hydroxy / acyloxy (U.S. Pat. No. 4,364,866) (e.g., prepared by converting maytansinol by Streptomyces); C-15-methoxy (U.S. Pat. Nos. 4,313,946 and 4,315,929) (e.g., prepared from Trewia spp. nudlflora); C-18-N-demethyl (U.S. Pat. Nos. 4,362,663 and 4,322,348) (prepared, for example, by demethylation of maytansinol by Streptomyces); and 4,5-deoxy (U.S. Pat. No. 4,371,533) (prepared, for example, by titanium trichloride / LAH reduction of maytansinol).
[0394] Many positions on maytansine compounds can be used as linking position.For example, conventional coupling technology can be used to form ester bond by reacting with hydroxyl.In some embodiments, reaction can occur at the C-3 position with hydroxyl, the C-14 position modified with hydroxyl, the C-15 position modified with hydroxyl and the C-20 position with hydroxyl.In some embodiments, key (linkage) is formed at the C-3 position of maytansinol or maytansinol analog.
[0395] Maytansine drug moieties include those having the following structure:
[0396]
[0397] Wherein wavy line represents the covalent connection of the sulphur atom of maytansine compound drug part and ADC linker.Each R can be H or C1-C6 alkyl independently.The alkylene chain by amide group being connected to sulphur atom can be methyl, ethyl or propyl, i.e. m is 1, 2 or 3 (U.S. Patent No. 633410; U.S. Patent No. 5208020; Chari et al., Cancer Res., vol.52, pp.127-131,1992; Liu et al., Proc. Nall. Acad. Sci. USA, vol.93, pp.8618-8623,1996).
[0398] For the ADC of the present invention, all stereoisomers of the drug portion of the maytansine compound are considered, i.e., any combination of R and S configurations on the chiral carbon (U.S. Patent No. 7,276,497; U.S. Patent No. 6,913,748; U.S. Patent No. 6,441,163; U.S. Patent No. 633,410 (RE39151); U.S. Patent No. 5,208,020; Widdison et al (2006) J. Med. Chem. 49: 4392-4408). In some embodiments, the drug portion of the maytansine compound has the following stereochemical structure:
[0399]
[0400] Exemplary embodiments of the drug moiety of maytansine compounds include, but are not limited to, DM1, DM3, and DM4 having the following structures:
[0401]
[0402]
[0403] The wavy line represents the covalent attachment of the sulfur atom of the drug to the linker (L) of the antibody-drug conjugate.
[0404] An exemplary antibody-drug conjugate in which DM1 is linked to a thiol group of an antibody via a BMPEO linker has the following structure and abbreviations:
[0405]
[0406] wherein Ab is an antibody; n is 0, 1, or 2; and p is 1 to about 20. In some embodiments, p is 1 to 10, p is 1 to 7, p is 1 to 5, or p is 1 to 4.
[0407] Immunoconjugates containing maytansine compounds, their preparation methods, and their therapeutic uses are disclosed in, for example, U.S. Patent Nos. 5,208,020 and 5,416,064; US 2005 / 0276812 A1; and European Patent No. 0,425,235 B1. See also Liu et al., Proc. Natl. Acad. Sci. USA, vol. 93, pp. 8618-8623, 1996; and Chari et al., Cancer Research, vol. 52, pp. 127-131, 1992.
[0408] In some embodiments, antibody-maytansine compound conjugates can be prepared by chemically connecting antibody to maytansine compound molecule without significantly reducing the biological activity of antibody or maytansine compound molecule.See, for example, U.S. Patent No. 5,208,020. In some embodiments, the ADC of each antibody molecule conjugated to an average of 3 to 4 maytansine compound molecules has been shown to enhance the cytotoxic effect of target cells without negatively affecting the function or solubility of the antibody. In some cases, compared to using naked antibodies, even a toxin / antibody molecule is also expected to enhance cytotoxicity.
[0409] Exemplary linking groups for preparing antibody-maytansinoid conjugates include, for example, those described herein and disclosed in US Pat. No. 5,208,020; EP Patent 0,425,235 Bl; Chari et al., Cancer Research, vol. 52, pp. 127-131, 1992; US 2005 / 0276812 Al; and US 2005 / 016993 Al.
[0410] 2) Auristatins and Dolastatins
[0411] The drug moiety includes dolastatins, auristatins, and their analogs and derivatives (U.S. Pat. No. 5,635,483; U.S. Pat. No. 5,780,588; U.S. Pat. No. 5,767,237; U.S. Pat. No. 6,124,431). Auristatins are derivatives of the marine mollusk compound dolastatin-10. While not intending to be bound by any particular theory, dolastatins and auristatins have been shown to interfere with microtubule dynamics, GTP hydrolysis, and nuclear and cell division (Woyke et al., Antimicrob. Agents and Chemother., vol. 45, pp. 3580-3584, 2001) and have anticancer activity (U.S. Pat. No. 5,663,149) and antifungal activity (Pettit et al., Antimicrob. Agents and Chemother., vol. 42, pp. 2961-2965, 1998). The dolastatin / auristatin drug moiety can be linked to the antibody via the N (amino) or C (carboxyl) terminus of the peptide drug moiety (WO 02 / 088172; Doronina et al., Nature Biotechnology, vol. 21, pp. 778-784, 2003; Francisco et al., Blood, vol. 102, pp. 1458-1465, 2003).
[0412] Exemplary auristatin embodiments include an N-terminally linked monomethyl auristatin drug moiety D E and D F , which are disclosed in U.S. Patent No. 7,498,298 and U.S. Patent No. 7,659,241:
[0413]
[0414] Among them D E and D F The wavy lines indicate the sites of covalent attachment to the antibody or antibody-linker component, and independently at each position:
[0415] R 2 Selected from H and C1-C8 alkyl;
[0416] R 3 is selected from the group consisting of H, C1-C8 alkyl, C3-C8 carbocycle, aryl, C1-C8 alkyl-aryl, C1-C8 alkyl-(C3-C8 carbocycle), C3-C8 heterocycle and C1-C8 alkyl-(C3-C8 heterocycle);
[0417] R 4is selected from the group consisting of H, C1-C8 alkyl, C3-C8 carbocycle, aryl, C1-C8 alkyl-aryl, C1-C8 alkyl-(C3-C8 carbocycle), C3-C8 heterocycle and C1-C8 alkyl-(C3-C8 heterocycle);
[0418] R 5 selected from H and methyl;
[0419] or R 4 and R 5 Together they form a carbon ring having the formula—(CR a R b ) n —where R a and R b independently selected from H, C1-C8 alkyl and C3-C8 carbocycle, n is selected from 2, 3, 4, 5 and 6;
[0420] R 6 Selected from H and C1-C8 alkyl;
[0421] R 7 is selected from the group consisting of H, C1-C8 alkyl, C3-C8 carbocycle, aryl, C1-C8 alkyl-aryl, C1-C8 alkyl-(C3-C8 carbocycle), C3-C8 heterocycle and C1-C8 alkyl-(C3-C8 heterocycle);
[0422] Each R 8 Independently selected from H, OH, C1-C8 alkyl, C3-C8 carbocycle and O—(C1-C8 alkyl);
[0423] R 9 Selected from H and C1-C8 alkyl;
[0424] R 10 Selected from aryl or C3-C8 heterocycle;
[0425] Z is O, S, NH or NR 12 , where R 12 is a C1-C8 alkyl group;
[0426] R 11 Selected from H, C1-C20 alkyl, aryl, C3-C8 heterocycle, -(R 13 O)m—R 14 or—(R 13 O)m—CH(R 15 )2;
[0427] m is an integer ranging from 1 to 1000;
[0428] R 13 is a C2-C8 alkyl group;
[0429] R 14is H or C1-C8 alkyl;
[0430] Each occurrence of e is independently H, COOH, -(CH2) n —N(R 16 )2, —(CH2) n —SO3H or —(CH2) n —SO3—C1-C8 alkyl;
[0431] Each occurrence of e is independently H, C1-C8 alkyl or -(CH2) n —COOH;
[0432] R 18 Selected from—C(R 8 )2—C(R 8 )2-aryl, -C(R 8 )2—C(R 8 )2-(C3-C8 heterocycle) and -C(R 8 )2—C(R 8 )2—(C3-C8 carbocycle); and
[0433] n is an integer ranging from 0 to 6.
[0434] In one embodiment, R 3 、R 4 and R 7 are independently isopropyl or sec-butyl, R 5 In an exemplary embodiment, R 3 and R 4 are all isopropyl, R 5 For—H, R 7 It is sec-butyl.
[0435] In another embodiment, R 2 and R 6 All are methyl, R 9 For—H.
[0436] In yet another embodiment, each occurrence of R 8 All are -OCH3.
[0437] In an exemplary embodiment, R 3 and R 4 Each is isopropyl, R 2 and R 6 Each is a methyl group, R 5 For—H, R 7 For sec-butyl, each occurrence of R 8 For -OCH3, R 9 For—H.
[0438] In one embodiment, Z is -O- or -NH-.
[0439] In one embodiment, R 10 It is an aryl group.
[0440] In an exemplary embodiment, R 10 It is -phenyl.
[0441] In an exemplary embodiment, when Z is —O—, R 11 It is -H, methyl or tert-butyl.
[0442] In one embodiment, when Z is -NH, R 11 for—CH(R 15 )2, where R 15 for—(CH2) n —N(R 16 )2,R 16 is -C1-C8 alkyl or -(CH2) n —COOH.
[0443] In another embodiment, when Z is -NH, R 11 for—CH(R 15 )2, where R 15 for—(CH2) n —SO3H.
[0444] Formula D E An exemplary auristatin embodiment is MMAE, wherein the wavy line represents the covalent attachment to the linker (L) of the antibody-drug conjugate:
[0445]
[0446] Formula D E An exemplary auristatin embodiment is MMAF, wherein the wavy line represents the covalent attachment to the linker (L) of the antibody-drug conjugate:
[0447]
[0448] Other exemplary embodiments include monomethyl valine compounds having a phenylalanine carboxyl group modified at the C-terminus of the pentapeptide auristatin drug moiety (WO2007 / 008848) and monomethyl valine compounds having a phenylalanine side chain modified at the C-terminus of the pentapeptide auristatin drug moiety (WO2007 / 008603).
[0449] Non-limiting exemplary embodiments of ADCs of Formula I comprising MMAF and various linker components also include Ab-MC-PAB-MMAF and Ab-PAB-MMAF. It has been demonstrated that immunoconjugates comprising MMAF linked to an antibody via a non-proteolytically cleavable linker have comparable activity to immunoconjugates comprising MMAF linked to an antibody via a proteolytically cleavable linker (Doronina et al., Bioconjugate Chem., vol. 17, pp. 114-124, 2006). In some such embodiments, it is believed that drug release is affected by antibody degradation in cells.
[0450] Typically, peptide-based drug moieties can be prepared by forming a peptide bond between two or more amino acids and / or peptide fragments. Such peptide bonds can be prepared, for example, by liquid phase synthesis (see, for example, E. and K. Lübke, "The Peptides", volume 1, pp 76-136, 1965, Academic Press). In some embodiments, the auristatin / dolastatin drug moiety can be prepared according to the following methods: U.S. Patent No. 7,498,298; U.S. Patent No. 5,635,483; U.S. Patent No. 5,780,588; Pettit et al., J. Am. Chem. Soc., vol. 111, pp. 5463-5465, 1998; Pettit et al., Anti-Cancer Drug Design, vol. 13, pp. 243-277, 1998; Pettit et al., Synthesis, vol. 6, pp. 719-725, 1996; Pettit et al., J. Chem. Soc. Perkin Trans. vol. 15, pp. 859-863, 1996; and Doronina, Nat. Biotechnol., vol. 21, pp. 778-784, 2003.
[0451] In some embodiments, the methods described below can be used to prepare compounds of formula D such as MMAE. E and MMAF of formula D EThe auristatin / dolastatin drug moieties and drug-linker intermediates such as MC-MMAF, MC-MMAE, MC-vc-PAB-MMAF and MC-vc-PAB-MMAE and their derivatives: U.S. Patent No. 7,498,298; Doronina et al., Bioconjugate Chem., vol. 17, pp. 114-124, 2006; and Doronina et al., Nat. Biotech., vol. 21, pp. 778-784, 2003, which are then conjugated to an antibody of interest.
[0452] 3) Calicheamicin
[0453] In some embodiments, the immunoconjugate comprises an antibody or antibody fragment conjugated to one or more calicheamicin molecules. The calicheamicin family of antibiotics and their analogs are capable of producing double-stranded DNA breaks at sub-picomolar concentrations (Hinman et al., Cancer Research, vol.53, pp.3336-3342, 1993; Lode et al., Cancer Research, vol.58, pp.2925-2928, 1998). Calicheamicin has an intracellular site of action, but in some cases is not easy to pass through the plasma membrane. Therefore, in some embodiments, the cellular uptake of these agents by antibody-mediated internalization can greatly enhance their cytotoxic effects. Non-limiting exemplary methods for preparing antibody-drug conjugates with calicheamicin drug moieties are described in, for example, U.S. Patent No. 5,712,374; U.S. Patent No. 5,714,586; U.S. Patent No. 5,739,116; and U.S. Patent No. 5,767,285.
[0454] 4) Pyrrolobenzodiazepines
[0455] In some embodiments, the ADC comprises a pyrrolobenzodiazepine (PBD). In some embodiments, the PBD dimer recognizes and binds to a specific DNA sequence. The natural product anthramycin, a PBD, was first reported in 1965 (Leimgruber et al., J. Am. Chem. Soc., vol. 87, pp. 5793-5795, 1965; Leimgruber et al., J. Am. Chem. Soc., vol. 87, pp. 5791-5793, 1965). Since then, a large number of PBDs have been reported, including naturally occurring and analogs (Thurston et al., Chem. Rev. vol. 1994, pp. 433-465 1994), including dimers of the tricyclic PBD scaffold (U.S. Pat. No. 6,884,799; U.S. Pat. No. 7,049,311; U.S. Pat. No. 7,067,511; U.S. Pat. No. 7,265,105; U.S. Pat. No. 7,511,032; U.S. Pat. No. 7,528,126; U.S. Pat. No. 7,557,099). Without being bound by any particular theory, it is believed that the dimer structure confers a three-dimensional shape that is compatible with the isohylicity of the minor groove of B-form DNA, resulting in a close fit of the binding site (Kohn, In Antibiotics III. Springer-Verlag, New York, pp. 3-11 (1975); Hurley and Needham-VanDevanter, Acc. Chem. Res., vol. 19, pp. 230-237, 1986). Dimeric PBD compounds with C2 aryl substituents have been shown to be useful as cytotoxic agents (Hartley et al Cancer Res., vol. 70, pp. 6849-6858, 2010; Antonow, J. Med. Chem. vol. 53, pp. 2927-2941, 2010; Howard et al., Bioorganic and Med. Chem. Letters, vol. 19, pp. 6463-6466, 2009).
[0456] PBD dimers have been conjugated to antibodies, and the resulting ADCs have been shown to have anticancer properties. Non-limiting exemplary attachment sites on PBD dimers include a five-membered pyrrole ring, a tether between PBD units, and an N10-C11 imine group (WO2009 / 016516; US2009 / 304710; US2010 / 047257; US2009 / 036431; US2011 / 0256157; WO2011 / 130598).
[0457] Non-limiting exemplary PBD dimer components of ADCs are:
[0458]
[0459] and salts and solvates thereof, wherein:
[0460] The wavy line indicates the site of covalent attachment to the linker;
[0461] The dashed line indicates the optional presence of a double bond between C1 and C2 or C2 and C3;
[0462] R 2 Independently selected from H, OH, ═O, ═CH2, CN, R, OR, ═CH-R D ,═C(R D )2, O-SO2-R, CO2R and COR, optionally further selected from halogen or dihalogen, wherein R D independently selected from R, CO2R, COR, CHO, CO2H and halogen;
[0463] R 6 and R 9 independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', NO2, Me3Sn and halogen;
[0464] R 7 independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', NO2, Me3Sn and halogen;
[0465] Q is independently selected from O, S and NH;
[0466] R 11 is H or R, or wherein Q is O, SO3M, wherein M is a metal cation;
[0467] R and R' are each independently selected from optionally substituted C 1-8 Alkyl, C 1-12 Alkyl, C 3-8 Heterocyclic group, C 3-20 Heterocyclic and C 5-20Aryl, optionally with respect to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-membered, 5-membered, 6-membered or 7-membered heterocyclic ring;
[0468] R 12 、R 16 、R 19 and R 17 R 2 、R 6 、R 9 and R 7 defined;
[0469] R″ is C 3-12 Alkylene, the chain of which may be interrupted by one or more heteroatoms, such as O, S, N(H), NMe, and / or aromatic rings, such as benzene or pyridine, which rings are optionally substituted; and
[0470] X and X' are independently selected from O, S and N(H).
[0471] In some embodiments, R and R' are each independently selected from optionally substituted C 1-12 Alkyl, C 3-20 Heterocyclic and C 5-20 Aryl, optionally with respect to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-membered, 5-membered, 6-membered or 7-membered heterocyclic ring. 9 and R 19 is H. In some embodiments, R 6 and R 16 For H.
[0472] In some embodiments, R 7 R 17 Both OR 7A , where R 7A is optionally substituted C 1-4 In some embodiments, R 7A In some embodiments, R 7A is CH2Ph, wherein Ph is phenyl. In some embodiments, X is O. In some embodiments, R 11 is H. In some embodiments, a double bond exists between C2 and C3 of each monomer unit.
[0473] In some embodiments, R 2 and R 12 are independently selected from H and R. In some embodiments, R 2 and R 12 is independently R. In some embodiments, R 2 and R 12are independently optionally substituted C 5-20 Aryl or C 5-7 Aryl or C 8-10 In some embodiments, R 2 and R 12 is independently optionally substituted phenyl, thienyl, naphthyl, pyridyl, quinolyl, or isoquinolyl. 2 and R 12 independently selected from ═O, ═CH2, ═CH—R D and ═C(R D )2. In some embodiments, R 2 and R 12 Each is ═CH2. In some embodiments, R 2 and R 12 Each is H. In some embodiments, R 2 and R 12 Each is =O. In some embodiments, R 2 and R 12 Each is =CF2. In some embodiments, R 2 and / or R 12 Independently ═C(R D )2. In some embodiments, R 2 and / or R 12 independently ═CH—R D .
[0474] In some embodiments, when R 2 and / or R 12 =CH-R D Each group can independently have any of the following configurations:
[0475]
[0476] In some embodiments, ═CH—R D In configuration (I). In some embodiments, R" is C3 alkylene or C5 alkylene.
[0477] The linkers of PBD dimer-val-cit-PAB-Ab and PBD dimer-Phe-Lys-PAB-Ab are protease-cleavable, while the linker of PBD dimer-maleimide-acetal is acid-labile.
[0478] PBD dimers and ADCs comprising PBD dimers can be prepared according to methods known in the art, see, for example, WO 2009 / 016516; US 2009 / 304710; US 2010 / 047257; US 2009 / 036431; US 2011 / 0256157; and WO 2011 / 130598.
[0479] 5) Anthracyclines
[0480] In some embodiments, ADC may include anthracyclines. Anthracyclines are antibiotic compounds with cytotoxic activity. Although not intended to be bound by any particular theory, studies have shown that anthracyclines can kill cells through a variety of different mechanisms, including: 1) inserting drug molecules into the DNA of cells, thereby inhibiting DNA-dependent nucleic acid synthesis; 2) generating free radicals from drugs, which then react with cell macromolecules to damage cells, and / or 3) interactions between drug molecules and cell membranes (see, for example, C. Peterson et al., " Transport And Storage Of Anthracycline In Experimental Systems And Human Leukemia " in Anthracycline Antibiotics In Cancer Therapy; NRBachur, " Free Radical Damage " id. at pp.97-102). Due to its cytotoxic potential, anthracyclines have been used to treat a variety of cancers such as leukemia, breast cancer, lung cancer, ovarian adenocarcinoma, and sarcoma (see, for example, PH-Wiernik, in Anthracycline: Current Status And New Developments, p.11).
[0481] Non-limiting exemplary anthracyclines include doxorubicin, epirubicin, idarubicin, daunomycin, nemorubicin, and derivatives thereof. Immunoconjugates and prodrugs of daunomycin and doxorubicin have been prepared and studied (Kratz et al., Current Med. Chem., vol. 13, pp. 477-523, 2006; Jeffrey et al., Bioorganic & Med. Chem. Letters, vol. 16, pp. 358-362. 1996; Torgov et al., Bioconj. Chem., vol. 16, pp. 717-721, 2005; Nagy et al., Proc. Natl. Acad. Sci. USA, vol. 97, pp. 829-834, 2000; Dubowchik et al., Bioorg. & Med. Chem. Letters, vol. 12, pp. 1529-1532, 2002; King et al., Bioorganic & Med. Chem. Letters, vol. 13, pp. 1529-1532, 2002). et al., J. Med. Chem., vol. 45, pp. 4336-4343, 2002; EP 0328147; U.S. Patent No. 6630579). The antibody-drug conjugate BR96-doxorubicin specifically reacts with the tumor-associated antigen Lewis-Y and has been evaluated in phase I and phase II studies (Saleh et al., J. Clin. Oncology, vol. 18, pp. 2282-2292, 2000; Ajani et al., Cancer Jour., vol. 6, pp. 78-81, 2000; Tolcher et al., J. Clin. Oncology, vol. 17, pp. 478-484, 1999).
[0482] PNU-159682 is a potent metabolite (or derivative) of nemorubicin (Quintieri et al., Clinical Cancer Research, vol. 11, pp. 1608-1617, 2005). Nemorubicin is a semisynthetic analog of doxorubicin with a 2-methoxymorpholino group on the glycoside amino group of doxorubicin. It is currently undergoing clinical evaluation (Grandi et al. Cancer Treat. Rev. vol. 17, pp. 133-138, 1990; Ripamonti et al. Brit. J. Cancer, vol. 65, pp. 703-707, 1992), including phase II / III clinical trials for liver cancer (Sun et al., Proceedings of the American Society for Clinical Oncology, vol. 22, Abs 1448, 2003; Quintieri, Proceedings of the American Association of Cancer Research, vol. 44: 1st Ed, Abs 4649, 2003; Pacciarini et al., Jour. Clin. Oncology, vol. 24, p. 14116, 2006).
[0483] Anthracyclines, including PNU-159682, can be conjugated to antibodies through several attachment sites and a variety of linkers, including those described herein (US2011 / 0076287; WO2009 / 099741; US2010 / 0034837; WO2010 / 009124).
[0484] The linker of PNU-159682 maleimide acetal-Ab is unstable to acid, while PNU-159682-val-cit-PAB-Ab, PNU-159682-val-cit-PAB-spacer-Ab and PNU-159682-val-cit-PAB-spacer(R 1 R 2 The linker of the )-Ab is protease cleavable.
[0485] 6) Other drugs
[0486] The drug portion also includes geldanamycin (Mandler et al., J. Nat. Cancer Inst., vol. 92, pp. 1573-1581, 2000; Mandler et al., Bioorganic & Med. Chem. Letters, vol. 10, pp. 1025-1028, 2000; Mandler et al., Bioconjugate Chem., vol. 13, pp. 786-791, 2002); and toxins and fragments thereof having enzymatic activity, including but not limited to diphtheria toxin A chain, non-binding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, α-sarcin, Aleurites fordii protein, dianthus toxin protein, Phytolaca aeruginosa americana proteins (PAPI, PAPII and PAP-S), momordica charantia inhibitors, curcin, crotin, sapaonaria officinalis inhibitors, gelonin, mitogellin, restrictocin, phenomycin, enomycin and tricothecenes. See, for example, WO 93 / 21232.
[0487] Drug moieties also include compounds with nucleolytic activity (eg, ribonucleases or DNA endonucleases).
[0488] In certain embodiments, the immunoconjugate may contain highly radioactive atoms. A variety of radioactive isotopes can be used to produce radioconjugated antibodies. Examples include At 211 , I 131 , I 125 、Y 90 、Re 186 、Re 188 、Sm 153 、Bi 212 、P 32 , Pb 212 In some embodiments, when the immunoconjugate is used for detection, it may contain radioactive isotopes such as Tc 99m or I 123Radioactive atoms for scintigraphic studies, or spin labels such as zirconium-89, iodine-123, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese, or iron for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, MRI). Zirconium-89 can be complexed with various metal chelators and conjugated to antibodies, for example, for PET imaging (WO2011 / 056983).
[0489] Radiolabels or other labels can be incorporated into the immunoconjugates in a known manner. For example, peptides can be biosynthesized or chemically synthesized using suitable amino acid precursors containing, for example, one or more fluorine-19 atoms replacing one or more hydrogens. In some embodiments, such as Tc 99 , I 123 、Re 186 、Re 188 and In 111 The label can be attached through a cysteine residue of the antibody. In some embodiments, yttrium-90 can be attached through a lysine residue of the antibody. In some embodiments, the IODOGEN method (Fraker et al., Biochem. Biophys. Res. Commun., vol. 80, pp. 49-57, 1978) can be used to incorporate iodine-123. "Monoclonal Antibodies in Immunoscintigraphy" (Chatal, CRC Press 1989) describes certain other methods.
[0490] In certain embodiments, the immunoconjugate may comprise an antibody conjugated to a prodrug activating enzyme. In some such embodiments, the prodrug activating enzyme converts a prodrug (e.g., a peptide-based chemotherapeutic agent, see WO81 / 01145) into an active drug such as an anticancer drug. In some embodiments, such immunoconjugates are useful in antibody-dependent enzyme-mediated prodrug therapy ("ADEPT") . Enzymes that can be conjugated to antibodies include, but are not limited to, alkaline phosphatase, which can be used to convert a phosphate-containing prodrug into a free drug; arylsulfatase, which can be used to convert a sulfate-containing prodrug into a free drug; cytosine deaminase, which can be used to convert non-toxic 5-fluorocytosine into the anticancer drug 5-fluorouracil; proteases such as serratia protease, thermolysin, subtilisin, carboxypeptidase, and cathepsin (e.g., cathepsin B and L), which can be used to convert a peptide-containing prodrug into a free drug.
[0014] Examples of the present invention include enzymes such as D-alanylcarboxypeptidases, which can be used to convert prodrugs containing D-amino acid substituents; carbohydrate cleavage enzymes such as β-galactosidase and neuraminidase, which can be used to convert glycosylated prodrugs into free drugs; β-lactamases, which can be used to convert drugs derivatized with β-lactams into free drugs; and penicillin amidases such as penicillin V amidase and penicillin G amidase, which can be used to convert drugs derivatized with phenoxyacetyl or phenylacetyl groups on their amine nitrogens, respectively, into free drugs. In some embodiments, the enzyme can be covalently bonded to the antibody using recombinant DNA techniques well known in the art. See, for example, Neuberger et al., Nature, vol. 312, pp. 604-608, 1984.
[0491] c) Drug Loading
[0492] Drug loading is represented by p, which is the average number of drug moieties per antibody in the Formula I molecule. The drug loading range can be 1 to 20 drug moieties (D) per antibody. The ADC of Formula I comprises a collection of antibodies conjugated to 1 to 20 drug moieties. The average number of drug moieties per antibody used in the process of preparing ADC by conjugation reaction can be characterized by conventional methods such as mass spectrometry, ELISA detection and HPLC. The quantitative distribution of ADC with respect to p can also be determined. In some cases, homogeneous ADCs with p being a specific value can be separated, purified and characterized from ADCs with other drug loads by methods such as reversed-phase HPLC or electrophoresis.
[0493] For some antibody-drug conjugates, p can be limited by the number of attachment sites on the antibody. For example, as described in some exemplary embodiments above, when the attachment site is a cysteine thiol, the antibody may have only one or more cysteine thiol groups, or may have only one or more reactive thiol groups, through which the connexon may be connected. In certain embodiments, a higher drug load, such as p>5, may result in aggregation, insolubility, toxicity, or loss of cell permeability of some antibody-drug conjugates. In certain embodiments, the average drug load of ADC ranges from 1 to about 8; from about 2 to about 6; or from about 3 to about 5. In fact, it has been shown that for some ADCs, the optimal ratio of the drug portion of each antibody can be less than 8, and can be from about 2 to about 5 (U.S. Patent No. 7,498,298).
[0494] In certain embodiments, during the conjugation reaction, less than the theoretical maximum amount of drug moiety is conjugated to the antibody. Antibodies may contain, for example, lysine residues that do not react with drug-linker intermediates or linker reagents as described below. Typically, antibodies do not contain many free and reactive cysteine thiol groups that can be connected to the drug moiety; in fact, most cysteine thiol residues in antibodies exist in the form of disulfide bonds. In certain embodiments, antibodies can be reduced under partial or complete reducing conditions with a reducing agent (e.g., dithiothreitol (DTT) or tricarbonylethylphosphine (TCEP)) to generate reactive cysteine thiol groups. In certain embodiments, antibodies are subjected to denaturing conditions to display reactive nucleophilic groups such as lysine or cysteine.
[0495] The loading (drug / antibody ratio) of the ADC can be controlled in different ways, for example, by (i) limiting the molar excess of the drug-linker intermediate or linker reagent relative to the antibody, (ii) limiting the conjugation reaction time or temperature, and (iii) using partial or limited reducing conditions for cysteine thiol modification.
[0496] It should be understood that when more than one nucleophilic group reacts with a drug-linker intermediate or linker reagent, the resulting product is an ADC mixture having a distribution of more than one drug portion connected to the antibody. The average number of drugs per antibody can be calculated from the mixture by a double ELISA antibody assay, which is specific for the antibody and specific for the drug. A single ADC can be identified in the mixture by mass spectrometry and separated by HPLC, such as hydrophobic interaction chromatography (hydrophobic interaction chromatography) (see, for example, McDonagh et al., Prot. Engr. Design & Selection, vol. 19, pp. 299-307, 2006; Hamblett et al., Clin. Cancer Res., vol. 10, pp. 7063-7070, 2004). In certain embodiments, a homogeneous ADC with a single loading value can be separated from the conjugated mixture by electrophoresis or chromatography.
[0497] d) Some methods for preparing immunoconjugates
[0498] ADC immunoconjugates of Formula I can be prepared by several routes using organic chemistry reactions, conditions, and reagents known to those skilled in the art, including: (1) reacting a nucleophilic group of an antibody with a divalent linker reagent to form Ab-L via a covalent bond, which is then reacted with a drug moiety, D; (2) reacting a nucleophilic group of a drug moiety with a divalent linker reagent to form DL via a covalent bond, which is then reacted with a nucleophilic group of an antibody. An exemplary method for preparing ADCs of Formula I by the latter route is described in U.S. Patent No. 7,498,298.
[0499] Nucleophilic groups on antibodies include, but are not limited to: (i) N-terminal amine groups, (ii) side chain amine groups such as lysine, (iii) side chain thiol groups such as cysteine, and (iv) sugar hydroxyl or amino groups in glycosylated antibodies. Amine, thiol, and hydroxyl groups are nucleophilic and can react with electrophilic groups on linker moieties and linker reagents to form covalent bonds. Linker reagents include: (i) active esters such as NHS esters, HOBt esters, haloformates, and acid halides; (ii) alkyl halides and benzyl halides such as haloacetamides; and (iii) aldehydes, ketones, carboxyl groups, and maleimide groups. Certain antibodies have reducible interchain disulfide bonds, i.e., cysteine bridges. Antibodies can be reacted with linker reagents for conjugation by treatment with a reducing agent such as DTT (dithiothreitol) or tricarbonylethylphosphine (TCEP), resulting in complete or partial reduction of the antibody. Thus, each cysteine bridge will theoretically form two reactive thiol nucleophiles. Additional nucleophiles can be introduced into antibodies by modifying lysine residues, for example, by reacting lysine residues with 2-iminothiolane (Traut's reagent) to convert amines into thiols. Reactive thiol groups can also be introduced into antibodies by introducing one, two, three, four, or more cysteine residues (e.g., by preparing variant antibodies containing one or more non-natural cysteine amino acid residues).
[0500] The antibody-drug conjugates of the present invention can also be produced by the reaction between an electrophilic group such as an aldehyde or ketone carbonyl group on an antibody or antibody fragment and a nucleophilic group on a linker reagent or drug. Useful nucleophilic groups on linker reagents include, but are not limited to, hydrazides, oximes, amino groups, hydrazines, thiosemicarbazones, hydrazinecarboxylates, and arylhydrazides. In one embodiment, the antibody is modified to introduce an electrophilic moiety that can react with a nucleophilic substituent on a linker reagent or drug. In another embodiment, the sugar of a glycosylated antibody can be oxidized by, for example, periodate oxidants to form an aldehyde or ketone group that can react with an amine group on a linker reagent or drug moiety. The resulting imine Schiff base group can form a stable bond, or can be reduced by, for example, a borohydride reagent to form a stable amine bond. In one embodiment, the reaction of the carbohydrate portion of a glycosylated antibody with galactose oxidase or sodium metaperiodate can generate carbonyl (aldehyde and ketone) groups in the antibody that can react with appropriate groups on the drug (Hermanson, Bioconjugate Techniques). In another embodiment, antibodies containing an N-terminal serine or threonine residue can be reacted with sodium metaperiodate to generate an aldehyde at the position of the first amino acid (Geoghegan & Stroh, Bioconjugate Chem., vol. 3, pp. 138-146, 1992; U.S. Patent No. 5,362,852). Such aldehydes can react with drug moieties or linker nucleophiles.
[0501] Exemplary nucleophilic groups on the drug moiety include, but are not limited to, amine, thiol, hydroxyl, hydrazide, oxime, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide groups that are capable of reacting with electrophilic groups on the linker moiety and linker reagents to form covalent bonds, including: (i) active esters such as NHS esters, HOBt esters, haloformates, and acyl halides; (ii) alkyl and benzyl halides such as haloacetamides; and (iii) aldehydes, ketones, carboxyl, and maleimide groups.
[0502] Non-limiting exemplary cross-linker reagents that can be used to prepare ADCs are described herein in the section entitled "Exemplary Linkers." Methods of using such cross-linker reagents to link two moieties (including protein moieties and chemical moieties) are known in the art. In some embodiments, a fusion protein comprising an antibody and a cytotoxic agent can be prepared, for example, by recombinant techniques or peptide synthesis. A recombinant DNA molecule can comprise regions encoding the antibody and cytotoxic moieties of the conjugate, adjacent to each other or separated by a region encoding a linker peptide that does not destroy the desired properties of the conjugate.
[0503] In another embodiment, the antibody or antibody fragment can be conjugated to a "receptor" (e.g., streptavidin) for tumor pretargeting, wherein the antibody / antibody fragment-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent, and then administration of a "ligand" (e.g., avidin) conjugated to a cytotoxic agent (e.g., a drug or radionucleotide).
[0504] C. Methods and Compositions for Diagnosis and Detection
[0505] In certain embodiments, any of the anti-ROR2 antibodies or antibody fragments provided herein can be used to detect the presence of ROR2 in a biological sample. As used herein, the term "detection" encompasses quantitative or qualitative detection. In certain embodiments, the biological sample comprises cells or tissues such as breast, pancreatic, esophageal, lung, and / or brain cells or tissues.
[0506] Another aspect of the invention relates to an anti-ROR2 antibody or antibody fragment of the invention for use in diagnosing and / or monitoring cancer or other diseases in which ROR2 expression levels are elevated or decreased relative to normal physiological levels in at least one part of the body.
[0507] In a preferred embodiment, the antibodies or antibody fragments of the present invention may be labeled with a detectable molecule or substance such as a fluorescent molecule, a radioactive molecule, or any other label known in the art, as described above. For example, the antibodies or antibody fragments of the present invention may be labeled with a radioactive molecule. For example, suitable radioactive molecules include, but are not limited to, 123 I. 124 I. 111 In, 186 Re and 188Re is a radioactive atom used for scintigraphic studies. The antibodies or antibody fragments of the present invention can also be labeled with spin labels for nuclear magnetic resonance (NMR) imaging such as iodine-123, iodine-131, indium-III, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron. After administration of the antibody, the distribution of the radiolabeled antibody in the patient's body is detected. Any suitable known method can be used. Some non-limiting examples include computed tomography (CT), positron emission tomography (PET), magnetic resonance imaging (MRI), fluorescence, chemiluminescence and ultrasound scanning.
[0508] The antibodies or antibody fragments of the present invention can be used for the diagnosis and staging of cancers and diseases associated with ROR2 overexpression. Cancers associated with ROR2 overexpression can include squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, glial cell tumors such as glioblastoma and neurofibromatosis, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatocellular carcinoma (hepatoma), breast cancer, colon cancer, melanoma, colorectal cancer, endometrial cancer, salivary gland cancer, kidney cancer (kidney cancer), renal cancer (renal cancer), prostate cancer, vulvar cancer, thyroid cancer, hepatic carcinoma, sarcomas such as fibrosarcoma and osteosarcoma, blood cancers (leukemia), astrocytomas, and various types of head and neck cancer or other hyperproliferative diseases in which ROR2 is expressed or overexpressed.
[0509] The antibodies or antibody fragments of the present invention can be used to diagnose diseases other than cancers in which ROR2 expression is increased or decreased. Both soluble and cellular ROR2 forms can be used for such diagnosis. Typically, such diagnostic methods involve the use of biological samples obtained from patients. The term "biological sample" as used herein encompasses a variety of sample types obtained from individuals that can be used for diagnosis or monitoring assays. Biological samples include, but are not limited to, blood and other liquid samples of biological origin, solid tissue samples such as biopsy specimens or tissue cultures or cells derived therefrom, and their progeny. For example, biological samples include cells obtained from tissue samples collected from individuals suspected of having cancer associated with ROR2 overexpression, in preferred embodiments, cells obtained from glioma, stomach, lung, pancreas, breast, prostate, kidney, liver, and endometrium. Biological samples include clinical samples, cultured cells, cell supernatants, cell lysates, serum, plasma, biological fluids, and tissue samples.
[0510] In a specific embodiment, the present invention is a method for diagnosing cancer associated with ROR2 overexpression in an individual by detecting ROR2 on cells from the individual using the antibody of the present invention. Specifically, the method may include the following steps:
[0511] (a) contacting a biological sample of the individual with an antibody or antibody fragment of the present invention under conditions suitable for the antibody or antibody fragment to form a complex with cells expressing ROR2 in the biological sample; and
[0512] (b) detecting and / or quantifying the complex, whereby detection of the complex is indicative of a cancer associated with ROR2 overexpression.
[0513] To monitor the progression of cancer, the method according to the present invention can be repeated at different times to determine whether the binding of the antibody to the sample increases or decreases, thereby determining whether the cancer is progressing, regressing, or stable.
[0514] In a specific embodiment, the present invention is a method for diagnosing diseases associated with expression or overexpression of ROR2 or a decrease or increase in the soluble form of ROR2. Examples of these diseases may include human immune disorders, thrombotic diseases (thrombosis and atherothrombosis), and cardiovascular diseases.
[0515] In one embodiment, an anti-ROR2 antibody or antibody fragment for use in a diagnostic or detection method is provided. On the other hand, a method for detecting the presence of ROR2 in a biological sample is provided. On the other hand, a method for quantifying the content of ROR2 in a biological sample is provided. In certain embodiments, the method comprises contacting a biological sample with an anti-ROR2 antibody or antibody fragment as described herein under conditions that allow the anti-ROR2 antibody or antibody fragment to bind to ROR2, and detecting whether a complex is formed between the anti-ROR2 antibody or antibody fragment and ROR2. Such methods can be performed in vitro or in vivo. In one embodiment, an anti-ROR2 antibody or antibody fragment is used to select individuals eligible for treatment. In some embodiments, treatment will include administering an anti-ROR2 antibody or antibody fragment to the individual.
[0516] In certain embodiments, labeled anti-ROR2 antibodies or antibody fragments are provided. Labels include, but are not limited to, directly detectable labels or moieties (e.g., fluorescent labels, chromophore labels, electron-dense labels, chemiluminescent labels, and radioactive labels), as well as moieties such as enzymes or ligands that are indirectly detected, for example, by enzymatic reactions or molecular interactions. Exemplary labels include, but are not limited to, radioisotopes. 32 P.14 C. 125 I. 3 H and 131 I. fluorophores (e.g., rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone), luciferases (e.g., firefly luciferase and bacterial luciferase) (U.S. Pat. No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, horseradish peroxidase (HRP), alkaline phosphatase, β-galactosidase, glucoamylase, lysozyme, carbohydrate oxidases (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclic oxidases (e.g., uricase and xanthine oxidase, coupled to enzymes that use hydrogen peroxide to oxidize dye precursors, such as HRP, lactoperoxidase, or microperoxidase), biotin / avidin, spin labels, phage labels, stable free radicals, and the like.
[0517] D. Pharmaceutical preparations
[0518] Anti-ROR2 antibodies or antibody fragments have cell-killing activity. This cell-killing activity extends to a variety of different cell lines. In addition, once these antibodies or antibody fragments are conjugated to a cytotoxic agent, they can reduce tumor size and exhibit reduced toxicity. See Example 2 of the present invention. Therefore, anti-ROR2 antibodies, fragments thereof, or immunoconjugates can be used to treat proliferative diseases associated with ROR2 expression. The antibodies, fragments, or immunoconjugates can be used alone or in combination with any suitable agent or other conventional treatment methods.
[0519] Anti-ROR2 antibodies or antibody fragments can be used to treat diseases related to ROR2 expression, overexpression or activation. In addition to requiring ROR2 expression, there is no particular limitation on the type of cancer or tissue that can be treated. Examples include squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, glial cell tumors such as glioblastoma and neurofibroma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatocellular carcinoma, breast cancer, colon cancer, melanoma, colorectal cancer, endometrial cancer, salivary gland cancer, kidney cancer, renal cancer, prostate cancer, vulvar cancer, thyroid cancer, liver cancer (hepatic carcinoma), sarcomas such as fibrosarcoma and osteosarcoma, blood cancer (leukemia), astrocytoma and various types of head and neck cancer. More typical treatment cancers are gliomas (glioma), gastric cancer, lung cancer, pancreatic cancer, breast cancer, prostate cancer, kidney cancer, liver cancer and endometrial cancer.
[0520] Anti-ROR2 antibodies or antibody fragments are potential activators of the innate immune response and can therefore be used to treat human immune diseases such as sepsis. The anti-ROR2 antibodies or antibody fragments of the present invention can also be used as immune adjuvants (e.g., for vaccines), as well as anti-infective agents against, for example, bacteria, viruses, and parasites.
[0521] Anti-ROR2 antibodies or antibody fragments can be used to prevent, prevent or treat thrombotic diseases such as venous and arterial thrombosis and atherothrombosis. Anti-ROR2 antibodies or antibody fragments can also be used to prevent, prevent and treat cardiovascular diseases and prevent or inhibit the invasion of viruses such as Lassa virus and Ebola virus and treat viral infections.
[0522] In each embodiment of the treatment methods described herein, the anti-ROR2 antibody, antibody fragment, or anti-ROR2 antibody or antibody fragment immunoconjugate can be delivered in a manner consistent with conventional methods for managing the disease or condition for which treatment is sought. According to the disclosure herein, an effective amount of the antibody, antibody fragment, or immunoconjugate is administered to an individual in need of such treatment for a period of time and under conditions sufficient to prevent or treat the disease or condition. Thus, one aspect of the invention relates to a method for treating a disease associated with ROR2 expression, comprising administering a therapeutically effective amount of an antibody, antibody fragment, or immunoconjugate of the invention to an individual in need thereof.
[0523] For administration, the anti-ROR2 antibody, antibody fragment, or immunoconjugate can be formulated as a pharmaceutical composition. Pharmaceutical compositions comprising the anti-ROR2 antibody, antibody fragment, or immunoconjugate can be formulated according to known methods for preparing pharmaceutical compositions. In such methods, the therapeutic molecule is typically combined with a mixture, solution, or composition containing a pharmaceutically acceptable carrier.
[0524] A pharmaceutically acceptable carrier is a material that can be tolerated by the patient receiving the treatment. Sterile phosphate-buffered saline is an example of a pharmaceutically acceptable carrier. Other suitable pharmaceutically acceptable carriers are well known to those skilled in the art (see, for example, Gennaro (ed.), Remington's Pharmaceutical Sciences (Mack Publishing Company, 19th ed. 1995)). The formulation may also include one or more excipients, preservatives, solubilizers, buffers, albumin to prevent protein loss on the surface of the vial, etc.
[0525] The form, route of administration, dosage and regimen of the pharmaceutical composition will naturally depend on the condition being treated, the severity of the disease, the age, weight and sex of the patient, etc. Those skilled in the art can consider these factors to formulate a suitable pharmaceutical composition. The pharmaceutical composition of the present invention can be formulated for topical, oral, parenteral, intranasal, intravenous, intramuscular, subcutaneous or intraocular administration, etc.
[0526] Preferably, the pharmaceutical composition contains a pharmaceutically acceptable carrier for an injectable formulation. These may in particular be isotonic, sterile saline solutions (mono- or disodium phosphate, sodium chloride, potassium chloride, calcium chloride or magnesium chloride, etc. or mixtures of these salts), or dried, in particular freeze-dried, compositions which, after addition of, for example, sterile water or physiological saline, allow the formation of injectable solutions.
[0527] In some embodiments, there is a tonicity agent (sometimes referred to as a "stabilizer") to adjust or maintain the tension of the liquid in the composition. When used with large charged biomolecules such as proteins and antibodies, they are generally referred to as "stabilizers" because they can interact with the charged groups of the amino acid side chains, thereby reducing the possibility of intermolecular and intramolecular interactions. The tonicity agent can be present in any amount of 0.1% to 25% by weight of the pharmaceutical composition, preferably 1% to 5% by weight. Preferred tonicity agents include polyols, preferably trivalent sugar alcohols or higher sugar alcohols such as glycerol, erythritol, arabitol, xylitol, sorbitol and mannitol.
[0528] Additional excipients include agents that can serve as one or more of the following: (1) bulking agents, (2) solubility enhancers, (3) stabilizers, and (4) agents that prevent denaturation or adhesion to the container wall. Such excipients may include: polysaccharide alcohols (listed above); amino acids such as alanine, glycine, glutamine, asparagine, histidine, arginine, lysine, ornithine, leucine, 2-phenylalanine, glutamic acid, threonine, etc.; and sucrose, lactose, lactitol, trehalose, stachyose, mannose, sorbose, xylose, ribose, ribitol, myoinisitose, myoinisitol, galactose, galactitol, glycerol, cycloalcohols (e.g., Examples of the present invention include organic sugars or sugar alcohols such as thiocyanate, inositol, polyethylene glycol, thioctic acid, sodium thioacetate, thioglycerol, α-monothioglycerol, and sodium thiosulfate; low molecular weight proteins such as human serum albumin, bovine serum albumin, gelatin, or other immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; monosaccharides (e.g., xylose, mannose, fructose, glucose); disaccharides (e.g., lactose, maltose, sucrose); trisaccharides (e.g., raffinose); and polysaccharides (e.g., dextrin or dextran).
[0529] A nonionic surfactant or detergent (also known as a "wetting agent") can be used to help dissolve the therapeutic agent and protect the therapeutic protein from agitation-induced aggregation, which also allows the formulation to be exposed to shear surface stress without causing denaturation of the active therapeutic protein or antibody. The nonionic surfactant can be present in a concentration range of about 0.05 mg / ml to about 1.0 mg / ml, preferably about 0.07 mg / ml to about 0.2 mg / ml.
[0530] Suitable nonionic surfactants include polysorbates (20, 40, 60, 65, 80, etc.), polyoxamers (184, 188, etc.), polyols, Polyoxyethylene sorbitan monoethers -20, -80, etc.), lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, polyoxyethylene hydrogenated castor oil 50 and polyoxyethylene hydrogenated castor oil 60, glyceryl monostearate, sucrose fatty acid ester, methylcellulose and carboxymethylcellulose. Anionic detergents that can be used include sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate. Cationic detergents include benzalkonium chloride or benzethonium chloride.
[0531] The dosage for administration can be adjusted as a function of various parameters, in particular as a function of the mode of administration used, the pathology concerned or, optionally, the desired duration of treatment. To prepare a pharmaceutical composition, an effective amount of the antibody or antibody fragment can be dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium.
[0532] Pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations containing sesame oil, peanut oil, or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
[0533] Solutions of the active compound as a free base or a pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, mixtures thereof, and oils. Under normal conditions of storage and use, these preparations contain preservatives to prevent the growth of microorganisms.
[0534] Anti-ROR2 antibodies or antibody fragments can be formulated into compositions in neutral or salt form. Pharmaceutically acceptable salts include acid addition salts (formed with free amino groups of proteins) formed with inorganic acids such as hydrochloric acid or phosphoric acid or organic acids such as acetic acid, oxalic acid, tartaric acid, mandelic acid, etc. Salts formed with free carboxyl groups can also be derived from inorganic bases such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, or ferric hydroxide, and organic bases such as isopropylamine, trimethylamine, histidine, procaine, etc.
[0535] In some embodiments, the present invention provides the preparation of the present invention.Carrier can also be a solvent or a dispersion medium containing for example water, ethanol, polyol (for example glycerol, propylene glycol, liquid polyethylene glycol etc.), their suitable mixture and vegetable oil.Can, for example, by using a coating such as lecithin, by maintaining required particle diameter and by using a surfactant to maintain suitable fluidity in the case of dispersion.Can play the effect of preventing microorganisms by various antibacterials and antifungals such as for example parabens, chlorobutanol (chlorobutanol), phenol, sorbic acid, thimerosal (thimerosal).In many cases, preferably include the isotonic agent of for example sugar or sodium chloride.Can play the prolongation absorption of injectable composition by using the medicament of the delayed absorption of for example aluminum monostearate and gelatin in compositions.
[0536] Sterile injectable solutions can be prepared by incorporating the desired amount of the active compound into an appropriate solvent with one or more of the above-mentioned other ingredients, and then sterilizing by filtration, if necessary. Typically, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle containing a basic dispersion medium and those other required ingredients listed above. For sterile powders for the preparation of sterile injectable solutions, preferred preparation methods are vacuum drying and freeze drying techniques, which yield a powder of the active ingredient plus any other required ingredients from a previously sterile-filtered solution.
[0537] Preparation of more concentrated or highly concentrated solutions for direct injection is also contemplated, with the use of dimethyl sulfoxide (DMSO) as a solvent envisioned to result in extremely rapid penetration, delivering high concentrations of active agent to small tumor areas.
[0538] After formulation, the solution will be administered in a manner compatible with the dosage form and in an amount that is therapeutically effective. The formulation can be readily administered in a variety of dosage forms, such as the injectable solution type described above, but drug release capsules and the like can also be employed.
[0539] For example, for parenteral administration with an aqueous solution, if necessary, the solution should be appropriately buffered, first making the liquid diluent isotonic with enough saline or glucose. These specific aqueous solutions are particularly suitable for intravenous administration, intramuscular administration, subcutaneous administration, and intraperitoneal administration. In this regard, in view of the present invention, those skilled in the art will know that usable sterile aqueous media. For example, a dose can be dissolved in an isotonic NaCl solution of 1ml, added to a subcutaneous perfusion fluid (hypodermoclysis fluid) of 1000ml or injected into a proposed infusion site (see, for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580). Depending on the individual condition of the patient being treated, some changes will inevitably occur in the dosage. In any case, the person responsible for administration will determine the appropriate dosage for a single individual.
[0540] The antibody or antibody fragment can be formulated in a therapeutic mixture to deliver about 0.0001 mg to 10.0 mg, or about 0.001 mg to 5 mg, or about 0.001 mg to 1 mg, or about 0.001 mg to 0.1 mg, or about 0.1 mg to 1.0 mg, or even about 10 mg per dose. Multiple doses can also be administered at selected time intervals.
[0541] In addition to compounds formulated for parenteral administration, such as intravenous or intramuscular injection, other pharmaceutically acceptable forms include, for example, tablets or other solids for oral administration; time release capsules; and any other forms currently used.
[0542] In certain embodiments, liposomes and / or nanoparticles are contemplated for use in introducing antibodies or antibody fragments into host cells. The formation and use of liposomes and / or nanoparticles are known to those skilled in the art.
[0543] Nanocapsules can typically entrap compounds in a stable and reproducible manner. To avoid side effects due to intracellular polymer overload, such ultrafine particles (approximately 0.1 μm in size) are typically designed using polymers that can degrade in vivo. The present invention contemplates the use of biodegradable polyalkyl-cyanoacrylate nanoparticles that meet these requirements and can be easily manufactured.
[0544] Liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles (MLVs). MLVs typically have diameters ranging from 25 nm to 4 μm. Sonication of MLVs results in vesicles with diameters ranging from 25 nm to 4 μm. to The physical properties of liposomes depend on pH, ionic strength, and the presence of divalent cations.
[0545] Pharmaceutical formulations containing the anti-ROR2 antibodies or antibody fragments described herein can be prepared in the form of lyophilized formulations or aqueous solutions by mixing such antibodies or antibody fragments having the desired purity with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)). Pharmaceutically acceptable carriers are generally non-toxic to recipients at the dosages and concentrations employed and include, but are not limited to: buffers such as phosphates, citrates, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (e.g., octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride); chloride); benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates including glucose, mannose or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants such as polyethylene glycol (PEG).
[0546] Exemplary pharmaceutically acceptable carriers herein also include interstitial drug dispersion agents, such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), such as human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 ( Baxter International, Inc. Certain exemplary sHASEGPs and methods of use thereof, including rHuPH20, are described in U.S. Patent Publication Nos. 2005 / 0260186 and 2006 / 0104968. In one aspect, sHASEGP is combined with one or more additional glycosaminoglycanases, such as chondroitinase.
[0547] Exemplary lyophilized antibody formulations are described in U.S. Patent No. 6267958. Aqueous antibody formulations include those described in U.S. Patent No. 6171586 and WO2006 / 044908, the latter formulations including a histidine-acetate buffer.
[0548] The formulations herein may also contain more than one active ingredient necessary for treating a specific indication. Preferably, components with complementary activities that do not adversely affect each other can be combined into a single formulation. For example, in addition to the anti-ROR2 antibodies, antibody fragments or immunoconjugates of the present invention, it may be desirable to provide an EGFR antagonist (e.g., erlotinib), an anti-angiogenic agent (e.g., a VEGF antagonist that can be an anti-VEGF antibody) or a chemotherapeutic agent (e.g., a taxane compound or a platinum drug). Such active ingredients are suitably present in an amount effective for the intended purpose.
[0549] The active ingredient can be encapsulated in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization. For example, hydroxymethylcellulose or gelatin microcapsules and poly(methyl methacrylate) microcapsules can be employed in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules) or in macroemulsions, respectively. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).
[0550] Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody or antibody fragment, which matrices can be in the form of shaped articles, eg, films or microcapsules.
[0551] Formulations for in vivo administration are generally sterile. Sterility can be readily achieved, for example, by filtration through sterile filtration membranes.
[0552] E. Methods of Treatment and Compositions
[0553] Any anti-ROR2 antibody or antibody fragment provided herein can be used in a method of treatment. In one aspect, an anti-ROR2 antibody or antibody fragment for use as a drug is provided. In a further aspect, an anti-ROR2 antibody or antibody fragment for use in treating cancer (e.g., breast cancer, non-small cell lung cancer, pancreatic cancer (pancreatic cancer), brain cancer, pancreatic cancer (cancer of pancreas), brain cancer, kidney cancer, ovarian cancer, gastric cancer, leukemia, endometrial cancer, colon cancer, prostate cancer, thyroid cancer, liver cancer, sarcomas such as fibrosarcoma and osteosarcoma, melanoma and / or various head and neck cancers) is provided. In certain embodiments, an anti-ROR2 antibody or antibody fragment is provided for use in a method of treatment. In certain embodiments, the present invention provides an anti-ROR2 antibody or antibody fragment for use in a method of treating an individual with cancer, comprising administering an effective amount of an anti-ROR2 antibody or antibody fragment to the individual. In certain embodiments, the present invention provides an anti-ROR2 antibody or antibody fragment for use in a method of treating an individual with an immune disorder (e.g., an autoimmune disease), a cardiovascular disease (e.g., atherosclerosis, hypertension, thrombosis), an infectious disease (e.g., Ebola virus, Marburg virus), or diabetes, comprising administering to the individual an effective amount of an anti-ROR2 antibody or antibody fragment. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, such as those described below. In a further embodiment, the present invention provides an anti-ROR2 antibody or antibody fragment for inhibiting angiogenesis, inhibiting cell proliferation, inhibiting immune function, inhibiting inflammatory cytokine secretion (e.g., from tumor-associated macrophages), inhibiting tumor vasculature (e.g., intratumoral vasculature or tumor-associated vasculature), and / or inhibiting tumor stromal function.
[0554] In certain embodiments, the present invention provides an anti-ROR2 antibody or antibody fragment for use in a method of inhibiting angiogenesis, inhibiting cell proliferation, inhibiting immune function, inhibiting inflammatory cytokine secretion (e.g., from tumor-associated macrophages), inhibiting tumor vasculature (e.g., intratumoral vasculature or tumor vasculature), and / or inhibiting tumor interstitial function in an individual, the method comprising administering to the individual an effective anti-ROR2 antibody or antibody fragment to inhibit angiogenesis, inhibiting cell proliferation, inhibiting immune function, inhibiting inflammatory cytokine secretion (e.g., from tumor-associated macrophages), inhibiting tumor vasculature development (e.g., intratumoral vasculature or tumor-associated vasculature), and / or inhibiting tumor interstitial function. The "individual" according to any of the above embodiments is preferably a human.
[0555] On the other hand, the present invention provides the use of anti-ROR2 antibodies or antibody fragments in the manufacture or preparation of medicines (medicament). In one embodiment, the medicine is used to treat cancer (in some embodiments, breast cancer, non-small cell lung cancer, pancreatic cancer, brain cancer, pancreatic cancer, brain cancer, kidney cancer, ovarian cancer, gastric cancer, leukemia, endometrial cancer, colon cancer, prostate cancer, thyroid cancer, liver cancer, sarcomas such as fibrosarcoma and osteosarcoma, melanoma and / or various head and neck cancers). In a further embodiment, the agent is used in a method for treating cancer, which includes administering an effective amount of the agent to an individual suffering from cancer. In a further embodiment, the agent is used in a method for treating immune disorders (e.g., autoimmune diseases), cardiovascular diseases (e.g., atherosclerosis, hypertension, thrombosis), infectious diseases (e.g., Ebola virus, Marburg virus) or diabetes, which includes administering an effective amount of an anti-ROR2 antibody or antibody fragment to the individual. In one such embodiment, the method further includes administering an effective amount of at least one additional therapeutic agent, such as those described below, to the individual. In a further embodiment, the agent is used to inhibit angiogenesis, inhibit cell proliferation, inhibit immune function, inhibit inflammatory cytokine secretion (e.g., derived from tumor-associated macrophages), inhibit tumor vasculature (e.g., intratumoral vasculature or tumor-associated vasculature) and / or inhibit tumor interstitial function. In a further embodiment, the agent is used in a method of inhibiting angiogenesis, inhibiting cell proliferation, inhibiting immune function, inhibiting inflammatory cytokine secretion (e.g., derived from tumor-associated macrophages), inhibiting tumor vasculature (e.g., intratumoral vasculature or tumor-associated vasculature) and / or inhibiting tumor interstitial function in an individual, which comprises administering to the individual an effective amount of the agent to inhibit angiogenesis, inhibit cell proliferation, promote immune function, induce inflammatory cytokine secretion (e.g., derived from tumor-associated macrophages), inhibit tumor vasculature development (e.g., intratumoral vasculature or tumor-associated vasculature) and / or inhibit tumor interstitial function. An "individual" according to any of the above embodiments may be a human.
[0556] In another aspect, the present invention provides a method for treating a tumor expressing ROR2 in an individual suffering from cancer. In one embodiment, the method comprises administering to the individual suffering from cancer an effective amount of an anti-ROR2 antibody or antibody fragment. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent as described below. The "individual" according to any of the above embodiments may be a human.
[0557] In this aspect of the invention, methods of treating tumors that express ROR2 are provided. In some embodiments, the methods comprise administering an immunoconjugate comprising an anti-ROR2 antibody or antibody fragment of the invention.
[0558] In one embodiment of this aspect, a method for treating a tumor expressing ROR2 comprises administering an immunoconjugate comprising an antibody or antibody fragment of the invention conjugated to an agent selected from a chemotherapeutic agent, a radioactive atom, a cytostatic agent, and a cytotoxic agent. The immunoconjugate is an antibody-drug conjugate (ADC) in which a conditionally active biologic (CAB) anti-ROR2 antibody or antibody fragment is conjugated to one or more drug moieties (CAB-ROR2-ADC) via a cleavable linker. For example, the CAB-ROR2-ADC can be BA3021-cleavable linker-MMAE (n) , wherein the drug moiety is monomethyl auristatin E (MMAE), and (n) is an integer between 1 and 4 (inclusive).
[0559] In one particular aspect, a method of treating a tumor expressing ROR2 comprises administering BA3021-cleavable linker-MMAE to a human subject in need of such treatment. (n) , wherein BA3021 is an antibody or antibody fragment having a heavy chain variable region and a light chain variable region, the heavy chain variable region having the amino acid sequence of SEQ ID NO: 16 and including CDRs H1, H2 and H3; the light chain variable region having the amino acid sequence of SEQ ID NO: 21 and including CDRs L1, L2 and L3; MMAE is monomethyl auristatin E (MMAE), and (n) is an integer between 1 and 4 (inclusive).
[0560] In some embodiments, the present invention provides for the use of, for example, BA3021-cleavable linker-MMAE (n) The CAB-ROR2-ADC treatment regimen is administered at a dose of about 0.3 mg / kg to about 3.3 mg / kg, once or twice every 21 days or 3 weeks, or once or twice every 14 days or 2 weeks. For example, BA3021-cleavable linker-MMAE (n)It can be administered once every 3 weeks (Q3W) at a dose of about 0.3 mg / kg to about 3.3 mg / kg, or twice every 3 weeks, for example on days 1 and 8 (2Q3W), at a dose range of 1.5 mg / kg to 1.8 mg / kg.
[0561] In certain embodiments, the present invention provides treatment regimens using CAB-ROR2-ADCs, such as BA3021-cleavable linker-MMAE (n) , administered at a dose of about 0.3 mg / kg to about 1.8 mg / kg, once or twice every 21 days or 3 weeks, or once or twice every 14 days or 2 weeks. For example, BA3021-cleavable linker-MMAE (n) The drug may be administered at a dose of about 0.3 mg / kg to about 1.8 mg / kg, twice every 14 days or 2 weeks, for example, on day 1 and day 8 every 14 days or 2 weeks. (n) The dosage of CAB-ROR2-ADC is about 0.8 mg / kg to about 1.8 mg / kg, administered once or twice every 21 days, for example, on day 1 and day 8 of every 21 days, or once or twice every 14 days, for example, on day 1 and day 8 of every 14 days. In one embodiment, CAB-ROR2-ADC is administered at a dose of 1.8 mg / kg on day 1 and day 8 of each 21-day cycle for more than one consecutive 21-day cycle.
[0562] Such treatment regimens are surprisingly effective because the antibody-drug conjugates of the present invention administered at such doses and such intervals provide surprisingly high response rates and acceptable toxicity or tolerability characteristics. Thus, the present method provides a safe and effective dosing regimen for administering CAB-ROR2-ADC antibody-drug conjugates to an individual. In some embodiments, the dosing regimen increases the probability that an individual will respond to treatment compared to other dosing regimens. In some embodiments, the dosing regimen does not increase the probability of an individual experiencing adverse events (including dose-limiting toxicities) compared to other dosing regimens. The present invention also provides maintenance therapy performed according to the dosing regimen.
[0563] In yet another embodiment, a method of treating a tumor expressing ROR2 comprises administering to a human subject in need of such treatment a composition comprising BA3021-cleavable linker-MMAE. (n) A pharmaceutical composition comprising a CAB-ROR2-ADC and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is administered by intravenous infusion at a dose of 1.8 mg / kg body weight of a human subject every 14 days.
[0564] For example, BA3021-cleavable linker-MMAE of the present invention (n) CAB-ROR2-ADCs bind preferentially under specific physiological conditions associated with different diseases and tissues. For example, in cancer, the unique cellular metabolism described by Warburg (Warburg 1924; Warburg 1956) contributes to a characteristic tumor microenvironment (TME), such as low pH and high lactate. (n) Utilizing a unique TME, it selectively binds to its target when in close proximity to ROR2-expressing tumors. BA3021-cleavable linker-MMAE (n) The activation binding properties of the protein are reversible, such that no permanent changes occur when it transitions from a normal to a diseased tissue microenvironment.
[0565] In yet another embodiment, the tumor membrane percent score (TmPS) of a tumor expressing ROR2 is at least 1, at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, or at least 95. In one embodiment, the tumor membrane P score of a tumor expressing ROR2 is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%.
[0566] In another aspect, the present invention provides methods for treating immune disorders (e.g., autoimmune diseases), cardiovascular diseases (e.g., atherosclerosis, hypertension, thrombosis), infectious diseases (e.g., Ebola virus, Marburg virus), or diabetes. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent as described below. The "individual" according to any of the above embodiments may be a human.
[0567] On the other hand, the present invention provides a method for inhibiting angiogenesis, inhibiting cell proliferation, inhibiting immune function, inhibiting inflammatory cytokine secretion (e.g., derived from tumor-associated macrophages), inhibiting tumor vasculature (e.g., intratumoral vasculature or tumor-associated vasculature) and / or inhibiting tumor interstitial function in an individual. In one embodiment, the method comprises administering to the individual an effective amount of an anti-ROR2 antibody or antibody fragment to inhibit angiogenesis, inhibit cell proliferation, promote immune function, induce inflammatory cytokine secretion (e.g., derived from tumor-associated macrophages), inhibit tumor vasculature development (e.g., intratumoral vasculature or tumor-associated vasculature) and / or inhibit tumor interstitial function. In one embodiment, an "individual" can be a human.
[0568] In another aspect, the present invention provides a pharmaceutical formulation comprising any of the anti-ROR2 antibodies or antibody fragments provided herein, for example, for use in any of the above-described treatment methods. In one embodiment, the pharmaceutical formulation comprises any of the anti-ROR2 antibodies or antibody fragments provided herein and a pharmaceutically acceptable carrier. In another embodiment, the pharmaceutical formulation comprises any of the anti-ROR2 antibodies or antibody fragments provided herein and at least one additional therapeutic agent, for example, as described below.
[0569] In each of the above-mentioned treatments, the antibodies or antibody fragments of the present invention can be used alone, as an immunoconjugate, or in combination with other agents in the treatment. For example, the antibodies of the present invention can be co-administered with at least one additional therapeutic agent. In certain embodiments, the additional therapeutic agent is an anti-angiogenic agent. In certain embodiments, the additional therapeutic agent is a VEGF antagonist (in some embodiments, an anti-VEGF antibody such as bevacizumab). In certain embodiments, the additional therapeutic agent is an EGFR antagonist (in some embodiments, erlotinib). In certain embodiments, the additional therapeutic agent is a chemotherapeutic agent and / or a cytostatic agent. In certain embodiments, the additional therapeutic agent is a taxane compound (e.g., paclitaxel) and / or a platinum agent (e.g., carboplatin). In certain embodiments, the additional therapeutic agent is an agent that enhances the patient's immunity or immune system.
[0570] Such combination therapies described above encompass both combined administration (wherein two or more therapeutic agents are contained in the same or separate formulations) and separate administration, in which case the administration of the antibody or antibody fragment can be performed before, simultaneously with, and / or after the administration of the additional therapeutic agent and / or adjuvant. The antibody or antibody fragment can also be used in combination with radiation therapy.
[0571] Antibodies or antibody fragments can be formulated, dosed, and administered in a manner consistent with good medical practice. In this context, factors to be considered include the specific disease being treated, the specific mammal being treated, the clinical condition of the individual patient, the cause of the disease, the delivery site of the medicament, the method of administration, the administration plan, and other factors known to medical practitioners. Antibodies or antibody fragments need not but are optionally formulated with one or more agents currently used to prevent or treat the disease in question. The effective amount of such other agents depends on the amount of the antibody or antibody fragment present in the formulation, the type of disease or treatment, and other factors discussed above. These are typically used in the same dosages and routes of administration as described herein, or about 1% to 99% of the dosages described herein, or in any dosage and any route determined to be suitable empirically / clinically.
[0572] For the prevention or treatment of disease, the appropriate dosage of the antibody or antibody fragment (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease being treated, the type of antibody or antibody fragment, the severity and course of the disease, whether the antibody or antibody fragment is used for prevention or treatment purposes, previous treatment, the patient's clinical history and the reaction to the antibody or antibody fragment and the judgment of the attending physician. The antibody or antibody fragment is suitable for one-time or a series of treatments administered to the patient. Depending on the type and severity of the disease, an antibody or antibody fragment of about 1 μg / kg to 40 mg / kg can be used as an initial candidate dose for administration to the patient, for example, by one or more separate administrations or by continuous infusion. According to the factors mentioned above, a typical daily dose range can be about 1 μg / kg to 100 mg / kg or more. For repeated administration over several days or longer, depending on the condition, treatment will typically continue until the disease symptoms are suppressed as desired. Such dosage can be intermittent, for example, administered weekly or every three weeks (for example, so that the patient receives about two to about twenty doses, or for example, about six doses of the antibody or antibody fragment). An initial higher loading dose may be administered, followed by one or more lower doses. However, other dosing regimens may also be useful. The progress of the treatment can be easily monitored by conventional techniques and assays.
[0573] It will be understood that any of the above-described formulations or treatment methods can be performed using an antibody fragment or immunoconjugate of the invention instead of or in addition to an anti-ROR2 antibody.
[0574] Enhancing the host's immune function to fight tumors is a topic of increasing interest. Conventional methods include (i) APC enhancement, such as (a) injecting DNA encoding exogenous MHC alloantigens into the tumor, or (b) transfecting biopsied tumor cells with genes that increase the probability of tumor immune antigen recognition (e.g., immunostimulatory cytokines, GM-CSF, costimulatory molecules B7.1, B7.2), (iii) adoptive cellular immunotherapy, or treatment with activated tumor-specific T cells. Adoptive cellular immunotherapy includes isolating tumor-infiltrating host T lymphocytes and expanding the cell population in vitro, for example, by IL-2 or tumor or both. In addition, the isolated dysfunctional T cells can also be activated by applying the anti-PD-L1 antibodies of the present invention in vitro. The T cells so activated can then be re-administered to the host. One or more of these methods can be used in combination with the administration of the antibodies, antibody fragments or immunoconjugates of the present invention.
[0575] Conventional treatments for cancer include: (i) radiation therapy (e.g., radiotherapy, X-ray therapy, irradiation), or the use of ionizing radiation to kill cancer cells and shrink tumors. Radiation therapy can be administered externally through external beam radiotherapy (EBRT) or internally through brachytherapy; (ii) chemotherapy, or the use of cytotoxic drugs that generally affect rapidly dividing cells; (iii) targeted therapy, or drugs that specifically affect unregulated proteins in cancer cells (e.g., tyrosine kinase inhibitors, imatinib, gefitinib; monoclonal antibodies, photodynamic therapy); (iv) immunotherapy, or boosting the host's immune response (e.g., vaccines); (v) hormone therapy, or hormone blockade (e.g., when the tumor is sensitive to hormones); (vi) angiogenesis inhibitors, or blocking blood vessel formation and growth; and (vii) palliative care, or treatments designed to improve the quality of care by reducing pain, nausea, vomiting, diarrhea, and bleeding. Analgesics such as morphine and oxycodone and antiemetics such as ondansetron and aprepitant may allow for more aggressive treatment regimens.
[0576] In the treatment of cancer, any conventional treatment previously described for treating cancer immunity can be performed before, after, or simultaneously with the administration of the anti-ROR2 antibody or antibody fragment. In addition, the anti-ROR2 antibody or antibody fragment can be administered before, after, or simultaneously with conventional cancer treatments, such as the administration of tumor-binding antibodies (e.g., monoclonal antibodies, toxin-conjugated monoclonal antibodies) and / or chemotherapeutic agents.
[0577] F. Medication regimen
[0578] The present invention provides a medication regimen for treating tumors expressing ROR2. The medication regimen comprises the following doses of a polypeptide, antibody, antibody fragment, or immunoconjugate of the present invention as described herein: about 0.3 mg / kg body weight to about 3.3 mg / kg body weight, about 0.4 mg / kg body weight to about 3.3 mg / kg body weight, about 0.5 mg / kg body weight to about 3.3 mg / kg body weight, about 0.6 mg / kg body weight to about 3.3 mg / kg body weight, about 0.7 mg / kg body weight to about 3.3 mg / kg body weight, about 0.8 mg / kg body weight to about 3.3 mg / kg body weight, about 0.9 mg / kg body weight to about 3.3 mg / kg body weight, about 1.0 mg / kg body weight to about 3.3 mg / kg body weight, about 1.1 mg / kg body weight About 3.3 mg / kg body weight, about 1.2 mg / kg body weight to about 3.3 mg / kg body weight, about 1.3 mg / kg body weight to about 3.3 mg / kg body weight, about 1.4 mg / kg body weight to about 3.3 mg / kg body weight, about 1.5 mg / kg body weight to about 3.3 mg / kg body weight, about 1.6 mg / kg body weight to about 3.3 mg / kg body weight, about 1.7 mg / kg body weight to about 3.3 mg / kg body weight, about 1.8 mg / kg body weight to about 3.3 mg / kg body weight, about 1.9 mg / kg body weight to about 3.3 mg / kg body weight, about 2.0 mg / kg body weight to about 3.3 mg / kg body weight, about 2.1 mg / kg body weight to about 3.3 mg / kg body weight about 3.3 mg / kg body weight, about 2.2 mg / kg body weight to about 3.3 mg / kg body weight, about 2.3 mg / kg body weight to about 3.3 mg / kg body weight, about 2.4 mg / kg body weight to about 3.3 mg / kg body weight, about 2.5 mg / kg body weight to about 3.3 mg / kg body weight, about 2.6 mg / kg body weight to about 3.3 mg / kg body weight, about 2.7 mg / kg body weight to about 3.3 mg / kg body weight, about 2.8 mg / kg body weight to about 3.3 mg / kg body weight, about 2.9 mg / kg body weight to about 3.3 mg / kg body weight, about 3.0 mg / kg body weight to about 3.3 mg / kg body weight, about 3.1 mg / kg body weight to about 3.3 mg / kg body weight, about 3.2 mg / kg body weight to about 3.3 mg / kg body weight, about 0.3 mg / kg body weight to about 1.8 mg / kg body weight, about 0.4 mg / kg body weight to about 1.8 mg / kg body weight, about 0.5 mg / kg body weight to about 1.8 mg / kg body weight, about 0.6 mg / kg body weight to about 1.8 mg / kg body weight, about 0.7 mg / kg body weight to about 1.8 mg / kg body weight, about 0.8 mg / kg body weight to about 1.8 mg / kg body weight, about 0.9 mg / kg body weight to about 1.8 mg / kg body weight, about 1.0 mg / kg body weight to about 1.8 mg / kg body weight, about 1.1 mg / kg body weight to about 1.In some embodiments, the dosage of the drug is from about 1.5 mg / kg body weight to about 1.8 mg / kg body weight, from about 1.4 mg / kg body weight to about 1.8 mg / kg body weight, from about 1.5 mg / kg body weight to about 1.8 mg / kg body weight, from about 1.6 mg / kg body weight to about 1.8 mg / kg body weight, or from about 1.7 mg / kg body weight to about 1.8 mg / kg body weight for at least 2 weeks (e.g., 14 days) or 3 weeks (e.g., 21 days). More preferably, from about 1.5 mg / kg body weight to about 1.8 mg / kg body weight for at least 2 weeks (e.g., 14 days) or 3 weeks (e.g., 21 days). Most preferably, from about 1.5 mg / kg body weight to about 1.8 mg / kg body weight for at least 2 weeks (e.g., 14 days). The dosage of each (bi) week ((bi) weekly dose) can be administered as a (bi) week dosage (once a week) or in split delivery (split delivery) (e.g., twice or more per (bi) week). In some embodiments, the (bi)weekly dose of a polypeptide, antibody or antibody fragment or immunoconjugate of the invention described herein may be 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2 or 3.3 mg / kg body weight of the individual.
[0579] In certain embodiments, the dosage regimen comprises the following doses of an anti-ROR2 antibody or antibody fragment of the invention as described herein, or an immunoconjugate comprising an anti-ROR2 antibody or antibody fragment: about 0.3 mg / kg body weight to about 3.3 mg / kg body weight, about 0.4 mg / kg body weight to about 3.3 mg / kg body weight, about 0.5 mg / kg body weight to about 3.3 mg / kg body weight, about 0.6 mg / kg body weight to about 3.3 mg / kg body weight, about 0.7 mg / kg body weight to about 3.3 mg / kg body weight, about 0.8 mg / kg body weight to about 3.3 mg / kg body weight, about 0.9 mg / kg body weight to about 3.3 mg / kg body weight, about 1.0 mg / kg body weight to about 3.3 mg / kg body weight. 3 mg / kg body weight, about 1.1 mg / kg body weight to about 3.3 mg / kg body weight, about 1.2 mg / kg body weight to about 3.3 mg / kg body weight, about 1.3 mg / kg body weight to about 3.3 mg / kg body weight, about 1.4 mg / kg body weight to about 3.3 mg / kg body weight, about 1.5 mg / kg body weight to about 3.3 mg / kg body weight, about 1.6 mg / kg body weight to about 3.3 mg / kg body weight, about 1.7 mg / kg body weight to about 3.3 mg / kg body weight, about 1.8 mg / kg body weight to about 3.3 mg / kg body weight, about 1.9 mg / kg body weight to about 3.3 mg / kg body weight, about 2.0 mg / kg body weight to about 3.3 mg / kg body weight , about 2.1 mg / kg body weight to about 3.3 mg / kg body weight, about 2.2 mg / kg body weight to about 3.3 mg / kg body weight, about 2.3 mg / kg body weight to about 3.3 mg / kg body weight, about 2.4 mg / kg body weight to about 3.3 mg / kg body weight, about 2.5 mg / kg body weight to about 3.3 mg / kg body weight, about 2.6 mg / kg body weight to about 3.3 mg / kg body weight, about 2.7 mg / kg body weight to about 3.3 mg / kg body weight, about 2.8 mg / kg body weight to about 3.3 mg / kg body weight, about 2.9 mg / kg body weight to about 3.3 mg / kg body weight, about 3.0 mg / kg body weight to about 3.3 mg / kg body weight, about 3.1 mg / kg body weight to about 3.3 mg / kg body weight, about 3.2 mg / kg body weight to about 3.3 mg / kg body weight, about 0.3 mg / kg body weight to about 1.8 mg / kg body weight, about 0.4 mg / kg body weight to about 1.8 mg / kg body weight, about 0.5 mg / kg body weight to about 1.8 mg / kg body weight, about 0.6 mg / kg body weight to about 1.8 mg / kg body weight, about 0.7 mg / kg body weight to about 1.8 mg / kg body weight, about 0.8 mg / kg body weight to about 1.8 mg / kg body weight, about 0.9 mg / kg body weight to about 1.8 mg / kg body weight, about 1.0 mg / kg body weight to about 1.8 mg / kg body weight, about 1.1 mg / kg body weight to about 1.The dosage of about 1.5mg / kg body weight is about 1.8mg / kg body weight, about 1.6mg / kg body weight is about 1.8mg / kg body weight or about 1.7mg / kg body weight is about 1.8mg / kg body weight, continues at least 2 weeks (for example 14 days) or 3 weeks (for example 21 days). More preferably, about 1.5mg / kg body weight is about 1.8mg / kg body weight, continues at least 2 weeks (for example 14 days) or 3 weeks (for example 21 days). Most preferably, about 1.5mg / kg body weight is about 1.8mg / kg body weight, continues at least 2 weeks (for example 14 days).The dosage of every (double) week can be used as a every (double) weekly dosage (once a week) or divided delivery and use (for example every (double) week twice or more times). In some embodiments, the amount per (bi-)weekly dose of an anti-ROR2 antibody or antibody fragment of the invention, or an immunoconjugate comprising an anti-ROR2 antibody or antibody fragment as described herein, is 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, or 3.3 mg / kg body weight of the individual.
[0580] In certain embodiments, the dosage regimen comprises an antibody-drug conjugate as described herein at a dose of about 0.3 mg / kg body weight to about 3.3 mg / kg body weight, about 0.4 mg / kg body weight to about 3.3 mg / kg body weight, about 0.5 mg / kg body weight to about 3.3 mg / kg body weight, about 0.6 mg / kg body weight to about 3.3 mg / kg body weight, about 0.7 mg / kg body weight to about 3.3 mg / kg body weight, about 0.8 mg / kg body weight to about 3.3 mg / kg body weight, about 0.9 mg / kg body weight to about 3.3 mg / kg body weight, about 1.0 mg / kg body weight to about 3.3 mg / kg body weight, about 1.1 mg / kg body weight to about 3.3 mg / kg body weight. body weight, about 1.2 mg / kg body weight to about 3.3 mg / kg body weight, about 1.3 mg / kg body weight to about 3.3 mg / kg body weight, about 1.4 mg / kg body weight to about 3.3 mg / kg body weight, about 1.5 mg / kg body weight to about 3.3 mg / kg body weight, about 1.6 mg / kg body weight to about 3.3 mg / kg body weight, about 1.7 mg / kg body weight to about 3.3 mg / kg body weight, about 1.8 mg / kg body weight to about 3.3 mg / kg body weight, about 1.9 mg / kg body weight to about 3.3 mg / kg body weight, about 2.0 mg / kg body weight to about 3.3 mg / kg body weight, about 2.1 mg / kg body weight to about 3.3 mg / kg body weight, about 2.2 mg / kg body weight g body weight to about 3.3 mg / kg body weight, about 2.3 mg / kg body weight to about 3.3 mg / kg body weight, about 2.4 mg / kg body weight to about 3.3 mg / kg body weight, about 2.5 mg / kg body weight to about 3.3 mg / kg body weight, about 2.6 mg / kg body weight to about 3.3 mg / kg body weight, about 2.7 mg / kg body weight to about 3.3 mg / kg body weight, about 2.8 mg / kg body weight to about 3.3 mg / kg body weight, about 2.9 mg / kg body weight to about 3.3 mg / kg body weight, about 3.0 mg / kg body weight to about 3.3 mg / kg body weight, about 3.1 mg / kg body weight to about 3.3 mg / kg body weight, about 3.2 mg / kg body weight to about 3.3 mg / kg body weight g / kg body weight, about 0.3 mg / kg body weight to about 1.8 mg / kg body weight, about 0.4 mg / kg body weight to about 1.8 mg / kg body weight, about 0.5 mg / kg body weight to about 1.8 mg / kg body weight, about 0.6 mg / kg body weight to about 1.8 mg / kg body weight, about 0.7 mg / kg body weight to about 1.8 mg / kg body weight, about 0.8 mg / kg body weight to about 1.8 mg / kg body weight, about 0.9 mg / kg body weight to about 1.8 mg / kg body weight, about 1.0 mg / kg body weight to about 1.8 mg / kg body weight, about 1.1 mg / kg body weight to about 1.8 mg / kg body weight, about 1.4 mg / kg body weight to about 1.8 mg / kg body weight, about 1.The dosage of each (double) week can be used as single every (double) weekly dose (every (double) weekly dose once) or divided delivery administration (for example every (double) weekly twice or more times). In some embodiments, the (bi)weekly dose of the antibody drug conjugate is 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, or 3.3 mg / kg body weight of the subject.
[0581] In certain embodiments, the dosage is delivered in divided doses or administered as a single weekly dose for at least one 2-week (e.g., 14-day) treatment cycle or at least one 3-week (e.g., 21-day) treatment cycle. In some embodiments, the dosage will be administered on the 1st and 8th day of a 14-day treatment cycle with a single dose. Preferably, the dosage is delivered in divided doses or administered as a single dose for two or more 14-day treatment cycles, even more preferably for three or more, four or more, five or even six or more treatment cycles. In some embodiments, the dosage is no more than 3, no more than 4, no more than 5 or no more than 6 treatment cycles. In some embodiments, the dosage is administered on the 1st and 8th day of a 21-day treatment cycle with a weekly dose. Preferably, the dosage is delivered in divided doses or administered as a single dose for two or more 21-day treatment cycles, even more preferably for three or more, four or more, five or even six or more treatment cycles. In some embodiments, the dosage is no more than 3, no more than 4, no more than 5 or no more than 6 treatment cycles. In some embodiments, there will be a rest period between treatment cycles.
[0582] For example, in some embodiments, the dosing regimen will be the following total weekly dose of the antibody-drug conjugate: about 0.3 mg / kg body weight to about 3.3 mg / kg body weight, about 0.4 mg / kg body weight to about 3.3 mg / kg body weight, about 0.5 mg / kg body weight to about 3.3 mg / kg body weight, about 0.6 mg / kg body weight to about 3.3 mg / kg body weight, about 0.7 mg / kg body weight to about 3.3 mg / kg body weight, about 0.8 mg / kg body weight to about 3.3 mg / kg body weight, about 0.9 mg / kg body weight to about 3.3 mg / kg body weight, about 1.0 mg / kg body weight to about 3.3 mg / kg body weight, about 1.1 mg / kg body weight to about 3.3 mg / kg body weight, about 1.2 mg / kg body weight to about 3.3 mg / kg body weight, about 0. In some embodiments, the treatment cycle will be more than 7 days. In some embodiments, treatment will be continued for at least two treatment cycles, with a 1-week rest period between each treatment cycle. In some embodiments, treatment will be more than 21 days. The weekly dose can be administered as a single weekly dose (once per week) or in divided deliveries (eg, two or more times per week).
[0583] In some preferred embodiments, the dosage regimen can be the following total biweekly dose of antibody-drug conjugate: about 0.8 mg / kg body weight to about 1.8 mg / kg body weight, about 0.9 mg / kg body weight to about 1.8 mg / kg body weight, about 1.0 mg / kg body weight to about 1.8 mg / kg body weight, about 1.1 mg / kg body weight to about 1.8 mg / kg body weight, about 1.2 mg / kg body weight to about 1.8 mg / kg body weight, about 1.3 mg / kg body weight to about 1.8 mg / kg body weight, about 1.4 mg / kg body weight to about 1.8 mg / kg body weight or about 1.5 mg / kg body weight to about 1.8 mg / kg body weight, for at least one biweekly (e.g., 14-day) treatment cycle. In some embodiments, the treatment cycle will exceed 14 days. In some embodiments, treatment will continue for at least two treatment cycles with a 2-week rest period (period of rest) between each treatment cycle (e.g., administering a single dose once a week for a total of six times over an eight-week period). In some embodiments, the treatment cycle will exceed 21 days. The biweekly dose can be administered as a single biweekly dose (once every 2 weeks) or in divided deliveries (eg, two or more times every 2 weeks).
[0584] In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in 2 weeks can be about 0.3 mg / kg body weight to about 1.8 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in two weeks can be about 0.4 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in two weeks can be about 0.5 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in two weeks can be about 0.6 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once every two weeks can be about 0.7 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once every two weeks can be about 0.8 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once every two weeks can be about 0.9 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once every two weeks can be about 1.0 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once every two weeks can be about 1.1 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once every two weeks can be about 1.2 mg / kg body weight, in a single weekly dose (once a week) or in divided doses (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once every two weeks can be about 1.3 mg / kg body weight, in a single weekly dose (once a week) or in divided doses (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once every two weeks can be about 1.4 mg / kg body weight, in a single weekly dose (once a week) or in divided doses (e.g., twice a week or more).In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in two weeks can be about 1.5 mg / kg body weight in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in two weeks can be about 1.6 mg / kg body weight in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in two weeks can be about 1.7 mg / kg body weight in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in two weeks can be about 1.8 mg / kg body weight in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once every two weeks can be 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, or 3.3 mg / kg body weight of the individual.
[0585] In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 0.3 mg / kg body weight to about 3.3 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 0.4 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 0.5 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 0.6 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 0.7 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 0.8 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 0.9 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 1.0 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 1.1 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 1.2 mg / kg body weight, in a single weekly dose (once a week) or in divided doses (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 1.3 mg / kg body weight, in a single weekly dose (once a week) or in divided doses (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 1.4 mg / kg body weight, in a single weekly dose (once a week) or in divided doses (e.g., twice a week or more).In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 1.5 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 1.6 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 1.7 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 1.8 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 1.9 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 2.0 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 2.1 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 2.2 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 2.3 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 2.4 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once every three weeks can be about 2.5 mg / kg body weight in a single weekly dose (once a week) or in divided doses (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once every three weeks can be about 2.6 mg / kg body weight in a single weekly dose (once a week) or in divided doses (e.g., twice a week or more).In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 2.7 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 2.8 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 2.9 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 3.0 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 3.1 mg / kg body weight, in a single weekly dose (once a week) or in a divided delivery (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be about 3.2 mg / kg body weight, in a single weekly dose (once a week) or in divided doses (e.g., twice a week or more). In some embodiments, the weekly dose of the antibody drug conjugate administered at least once in three weeks can be 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2 or 3.3 mg / kg body weight of the individual.
[0586] The treatment cycle of 2 weeks (14 days) with a rest period of one week between the treatment cycles can also be referred to as 3 weeks (21 days) treatment cycles, wherein in 3 weeks in 3 weeks of the treatment cycles, there are 2 weeks to deliver antibody-drug conjugates. Similarly, the treatment cycle of 3 weeks (21 days) with a rest period of one week between the treatment cycles can also be referred to as 4 weeks (28 days) treatment cycles, wherein in 4 weeks in 4 weeks of the treatment cycles, there are 3 weeks to deliver antibody-drug conjugates. Thus, in some embodiments, 2 weeks in 3 weeks in 3 weeks of the treatment cycles, dosage is applied weekly in the mode of fractional delivery or single weekly dose, or 3 weeks in 4 weeks in 4 weeks of the treatment cycles, dosage is applied weekly in the mode of fractional delivery or single weekly dose. In some embodiments, the dosage can be applied on the 1st day and the 8th day of 14 day treatment cycles as a single weekly dose, the dosage can be applied on the 1st day and the 8th day of 21 day treatment cycles as a single weekly dose, or the dosage can be applied on the 1st day and the 8th day of 28 day treatment cycles as a single weekly dose. Preferably, the weekly dose is administered in divided doses or a single weekly dose for two or more 4-week treatment cycles, even more preferably for three or more, four or more, five or more, or even six or more 4-week treatment cycles (e.g., 2, 3, 4, 5, or 6 consecutive treatment cycles). In some embodiments, the weekly dose is administered for no more than 3, no more than 4, no more than 5, or no more than 6 treatment cycles.
[0587] For example, in some embodiments, the dosage regimen can be weekly dosages, delivered in divided doses or in a single weekly dose, with a total weekly dosage of the antibody-drug conjugate of about 0.8 mg / kg body weight to about 1.8 mg / kg body weight, about 0.9 mg / kg body weight to about 1.8 mg / kg body weight, about 1.0 mg / kg body weight to about 1.8 mg / kg body weight, about 1.1 mg / kg body weight to about 1.8 mg / kg body weight, about 1.2 mg / kg body weight to about 1.8 mg / kg body weight, about 1.3 mg / kg body weight to about 1.8 mg / kg body weight, about 1.4 mg / kg body weight to about 1.8 mg / kg body weight, about 1.5 mg / kg body weight to about 1.8 mg / kg body weight, about 1.6 mg / kg body weight to about 1.8 mg / kg body weight, about 1.7 mg / kg body weight to about 1.8 mg / kg body weight, or about 1.8 mg / kg body weight for at least one 2-week treatment cycle, administered 1 week out of 2 weeks in a cycle, or for at least two 3-week treatment cycles, administered 2 weeks out of 3 weeks in a cycle.
[0588] For example, in some embodiments, the dosing regimen can be weekly dosing, with a total weekly dose of the antibody drug conjugate being about 0.8 mg / kg body weight to about 3.3 mg / kg body weight, about 0.9 mg / kg body weight to about 3.3 mg / kg body weight, about 1.0 mg / kg body weight to about 3.3 mg / kg body weight, about 1.1 mg / kg body weight to about 3.3 mg / kg body weight, about 1.2 mg / kg body weight to about 3.3 mg / kg body weight, about 1.3 mg / kg body weight to about 3.3 mg / kg body weight, about 1.4 mg / kg body weight to about 3.3 mg / kg body weight, about 1.5 mg / kg body weight to about 3.3 mg / kg body weight, about 1.6 mg / kg body weight to about 3.3 mg / kg body weight, about 1.7 mg / kg body weight to about 3.3 mg / kg body weight, about 1.8 mg / kg body weight to about 3.3 mg / kg body weight, about 1.9 mg / kg body weight to about 3.3 mg / kg body weight, in divided doses or in a single weekly dose. , about 2.0 mg / kg body weight to about 3.3 mg / kg body weight, about 2.1 mg / kg body weight to about 3.3 mg / kg body weight, about 2.2 mg / kg body weight to about 3.3 mg / kg body weight, about 2.3 mg / kg body weight to about 3.3 mg / kg body weight, about 2.4 mg / kg body weight to about 3.3 mg / kg body weight, about 2.5 mg / kg body weight to about 3.3 mg / kg body weight, about 2.6 mg / kg body weight to about 3.3 mg / kg body weight, about 2.7 mg / kg body weight to about 3.3 mg / kg body weight, about 2.8 mg / kg body weight to about 3.3 mg / kg body weight, about 2.9 mg / kg body weight to about 3.3 mg / kg body weight, about 3.0 mg / kg body weight to about 3.3 mg / kg body weight, about 3.1 mg / kg body weight to about 3.3 mg / kg body weight, about 3.2 mg / kg body weight to about 3.3 mg / kg body weight, or about 3.3 mg / kg body weight, for 2 weeks out of 3 for at least one 3 week treatment cycle. In some embodiments, the weekly dose of the antibody drug conjugate administered 2 out of 3 weeks can be 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, or 3.3 mg / kg body weight of the individual.
[0589] In some embodiments, the dosage regimen can be a weekly dose, with a total weekly dose of the antibody drug conjugate being about 0.8 mg / kg body weight to about 3.3 mg / kg body weight, about 0.9 mg / kg body weight to about 3.3 mg / kg body weight, about 1.0 mg / kg body weight to about 3.3 mg / kg body weight, about 1.1 mg / kg body weight to about 3.3 mg / kg body weight, about 1.2 mg / kg body weight to about 3.3 mg / kg body weight, about 1.3 mg / kg body weight to about 3.3 mg / kg body weight, about 1.4 mg / kg body weight to about 3.3 mg / kg body weight, about 1.5 mg / kg body weight to about 3.3 mg / kg body weight, about 1.6 mg / kg body weight to about 3.3 mg / kg body weight, about 1.7 mg / kg body weight to about 3.3 mg / kg body weight, about 1.8 mg / kg body weight to about 3.3 mg / kg body weight, about 1.9 mg / kg body weight to about 3.3 mg / kg body weight, about 2 0 mg / kg body weight to about 3.3 mg / kg body weight, about 2.1 mg / kg body weight to about 3.3 mg / kg body weight, about 2.2 mg / kg body weight to about 3.3 mg / kg body weight, about 2.3 mg / kg body weight to about 3.3 mg / kg body weight, about 2.4 mg / kg body weight to about 3.3 mg / kg body weight, about 2.5 mg / kg body weight to about 3.3 mg / kg body weight, about 2.6 mg / kg body weight to about 3.3 mg / kg body weight, about 2.7 mg / kg body weight to about 3.3 mg / kg body weight, about 2.8 mg / kg body weight to about 3.3 mg / kg body weight, about 2.9 mg / kg body weight to about 3.3 mg / kg body weight, about 3.1 mg / kg body weight to about 3.3 mg / kg body weight, about 3.2 mg / kg body weight to about 3.3 g body weight to about 3.3 mg / kg body weight, about 2.8 mg / kg body weight to about 3.3 mg / kg body weight, about 2.9 mg / kg body weight to about 3.3 mg / kg body weight, about 3.0 mg / kg body weight to about 3.3 mg / kg body weight, about 3.1 mg / kg body weight to about 3.3 mg / kg body weight, about 3.2 mg / kg body weight to about 3.3 mg / kg body weight, or about 3.3 mg / kg body weight for at least two 4-week treatment cycles, 3 weeks out of 4 weeks in each cycle.
[0590] In some embodiments, the dosage regimen can be weekly doses, delivered in divided doses or in a single weekly dose, with a total weekly dose of the antibody drug conjugate being about 0.8 mg / kg body weight to about 3.3 mg / kg body weight, about 0.9 mg / kg body weight to about 3.3 mg / kg body weight, about 1.0 mg / kg body weight to about 3.3 mg / kg body weight, about 1.1 mg / kg body weight to about 3.3 mg / kg body weight, about 1.2 mg / kg body weight to about 3.3 mg / kg body weight, about 1.3 mg / kg body weight to about 3.3 mg / kg body weight, or about 1.3 mg / kg body weight to about 3.3 mg / kg body weight. about 3.3 mg / kg body weight, about 1.4 mg / kg body weight to about 3.3 mg / kg body weight, about 1.5 mg / kg body weight to about 3.3 mg / kg body weight, about 1.6 mg / kg body weight to about 3.3 mg / kg body weight, about 1.7 mg / kg body weight to about 3.3 mg / kg body weight, about 1.8 mg / kg body weight to about 3.3 mg / kg body weight, about 1.9 mg / kg body weight to about 3.3 mg / kg body weight, about 2.0 mg / kg body weight to about 3.3 mg / kg body weight, about 2.1 mg / kg body weight to about 3.3 mg / kg body weight, about 2.2 mg / kg body weight to about 3.3 mg / kg body weight, about 2.3 mg / kg body weight to about 3.3 mg / kg body weight, about 2.4 mg / kg body weight to about 3.3 mg / kg body weight, about 2.5 mg / kg body weight to about 3.3 mg / kg body weight, about 2.6 mg / kg body weight to about 3.3 mg / kg body weight, about 2.7 mg / kg body weight to about 3.3 mg / kg body weight, about 2.8 mg / kg body weight to about 3.3 mg / kg body weight, about 2.9 mg / kg body weight to about 3.3 mg / kg body weight, / kg body weight to about 3.3 mg / kg body weight, about 3.0 mg / kg body weight to about 3.3 mg / kg body weight, about 3.1 mg / kg body weight to about 3.3 mg / kg body weight, about 3.2 mg / kg body weight to about 3.3 mg / kg body weight, or about 3.3 mg / kg body weight for one, two, three, four, or five 4-week treatment cycles, administered 2 weeks out of 3 weeks in a cycle (e.g., four single weekly doses over a 6-week period, six single weekly doses over a 9-week period, or eight single weekly doses over a 12-week period).
[0591] In some embodiments, the dosage regimen can be weekly dosages, delivered in divided doses or in a single weekly dose, with a total weekly dosage of the antibody drug conjugate being about 0.8 mg / kg body weight to about 3.3 mg / kg body weight, about 0.9 mg / kg body weight to about 3.3 mg / kg body weight, about 1.0 mg / kg body weight to about 3.3 mg / kg body weight, about 1.1 mg / kg body weight to about 3.3 mg / kg body weight, about 1.2 mg / kg body weight to about 3.3 mg / kg body weight, about 1.3 mg / kg body weight to about 3.3 mg / kg body weight, or about 1.3 mg / kg body weight to about 3.3 mg / kg body weight. 3.3 mg / kg body weight, about 1.4 mg / kg body weight to about 3.3 mg / kg body weight, about 1.5 mg / kg body weight to about 3.3 mg / kg body weight, about 1.6 mg / kg body weight to about 3.3 mg / kg body weight, about 1.7 mg / kg body weight to about 3.3 mg / kg body weight, about 1.8 mg / kg body weight to about 3.3 mg / kg body weight, about 1.9 mg / kg body weight to about 3.3 mg / kg body weight, about 2.0 mg / kg body weight to about 3.3 mg / kg body weight, about 2.1 mg / kg body weight to about 3.3 mg / kg body weight about 3.3 mg / kg body weight, about 2.2 mg / kg body weight to about 3.3 mg / kg body weight, about 2.3 mg / kg body weight to about 3.3 mg / kg body weight, about 2.4 mg / kg body weight to about 3.3 mg / kg body weight, about 2.5 mg / kg body weight to about 3.3 mg / kg body weight, about 2.6 mg / kg body weight to about 3.3 mg / kg body weight, about 2.7 mg / kg body weight to about 3.3 mg / kg body weight, about 2.8 mg / kg body weight to about 3.3 mg / kg body weight, about 2.9 mg / kg body weight The dosage may be about 3.3 mg / kg body weight, about 3.0 mg / kg body weight to about 3.3 mg / kg body weight, about 3.1 mg / kg body weight to about 3.3 mg / kg body weight, about 3.2 mg / kg body weight to about 3.3 mg / kg body weight, or about 3.3 mg / kg body weight, optionally for one, two, three, four, or five 4-week treatment cycles, administered 3 weeks out of every 4 weeks (e.g., six single weekly doses over an 8-week period, nine single weekly doses over a 12-week period, or twelve single weekly doses over a 16-week period). In some embodiments, each dose of the antibody drug conjugate may be 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, or 3.3 mg / kg body weight of the individual.
[0592] In some preferred embodiments, the dosing regimen can be a biweekly dose, delivered in divided doses or a single biweekly dose, with a total biweekly dose of the antibody drug conjugate being about 0.8 mg / kg body weight to about 3.3 mg / kg body weight, about 0.9 mg / kg body weight to about 3.3 mg / kg body weight, about 1.0 mg / kg body weight to about 3.3 mg / kg body weight, about 1.1 mg / kg body weight to about 3.3 mg / kg body weight, about 1.2 mg / kg body weight to about 3.3 mg / kg body weight, or about 1.3 mg / kg body weight to about 3.3 mg / kg body weight. g / kg body weight, about 1.3 mg / kg body weight to about 3.3 mg / kg body weight, about 1.4 mg / kg body weight to about 3.3 mg / kg body weight, about 1.5 mg / kg body weight to about 3.3 mg / kg body weight, about 1.6 mg / kg body weight to about 3.3 mg / kg body weight, about 1.7 mg / kg body weight to about 3.3 mg / kg body weight, about 1.8 mg / kg body weight to about 3.3 mg / kg body weight, about 1.9 mg / kg body weight to about 3.3 mg / kg body weight, about 2 0 mg / kg body weight to about 3.3 mg / kg body weight, about 2.1 mg / kg body weight to about 3.3 mg / kg body weight, about 2.2 mg / kg body weight to about 3.3 mg / kg body weight, about 2.3 mg / kg body weight to about 3.3 mg / kg body weight, about 2.4 mg / kg body weight to about 3.3 mg / kg body weight, about 2.5 mg / kg body weight to about 3.3 mg / kg body weight, about 2.6 mg / kg body weight to about 3.3 mg / kg body weight, about 2.7 mg / kg body weight to about 3.3 mg / kg body weight, about 2.8 mg / kg body weight to about 3.3 mg / kg body weight, about 2.9 mg / kg body weight to about 3.3 mg / kg body weight, about 3.0 mg / kg body weight to about 3.3 mg / kg body weight, about 3.1 mg / kg body weight to about 3.3 mg / kg body weight, about 3.2 mg / kg body weight to about 3.3 mg / kg body weight, or about 3.3 mg / kg body weight, optionally for one, two, three, four, or five four biweekly treatment cycles, with three biweekly doses administered every four biweekly cycles (e.g., six single biweekly doses over a 14-week period, nine single biweekly doses over a 20-week period, or twelve single weekly doses over a 26-week period). In some embodiments, each dose of the antibody drug conjugate administered biweekly may be 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, or 3.3 mg / kg body weight of the individual.
[0593] After or during one or more treatment cycles (e.g., during day 14 to day 21 of the second treatment cycle or day 21 to day 28 of the second treatment cycle), the individual can be evaluated (e.g., by clinical testing or diagnostic testing) to determine whether the individual should continue to maintain the treatment regimen. For example, after or during one or more 28-day treatment cycles (e.g., 1, 2, 3, 4, 5, or 6 28-day treatment cycles), the individual can be evaluated (e.g., clinical evaluation and / or diagnostic evaluation). Based on the results of the evaluation, the individual will stop treatment, continue treatment for additional treatment cycles, or begin maintenance treatment by continuing treatment until there is progression or unacceptable toxicity. If the individual continues treatment, the individual can be further evaluated after one or more additional treatment cycles. Based on each successive evaluation, the individual will stop treatment, continue treatment for additional treatment cycles, or begin maintenance treatment by continuing treatment until there is progression or unacceptable toxicity.
[0594] Embodiments encompassed by the present invention are where after an evaluation indicates that the individual has no detectable cancer, e.g., after a diagnostic test for a ROR2-expressing cancer is negative (i.e., the diagnostic test is unable to detect any cancer in the individual), the individual will continue to be in a treatment cycle (e.g., a 2-week treatment cycle or a 3-week treatment cycle). For example, in some embodiments, the individual will continue to be in a treatment cycle for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more treatment cycles after such an evaluation. In some embodiments, the individual will continue to be in a treatment cycle for at least 2 treatment cycles, but no more than 3, no more than 4, no more than 5, or no more than 6 treatment cycles. An example of a diagnostic test for determining the presence and severity of cancer is positron emission tomography (PET).
[0595] In some embodiments, the individual will start maintenance therapy by continuing treatment until there is progress or unacceptable toxicity after more than one, preferably more than two (e.g., 1, 2, 3, 4, 5, or 6) treatment cycles (e.g., 4-week treatment cycles). In some embodiments, after an evaluation shows that the individual has almost no or no detectable cancer, for example, after an evaluation shows that the individual has had a complete response, the individual will start maintenance therapy by continuing treatment until there is progress or unacceptable toxicity. As used herein, maintenance therapy refers to treatment with an antibody-drug conjugate, but using a simplified dosing regimen at the same or different doses, by continuing treatment until there is progress or unacceptable toxicity. During maintenance therapy, the antibody-drug conjugate is preferably administered at least once per 2-week treatment period, once per 3-week treatment period, on the 1st and 8th day of every 2-week treatment period, or on the 1st and 8th day of every 3-week treatment period. After these maintenance treatment cycles, the individual can be further evaluated (e.g., by clinical testing or diagnostic testing) to determine whether the individual should continue maintenance therapy, continue conventional treatment, or stop treatment. In some embodiments, maintenance therapy is performed once every 2 to 4 weeks or once every 3 to 6 weeks. The dosage range of the antibody drug conjugate administered during maintenance therapy can be, for example, from about 0.3 mg / kg body weight to about 3.3 mg / kg body weight, preferably from about 0.6 mg / kg body weight to about 1.8 mg / kg body weight, preferably from about 1.2 mg / kg body weight to about 2.0 mg / kg body weight, more preferably from about 1.5 mg / kg body weight to about 2.4 mg / kg body weight, wherein 1.8 mg / kg body weight is an exemplary dose.
[0596] In some embodiments, after completing weekly or biweekly treatment and evaluation at a dose of about 0.3 mg / kg body weight to about 3.3 mg / kg body weight of the antibody drug conjugate, more preferably about 1.5 mg / kg body weight to about 1.8 mg / kg body weight, the individual will begin maintenance therapy comprising administration of the antibody-drug conjugate once every 2 to 4 weeks or once every 3 to 6 weeks at a dose of about 0.3 mg / kg body weight to about 3.3 mg / kg body weight, preferably about 0.6 mg / kg body weight to about 1.8 mg / kg body weight, preferably about 1.2 mg / kg body weight to about 2.0 mg / kg body weight, more preferably about 1.5 mg / kg body weight to about 2.4 mg / kg body weight, wherein a dose of about 1.8 mg / kg body weight is preferred, preferably administered in a biweekly manner.
[0597] In some embodiments, after completion of treatment (e.g., one, two, three, four, or five treatment cycles), the subject will begin a bi-weekly regimen of antibody drug conjugate administration (e.g., treatment on day 1 of a two-week maintenance treatment cycle) at a dose of about 0.3 mg / kg body weight to about 3.3 mg / kg body weight, preferably about 0.6 mg / kg body weight to about 1.8 mg / kg body weight, preferably about 1.2 mg / kg body weight to about 2.0 mg / kg body weight, more preferably about 1.5 mg / kg body weight to about 2.4 mg / kg body weight, with about 1.8 mg / kg body weight being preferred.
[0598] In some embodiments, after completion of treatment (e.g., one, two, three, four, or five treatment cycles), the subject begins a once-every-three-week regimen of antibody drug conjugate administration (e.g., treatment on Day 1 of a three-week maintenance treatment cycle) at a dose of about 0.3 mg / kg body weight to about 3.3 mg / kg body weight, preferably about 0.6 mg / kg body weight to about 1.8 mg / kg body weight, preferably about 1.2 mg / kg body weight to about 2.0 mg / kg body weight, more preferably about 1.5 mg / kg body weight to about 2.4 mg / kg body weight, with about 1.8 mg / kg body weight being preferred.
[0599] Contemplated embodiments are those in which a weekly dose of the antibody drug conjugate can be administered to a subject in divided doses or in a single weekly dose, for a total weekly dose of about 0.3 mg / kg body weight to about 3.3 mg / kg body weight, about 0.6 mg / kg body weight to about 1.8 mg / kg body weight, about 1.2 mg / kg body weight to about 2.0 mg / kg body weight, about 1.5 mg / kg body weight to about 2.4 mg / kg body weight, preferably about 1.8 mg / kg body weight, for one, two, three, four, five, or six 21-day treatment cycles, administered for two of the three weeks of a cycle, followed by a dose every two to four weeks, preferably a dose every two weeks of the antibody drug conjugate at a dose of about 0.4 mg / kg body weight to about 2 mg / kg body weight, about 0.6 mg / kg body weight to about 2.0 mg / kg body weight, or about 0.8 mg / kg body weight to about 1.8 mg / kg body weight, for two or more maintenance treatment cycles. In some embodiments, weekly administration may continue for 2, 3, 4, 5, 6, 7, 8, 9 or more treatment cycles, and biweekly administration may continue for 2, 3, 4, 5, 6, 7, 8, 9 or more maintenance treatment cycles. In some embodiments, the (bi)weekly administration cycle may not exceed 2, 3, 4, 5 or 6 treatment cycles.
[0600] Contemplated embodiments are those in which a weekly dose of the antibody drug conjugate can be administered to a subject in divided doses or in a single weekly dose, with a total weekly dose of about 0.3 mg / kg body weight to about 3.3 mg / kg body weight, about 0.6 mg / kg body weight to about 1.8 mg / kg body weight, about 1.2 mg / kg body weight to about 2.0 mg / kg body weight, about 1.5 mg / kg body weight to about 2.4 mg / kg body weight, for one, two, three, four, five, or six 28-day treatment cycles, with administration for three of four weeks in each cycle, followed by a dose every three to six weeks, preferably a dose of the antibody drug conjugate at a dose of about 0.3 mg / kg body weight to about 3.3 mg / kg body weight, about 0.6 mg / kg body weight to about 1.8 mg / kg body weight, or about 1.2 mg / kg body weight to about 2.0 mg / kg body weight every three weeks for two or more maintenance treatment cycles. In some embodiments, the weekly administration cycle can continue for 2, 3, 4, 5, 6, 7, 8, 9 or more treatment cycles, and the 3-week administration regimen can continue for 2, 3, 4, 5, 6, 7, 8, 9 or more maintenance treatment cycles. In some embodiments, the 3-week administration cycle may not exceed 2, 3, 4, 5 or 6 treatment cycles.
[0601] The present invention encompasses embodiments in which weekly doses of an antibody drug conjugate are administered to an individual in divided doses or in a single weekly dose, with a total weekly dose of about 0.8 mg / kg of the individual's body weight to about 1.8 mg / kg for one, two, three, four, five, or six 21-day treatment cycles, administered for 2 of the 3 weeks in each cycle (e.g., on days 1 and 8 of a 21-day treatment cycle), followed by a dose every 2 to 4 weeks, preferably a dose of about 1.8 mg / kg of body weight of the antibody drug conjugate every 2 weeks for more than 2 maintenance treatment cycles (e.g., a dose of about 1.8 mg / kg of body weight administered every 2 weeks for more than 2 2-week maintenance treatment cycles). Preferably, the biweekly dose of the antibody drug conjugate is about 0.8 mg / kg of body weight for more than 2 maintenance treatment cycles (e.g., a dose of about 0.8 mg / kg of body weight administered every 2 weeks for more than 2 2-week maintenance treatment cycles).
[0602] The embodiment encompassed by the present invention is wherein the antibody drug conjugate is administered to an individual in a fractionated delivery or in a single weekly dose, with a total weekly dose of about 0.8 mg / kg body weight to about 1.8 mg / kg body weight for one, two, three, four, five, or six 28-day treatment cycles, with 3 weeks of administration in each treatment cycle (e.g., on the 1st and 8th day of a 28-day treatment cycle), followed by one dose every 3 to 6 weeks. The antibody drug conjugate administered once every 3 weeks can be a dose of about 1.8 mg / kg body weight for more than 2 maintenance treatment cycles (e.g., a dose of about 1.8 mg / kg body weight once every 3 weeks for more than two 3-week maintenance treatment cycles). The antibody drug conjugate administered once every 3 weeks can be a dose of about 0.8 mg / kg body weight for more than 2 maintenance treatment cycles (e.g., a dose of about 0.8 mg / kg body weight once every 3 weeks for more than two 3-week maintenance treatment cycles).
[0603] The present invention encompasses embodiments wherein mAbBA301-cleavable linker-MMAE of the present invention is used. (n) Individuals treated with an antibody-drug conjugate, but treated with a regimen other than a bi-weekly regimen (e.g., an antibody drug conjugate administered at a dose of about 1.8 mg / kg body weight every 1 or 2 weeks for more than one 2-week treatment cycle, or administered once every 3 weeks for more than one 3-week treatment cycle), are switched to a weekly regimen as described herein for no more than 1, 2, 3, 4, 5, or 6 treatment cycles. Following the weekly regimen, the patient may optionally begin maintenance therapy as described herein.
[0604] Preferably, antibody-drug conjugates are administered as monotherapy. The term "monotherapy" refers to that the antibody drug conjugate is the only anticancer agent administered to an individual during the treatment cycle. However, as described herein, other therapeutic agents can be administered to an individual. For example, programmed death receptor-1 (PD-1) blocking antibodies or granulocyte colony stimulating factor or its analog can be co-administered with the antibody drug conjugate. In addition, anti-inflammatory agents or other drugs can be administered to an individual with cancer during monotherapy to treat symptoms associated with cancer, but potential cancer itself, including, for example, inflammation, pain, weight loss, and general discomfort, can be used. The individual treated by this method can preferably complete the prior treatment of any anticancer agent before administering the antibody drug conjugate. In some embodiments, the individual will complete any prior treatment with an anticancer agent at least 1 week (preferably 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, or 8 weeks) before treatment with the antibody drug conjugate. Preferably, the individual can not receive any additional anticancer agent for at least two weeks (preferably at least 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks or 8 weeks) after completing the first treatment cycle with the antibody drug conjugate, and preferably, at least two weeks (preferably at least 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks or 8 weeks) after completing the last dose of the antibody drug conjugate, and not receive any additional anticancer agent for treatment. The method of the present invention comprises administering an anti-ROR2 antibody or antibody fragment of the present invention or an immunoconjugate comprising an anti-ROR2 antibody or antibody fragment to an individual for treating a tumor expressing ROR2.
[0605] In some embodiments, an immunoconjugate comprising an anti-ROR2 antibody or antibody fragment of the present invention is administered to an individual and the anti-ROR2 antibody is bound to a tumor cell expressing ROR2, and then the antibody-drug conjugate is internalized into the cell and releases the drug. For example, the method of the present invention comprises administering BA3021-cleavable linker-MMAE to an individual. (n) Antibody-drug conjugates are used to treat tumors expressing ROR2. After binding to tumor cells, BA3021 cleaves the linker-MMAE. (n) The antibody-drug conjugate is internalized into tumor cells, where the peptide linker is cleaved by proteases to release MMAE. Specific delivery of MMAE to ROR2-expressing tumor cells is expected to prevent further tumor cell proliferation and lead to tumor shrinkage.
[0606] Individuals treated with the methods of the present invention are those who have been diagnosed with or are suspected of having a cancer that expresses ROR2. Diagnosis can be made by methods known in the art, including, for example, tissue biopsy.
[0607] G. Products and Kits
[0608] In another aspect of the present invention, a product containing an anti-ROR2 antibody or antibody fragment and other substances that can be used to treat, prevent and / or diagnose the above-mentioned diseases is provided. The product includes a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The container can be made of a variety of materials, such as glass or plastic. The container holds a composition that is effective for treating, preventing and / or diagnosing a condition by itself or in combination with another composition, and can have a sterile access port (for example, the container can be an intravenous infusion bag or a vial with a stopper pierceable by a hypodermic needle). At least one active agent in the composition is an antibody or antibody fragment of the present invention. The label or package insert indicates that the composition is used to treat a selected condition. In addition, the product may include (a) a first container containing a composition, wherein the composition includes an antibody or antibody fragment; and (b) a second container containing a composition, wherein the composition includes an additional cytotoxic agent or other therapeutic agent. The product in this embodiment of the invention may also include a package insert indicating that the composition can be used to treat a specific condition. Alternatively or additionally, the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and dextrose solution. It may also comprise other substances desirable from a commercial and user perspective, including other buffers, diluents, filters, needles, and syringes.
[0609] It will be understood that any of the aforementioned articles of manufacture may include an immunoconjugate of the invention instead of, or in addition to, an anti-ROR2 antibody or antibody fragment.
[0610] Finally, the present invention also provides a kit comprising at least one antibody or antibody fragment of the present invention. Kits containing polypeptides, antibodies or antibody fragments or antibody drug conjugates of the present invention can be used to detect ROR2 expression (increase or decrease), or for therapeutic or diagnostic assays. The kits of the present invention can contain antibodies coupled to a solid support such as a tissue culture plate or beads (e.g., agarose beads). A kit containing antibodies can be provided for detecting and quantifying ROR2 in vitro (e.g., in ELISA or Western blot). Such antibodies that can be used for detection can be labeled with, for example, a fluorescent marker or a radioactive marker.
[0611] The kit also includes instructions for use. In some embodiments, the instructions include instructions required by the U.S. Food and Drug Administration for in vitro diagnostic kits. In some embodiments, the kit also includes instructions for diagnosing the presence or absence of cerebrospinal fluid in the sample based on the presence or absence of ROR2 in the sample. In some embodiments, the kit includes more than one antibody or antibody fragment. In other embodiments, the kit also includes more than one enzyme, enzyme inhibitor or enzyme activator. In other embodiments, the kit also includes more than one chromatographic compound. In other embodiments, the kit also includes more than one compound for preparing a sample for spectroscopic determination. In a further embodiment, the kit also includes a comparative reference substance to interpret the presence or absence of ROR2 based on the intensity, chromatography or other physical properties of the indicator.
[0612] H. Plasma membrane scoring of ROR2 in tumors (tumor cell membrane P score)
[0613] In tumor cells, ROR2 is primarily localized to the plasma membrane but can also be observed in the cytoplasm.
[0614] The present invention uses a scoring method to compare ROR2 staining in serial sections of each sample. Using this method, ROR2 plasma membrane staining is scored only in tumor cells to provide a ROR2 tumor score (hereinafter referred to as "tumor cell membrane percentage score" or (TmPS)).
[0615] Methods for scoring ROR2 can be detected by immunohistochemistry (IHC) methods including, but not limited to, those described below, in formalin-fixed, paraffin-embedded (FFPE) tumor samples. All samples were also stained with hematoxylin and eosin (H&E) to assist in scoring by morphological evaluation.
[0616] ROR2 plasma membrane expression in tumors was scored semi-quantitatively for plasma membrane staining (full or partial) and cytoplasmic staining (diffuse or granular). Plasma membrane and cytoplasmic reactivity were scored separately. For ROR2 plasma membrane staining, the main components of the score were the percentages at differential intensities, H-score, and score ≥ 1 + percentage as described below. For ROR2 cytoplasmic staining, the main components of the score were the percentages at differential intensities and H-score.
[0617] When ROR2 is scored for tumor tissue, the numerical score excludes any surrounding staining in the stroma, non-tumor areas, and adjacent normal tissue. Areas of ischemia or necrosis are not scored in any indication. A percentage score is assigned to describe the permeability of the plasma membrane staining for each sample. Percentages are estimated and reported in increments, including but not limited to one of the following increments: 0, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100%. In certain embodiments of the invention, the TmPS of tumors expressing ROR2 is at least 1, at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, or at least 95%.
[0618] To comprehensively understand ROR2 expression on the tumor plasma membrane beyond macrophages across various cancer indications, standard percentage score and H-score methods were used to capture the observed patterns of reactivity.
[0619] Both methods require semi-quantitative recording of the percentage of tumor cells that stain with ROR2 at different intensities using a four-point scale (0, 1+, 2+, 3+). On this scale, 0 = no staining, negative staining, or nonspecific staining, 1+ = low or weak staining, 2+ = moderate or moderate staining, and 3+ = high or strong staining.
[0620] Percentage scoring method
[0621] The percentage score was calculated by summing the percentages of intensities ≥1+, ≥2+, or ≥3+, thus ranging from 0 to 100.
[0622] Percent score ≥ 1+ = (% 1+) + (% 2+) + (% 3+)
[0623] Percent score ≥ 2+ = (% 2+) + (% 3+)
[0624] Percentage score ≥3+ = (%3+)
[0625] H-score method
[0626] The H score is calculated by multiplying the percentage of cells with expression intensity (brown staining) by their corresponding different intensities on a four-point semiquantitative scale (0, 1+, 2+, 3+) and summing the scores. Thus, the score ranges from 0 to 300.
[0627] H score = [(%<1) x 0] + [(%1+) x 1] + [(%2+) x 2] + [(%3+) x 3]
[0628] For analysis of ROR2 expression in human cancer tissues, the evaluation is semi-quantitative, providing numerical score data as a measure of reactivity. A sample is considered "positive" for ROR2 if it shows plasma membrane staining of ≥1+ intensity in ≥10% of tumor cells.
[0629] The following examples are illustrative of the soft gelatin capsules of the present invention, but not limiting. It will be apparent to those skilled in the art that other appropriate modifications and adjustments of the various conditions and parameters normally encountered in the art are within the scope of the present invention.
[0630] Example
[0631] Example 1: Conditionally Active Biological (CAB) Antibodies Against ROR2
[0632] This example produces antibodies against human ROR2. A humanized antibody against ROR2 was used as a wild-type antibody to generate a CAB antibody against ROR2. DNA encoding the wild-type antibody (heavy chain and light chain variable regions) was evolved to generate a library of mutant antibody heavy chain variable regions and light chain variable regions. The mutant heavy chain variable regions and mutant light chain variable regions in the library were screened by ELISA to determine their selective binding affinity for human ROR2, i.e., at pH 6.0 relative to the binding affinity at pH 7.4 ( Figures 2A to 2B and Figures 3A to 3B ). At the same time, the expression level of the mutant antibody was also optimized to provide higher yields in the subsequent manufacturing process. Screening was performed in serum using a FLAG tag because the presence of human antibodies in serum could result in false positives in screening. The generated conditionally active antibodies were found to have higher binding affinity for ROR2 at pH 6.0 than at pH 7.4 (Tables 1 and 2).
[0633] like Figure 4 As shown in Figure 2, the CAB antibodies did not show aggregation in the buffer. The CAB antibodies were analyzed by size exclusion chromatography. Figure 4 As shown, only one peak was detected, indicating little or no aggregation of the antibody. Figure 5 It was shown that some selected mutant antibodies (scFv) exhibited higher binding affinity to ROR2 at pH 6.0 than at pH 7.4. Figure 5 It was also shown that increasing the temperature from room temperature to 60°C did not significantly change the selectivity of the antibody.
[0634] The conditionally active antibodies all exhibited high expression levels as shown in Table 4 below, with the antibodies shown in the "Clone" column and the expression levels in "mg / ml" shown in the second column.
[0635] Clones of these antibodies were sent to the service provider with expression levels specified that represented the expected expression levels ("amount ordered"). However, the actual expression levels of several of the antibodies ("amount delivered") were significantly higher than the expected expression levels. At least three clones expressed levels exceeding the expected expression levels (BAP048.7.067-HC-FLAG, BAP048.7-C02D09-FLAG, and BAP048.7-A03F01-FLAG).
[0636] Table 4 Antibodies with high expression levels
[0637] clone [mg / mL] Estimated yield Actual yield BAP048.1-06-07 4.9 100 137 BAP048.7-06-07 3.7 100 94 BAP048.7-C02D09 3.8 30 57 BAP048.7-A03F01 4.4 30 65 BAP048.7-A03C05 4.2 30 36
[0638] Conditionally active antibodies were also assayed using surface plasmon resonance (SPR) to measure their on and off rates for binding to ROR2. The SPR assay can be used to measure the on and off rates of protein binding. The on and off rates of conditionally active antibodies in vivo (in animals and humans) are an important characteristic.
[0639] It was observed that the conditionally active antibodies had good binding activity at pH 6.0, but had very low or no binding activity at pH 7.4 ( Figures 6A to 6B SPR assays showed that these same conditionally active antibodies were highly selective at pH 6.0 compared to pH 7.4 ( Figures 6A to 6B ).
[0640] Example 2: Anti-ROR2 antibody conjugated to a model toxin
[0641] The anti-ROR2 antibodies of the present invention are conjugated to a model toxin (eg, paclitaxel) to generate a conditionally active antibody-drug conjugate (ROR2-CAB-ADC).
[0642] Tumors were induced in mice by injecting MDA-MB-436 tumor cells to generate xenograft mice. ROR2-CAB-ADC was then injected into the xenograft mice at a dose of 0.3 mg / kg or 1 mg / kg once a week for 2 weeks. The controls used in this study included PBS buffer as a vehicle and a single toxin (paclitaxel). The study showed that ROR2-CAB-ADC significantly reduced tumor size by more ( 0.1% vs. ... 7A to 7C ). Figure 7B The results of the 0.3 mg / kg dose group are shown in FIG. Figure 7C Results for the 1 mg / kg dose group are shown in . This study demonstrates that anti-ROR2 antibodies conjugated to a toxin can effectively reduce tumor size.
[0643] Example 3: pH-dependent binding affinity of conditionally active antibody BAP048
[0644] The binding affinity of one of the conditionally active antibodies identified in the present invention, BAP048 (or BAP048.7 as shown in some figures), was tested by pH titration. The wild-type antibody was used as a control. Figure 8 As shown, the conditionally active antibody BAP048 is more active at pH values below pH 6.5, but less active at pH 7.0. The wild-type antibody does not show pH dependence for its bind...
Claims
1. A method for treating cancer, comprising the step of administering to an individual in need of such treatment a polypeptide that specifically binds to a ROR2 protein at the following doses: (i) 0.3 mg / kg to 3.3 mg / kg of the individual's body weight every 2 weeks or every 3 weeks, (ii) 0.3 mg / kg to 1.8 mg / kg of the individual's body weight every 2 weeks, or (iii) 1.8 mg / kg of the individual's body weight on days 1 and 8 every 3 weeks, wherein the polypeptide comprises a heavy chain variable region comprising three complementary determining regions, wherein the three complementary determining regions have an H1 sequence, an H2 sequence, and an H3 sequence, in: (a) H1 sequence is GYTX 1 TEX 2 X 3 X 4 H (SEQ ID NO: 1) or GYSITTGX 29 YWN (SEQ ID NO: 4); (b) H2 sequence is X 5 X 6 X 7 X 8 NNGGTGYNQKFKG(SEQ ID NO:2) or YITYDGSX 30 NYNPSLKN (SEQ ID NO: 5); and (c) H3 sequence is X 9 X 10 X 11 SX 12 YX 13 YX 14 X 15 SYFX 16 X 17 X 18 (SEQ ID NO:3) or CSX 31 X 32 X 33 X 34 VX 35 X 36 X 37 LDX 38 (SEQ ID NO:6); in X 1 is F or E, X 2 is Y or D, X 3 is T or C, X 4 It is M or D or E or Y, X 5 is G or S, X 6 is I or E, X 7 It is N or C or L or V, X 8 It is T or D or E, X 9 It's A or M or T. X 10 is R or H, X 11 is G or E, X 12 is L or F, X 13 is S or G, X 14 is G or D, X 15 is N or E, X 16 is D or L, X 17 It is Y or C or T, X 18 is W or L, X 29 It is Y or E or R or T, X 30 is K or N, X 31 is R or G or H or W or Y, X 32 It's F or C or N or Q, X 33 is E or S, X 34 It's G or E or F or H or M or Q or S, X 35 It is W or A or I or P or Q or T or V, X 36 It is Y or G or N or Q, X 37 is G or S or T, and X 38 is Y or I; and A light chain variable region comprising three complementarity determining regions, an L1 sequence, an L2 sequence and an L3 sequence, wherein: (d) L1 sequence is SATSSX 19 X 20 X 21 MX 22 (SEQ ID NO:7) or RASESVDRYGNSX 39 IH (SEQ ID NO: 10); (e) L2 sequence is X 23 TSNLAS (SEQ ID NO: 8) or X 40 TYX 41 LES (SEQ ID NO: 11); and (f) L3 sequence is QX 24 X 25 SX 26 YPFX 27 X 28 (SEQ ID NO:9) or QQX 42 NX 43 DPX 44 TX 45 (SEQ ID NO: 12); in X 19 is V or E, X 20 is S or D, X 21 It is Y or C or D, X 22 It is H or G or L, X 23 It's G or C or H or P, X 24 It is Q or E, X 25 is R or H, X 26 It is S or D or G or I or Q or V, X 27 is T or D, X 28 It is F or D or E, X 39 It is F or S or T, X 40 It is R or C or D or E or W, X 41 is N or D, X 42 It is T or I or P, X 43 is E or V, X 44 is W or T, and X 45 is F or T, The condition is X 1 To X 28 It cannot be F, Y, T, M, G, I, N, T, A, R, G, L, S, G, N, D, Y, W, V, S, Y, H, G, Q, R, S, T, and F at the same time.
2. The method according to claim 1, wherein the heavy chain variable region has an amino acid sequence selected from the group consisting of SEQ ID NOs: 18-26.
3. The method according to any one of claims 1 to 2, wherein the light chain variable region has an amino acid sequence selected from SEQ ID NOs: 13-17 and 27.
4. The method according to any one of claims 1 to 2, wherein the light chain variable region comprises three complementarity determining regions L1, L2 and L3, and L1, L2 and L3 have the sequences of SEQ ID NOs: 10-12, respectively.
5. The method according to any one of claims 1 to 4, wherein X 29 It is Y.
6. The method according to any one of claims 1 to 4, wherein X 29 It's E.
7. The method according to any one of claims 1 to claim 6, wherein the dosage is 0.3 mg / kg to 1.8 mg / kg of subject body weight every 2 weeks.
8. The method of any one of claims 1 to 6, wherein the individual has non-small cell lung cancer and the dosage is 1.8 mg / kg of the individual's body weight every 2 weeks.
9. The method according to any one of claims 1 to 6, wherein the dosage is 1.8 mg / kg of subject body weight on day 1 and day 8 every 3 weeks.
10. The method of any one of claims 1 to 9, wherein the polypeptide is an anti-ROR2 antibody or antibody fragment.
11. The method according to claim 10, in, The antibody or antibody fragment has a higher binding affinity for the ROR2 protein at a certain value of a certain condition in a tumor microenvironment than at a different value of the same condition in a non-tumor microenvironment.
12. The method of claim 11, wherein the condition is pH.
13. The method of claim 12, wherein the pH in the tumor microenvironment is in the range of 5.8 to 6.8, and the pH in the non-tumor microenvironment is in the range of 7.0 to 7.
6.
14. The method of any one of claims 10 to 13, wherein the ratio of the binding affinity of the antibody or antibody fragment to the ROR2 protein at a certain value of the condition in the tumor microenvironment to the binding affinity of the ROR2 protein at a different value of the same condition in the non-tumor microenvironment is at least about 1.5:1, at least about 2:1, at least about 3:1, at least about 4:1, at least about 5:1, at least about 6:1, at least about 7:1, at least about 8:1, at least about 9:1, at least about 10:1, at least about 20:1, at least about 30:1, at least about 50:1, at least about 70:1, or at least about 100:
1.
15. The method according to any one of claims 10 to claim 14, wherein the antibody or antibody fragment is a chimeric antibody, a multispecific antibody or a humanized antibody.
16. The method of any one of claims 1 to 15, wherein the polypeptide, antibody or antibody fragment is administered to the individual in the form of an immunoconjugate comprising the polypeptide, antibody or antibody fragment conjugated to at least one agent for treating a cancer or symptom experienced by the individual.
17. The method of claim 16, wherein the at least one agent is selected from the group consisting of a chemotherapeutic agent, a radioactive atom, a cytostatic agent, and a cytotoxic agent.
18. The method of any one of claims 16 to 17, wherein the immunoconjugate comprises at least two of the agents.
19. The method of any one of claims 16 to 18, wherein the polypeptide, antibody or antibody fragment and the at least one agent are covalently bonded to a linker molecule.
20. The method of any one of claims 16 to 19, wherein the at least one agent is an anti-tumor agent.
21. The method of any one of claims 16 to 20, wherein the at least one agent is selected from the group consisting of maytansines, auristatins, dolastatins, calicheamicins, pyrrolobenzodiazepines, and anthracyclines.
22. The method of any one of claims 1 to 21, wherein the polypeptide, antibody, antibody fragment or immunoconjugate is administered in the form of a composition comprising a pharmaceutically acceptable carrier.
23. The method of claim 22, wherein the composition further comprises a tonicity agent.
24. The method of any one of claims 1 to 22, wherein the individual has or has previously had a cancer that expresses ROR2.
25. The method of any one of claims 1 to 23, wherein the individual has a tumor that expresses ROR2.
26. The method of claim 25, wherein the tumor expressing ROR2 has a tumor cell membrane P score of at least 1.
27. The method of any one of claims 1 to 26, wherein the cancer is selected from sarcoma, ovarian cancer, melanoma, non-small cell lung cancer, breast cancer, and head and neck cancer.
28. The method of any one of claims 16 to 27, wherein the immunoconjugate comprising BA3021-cleavable linker-MMAE is administered to the individual. n , wherein BA3021 is the antibody or antibody fragment having a heavy chain variable region comprising SEQ ID NO: 16 and a light chain variable region comprising SEQ ID NO: 21; n is an integer from 1 to 4, inclusive.
29. The method of any one of claims 16 to 28, wherein the immunoconjugate is administered to the individual in a single dose at a dose of 1.8 mg / kg of the individual's body weight once every 2 weeks.
30. The method of any one of claims 16 to claim 28, wherein the immunoconjugate is administered to the individual at a dose of 1.8 mg / kg of the individual's body weight on days 1 and 8 of more than one consecutive 21 -day cycle.
31. The method of any one of claims 16 to claim 28, wherein the immunoconjugate is administered to the individual at a dose of 0.3 mg / kg to 3.3 mg / kg of the individual's body weight every 2 weeks or every 3 weeks.
32. The method of any one of claims 16 to claim 28, wherein the immunoconjugate is administered to the individual at a dose of 0.3 mg / kg to 1.8 mg / kg of the individual's body weight every 2 weeks.
33. The method of any one of claims 1 to 32, wherein the individual is a human.
34. Use of an immunoconjugate for treating cancer at a dose of: (i) 0.3 mg / kg to 3.3 mg / kg of individual body weight every 2 weeks or every 3 weeks, (ii) 0.3 mg / kg to 1.8 mg / kg of individual body weight every 2 weeks, or (iii) 1.8 mg / kg of individual body weight on day 1 and day 8 every 3 weeks, wherein the immunoconjugate comprises a polypeptide, an antibody or an antibody fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises three complementarity determining regions, wherein the complementarity determining regions have an H1 sequence, an H2 sequence and an H3 sequence, in: (a) H1 sequence is GYTX 1 TEX 2 X 3 X 4 H (SEQ ID NO: 1) or GYSITTGX 29 YWN (SEQ ID NO: 4); (b) H2 sequence is X 5 X 6 X 7 X 8 NNGGTGYNQKFKG(SEQ ID NO:2) or YITYDGSX 30 NYNPSLKN (SEQ ID NO: 5); and (c) H3 sequence is X 9 X 10 X 11 SX 12 YX 13 YX 14 X 15 SYFX 16 X 17 X 18 (SEQ ID NO:3) or CSX 31 X 32 X 33 X 34 VX 35 X 36 X 37 LDX 38 (SEQ ID NO:6); in X 1 is F or E, X 2 is Y or D, X 3 is T or C, X 4 It is M or D or E or Y, X 5 is G or S, X 6 is I or E, X 7 It is N or C or L or V, X 8 It is T or D or E, X 9 It's A or M or T. X 10 is R or H, X 11 is G or E, X 12 is L or F, X 13 is S or G, X 14 is G or D, X 15 is N or E, X 16 is D or L, X 17 It is Y or C or T, X 18 is W or L, X 29 It is Y or E or R or T, X 30 is K or N, X 31 is R or G or H or W or Y, X 32 It's F or C or N or Q, X 33 is E or S, X 34 It's G or E or F or H or M or Q or S, X 35 It is W or A or I or P or Q or T or V, X 36 It is Y or G or N or Q, X 37 is G or S or T, and X 38 is Y or I; and The light chain variable region includes three complementary determining regions: L1 sequence, L2 sequence and L3 sequence, wherein: (d) L1 sequence is SATSSX 19 X 20 X 21 MX 22 (SEQ ID NO:7) or RASESVDRYGNSX 39 IH (SEQ ID NO: 10); (e) L2 sequence is X 23 TSNLAS (SEQ ID NO: 8) or X 40 TYX 41 LES (SEQ ID NO: 11); and (f) L3 sequence is QX 24 X 25 SX 26 YPFX 27 X 28 (SEQ ID NO:9) or QQX 42 NX 43 DPX 44 TX 45 (SEQ ID NO: 12); in X 19 is V or E, X 20 is S or D, X 21 It is Y or C or D, X 22 It is H or G or L, X 23 It's G or C or H or P, X 24 It is Q or E, X 25 is R or H, X 26 It is S or D or G or I or Q or V, X 27 is T or D, X 28 It is F or D or E, X 39 It is F or S or T, X 40 It is R or C or D or E or W, X 41 is N or D, X 42 It is T or I or P, X 43 is E or V, X 44 is W or T, and X 45 is F or T, The condition is X 1 To X 28 It cannot be F, Y, T, M, G, I, N, T, A, R, G, L, S, G, N, D, Y, W, V, S, Y, H, G, Q, R, S, T, and F at the same time.
35. The use according to claim 34, wherein the heavy chain variable region has an amino acid sequence selected from the group consisting of SEQ ID NOs: 18-26.
36. The method of any one of claims 34 to 35, wherein the light chain variable region has an amino acid sequence selected from SEQ ID NOs: 13-17 and 27.
37. The use according to any one of claims 34 to 35, wherein the light chain variable region comprises three complementarity determining regions L1, L2 and L3, and L1, L2 and L3 have the sequences of SEQ ID NOs: 10-12 respectively.
38. The use according to any one of claims 34 to 36, wherein X 29 It is Y.
39. The use according to any one of claims 34 to 37, wherein X 29 It's E.
40. The use according to any one of claims 34 to 39, wherein the polypeptide is an anti-ROR2 antibody or antibody fragment.
41. The use according to claim 40, in, The antibody or antibody fragment has a higher binding affinity for the ROR2 protein at a certain value of a certain condition in a tumor microenvironment than at a different value of the same condition in a non-tumor microenvironment.
42. The use according to claim 41, wherein the condition is pH.
43. The use according to claim 42, wherein the pH in the tumor microenvironment is in the range of 5.8 to 6.8, and the pH in the non-tumor microenvironment is in the range of 7.0 to 7.
6.
44. The use according to any one of claims 41 to 43, wherein the ratio of the binding affinity of the antibody or antibody fragment to the ROR2 protein at a certain value of the condition in the tumor microenvironment to the binding affinity of the ROR2 protein at a different value of the same condition in the non-tumor microenvironment is at least about 1.5:1, at least about 2:1, at least about 3:1, at least about 4:1, at least about 5:1, at least about 6:1, at least about 7:1, at least about 8:1, at least about 9:1, at least about 10:1, at least about 20:1, at least about 30:1, at least about 50:1, at least about 70:1 or at least about 100:
1.
45. The use according to any one of claims 40 to 44, wherein the antibody or antibody fragment is a chimeric antibody, a multispecific antibody or a humanized antibody.
46. The use of any one of claims 34 to 45, wherein the polypeptide, antibody or antibody fragment is administered to the individual in the form of an immunoconjugate comprising the polypeptide, antibody or antibody fragment conjugated to at least one agent for treating a cancer or symptom experienced by the individual.
47. The use according to claim 46, wherein the at least one agent is selected from a chemotherapeutic agent, a radioactive atom, a cytostatic agent and a cytotoxic agent.
48. The use of any one of claims 46 to 47, wherein the immunoconjugate comprises at least two of the agents.
49. The use according to any one of claims 46 to 48, wherein the polypeptide, antibody or antibody fragment and the at least one agent are covalently bonded to a linker molecule.
50. The use according to any one of claims 46 to 49, wherein the at least one agent is an anti-tumor agent.
51. The use of any one of claims 46 to 50, wherein the at least one agent is selected from the group consisting of maytansines, auristatins, dolastatins, calicheamicins, pyrrolobenzodiazepines, and anthracyclines.
52. The use according to any one of claims 34 to claim 51, wherein the polypeptide, antibody, antibody fragment or immunoconjugate is administered in the form of a composition comprising a pharmaceutically acceptable carrier.
53. The use according to claim 52, wherein the composition further comprises a tonicity agent.
54. The use of any one of claims 34 to 53, wherein the individual has or has previously had a cancer that expresses ROR2.
55. The use of any one of claims 34 to 53, wherein the individual has a tumor expressing ROR2.
56. The use of claim 55, wherein the tumor cell membrane P score of the tumor expressing ROR2 is at least 1.
57. The use of any one of claims 34 to 56, wherein the cancer is selected from sarcoma, ovarian cancer, melanoma, non-small cell lung cancer, breast cancer, and head and neck cancer.
58. The use of any one of claims 46 to 57, wherein the immunoconjugate comprising BA3021-cleavable linker-MMAE is administered to the individual. n , wherein BA3021 is the antibody or antibody fragment having the heavy chain variable region comprising SEQ ID NO: 16 and the light chain variable region comprising SEQ ID NO: 21; n is an integer from 1 to 4, inclusive.
59. The use according to any one of claims 46 to claim 58, wherein the immunoconjugate is administered to the individual in a single dose at a dose of 1.8 mg / kg of the individual's body weight once every 2 weeks.
60. The use of any one of claims 46 to 58, wherein the immunoconjugate is administered to the individual at a dose of 0.3 mg / kg to 3.3 mg / kg of the individual's body weight every 2 weeks or every 3 weeks.
61. The use of any one of claims 46 to 58, wherein the immunoconjugate is administered to the individual at a dose of 0.3 mg / kg to 1.8 mg / kg of the individual's body weight every 2 weeks.
62. The use according to any one of claims 34 to 58, wherein the subject suffers from non-small cell lung cancer and the dosage is 1.8 mg / kg of the subject's body weight every 2 weeks.
63. The use according to any one of claims 34 to 58, wherein the dosage is 1.8 mg / kg on day 1 and day 8 every 3 weeks.
64. The use according to any one of claims 42 to 54, wherein the individual is a human.
